

Index

Note: page numbers in *italics* refer to figures; those in **bold** to tables or boxes.

A list of abbreviations used in subheadings can be found on page xvii.

- A4 trial 599
- AASK trial 172, 173
- ABCA1 transporter gene 271, 297
 - drugs acting on 1161
- ABCG5/8 gene 272
- abciximab
 - acute STEMI
 - fibrinolysis and 479–80
 - primary PCI 480–1
 - NSTE acute coronary syndrome 425–7, 431, 1145
 - PCI 366–8
- abdominal aortic aneurysms *see* aortic aneurysms, abdominal
- abdominal obesity *see* obesity, abdominal
- abdominal surgery, cardiac risk 1071–3
- ablation therapy
 - catheter *see* catheter ablation
 - surgical *see* MAZE procedure
- Aboriginal populations 248–50
- abscess, paravalvular 952
- acarbose 186
- accessory pathways
 - atrioventricular reciprocating tachycardia 613
 - catheter ablation 614
 - Ebstein anomaly 1025
- ACCOMPLISH study 173, 174
- ACCORD study 158, 185, 186, 1057
- ACE inhibitors *see* angiotensin-converting enzyme inhibitors
- acenocoumarol
 - atrial fibrillation 585
 - prosthetic valve recipients 959, 964
- acetaminophen, acute stroke 973
- acetylsalicylic acid *see* aspirin
- acid maltase deficiency 816
- ACIP study 370, 380, 401
- aclarubicin, intrapericardial 854
- ACME trial 369–70
- A-COMET-II study 546, 547, 550
- ACTH, rheumatic fever 865
- alpha-actin, cardiac (ACTC) 293, 294, 295
- active compression decompression (ACD) CPR 699
- ACTIVE trials 572, 585
- ACTIV study 770
- ACUTY study 369, 430, 488, 1146
- ACUTY-Timing study 427
- acute aortic syndromes 1081–2
 - descending thoracic and thoracoabdominal aorta 1089
 - incidence 1084
 - management 1087–90
 - root, ascending aorta and arch 1087–8, 1089
- acute coronary syndromes (ACS) 409–36
 - atrial fibrillation prevention 572
 - global perspective 106
 - non-cardiac surgery 1070
 - non-ST segment elevation (NSTEMI-ACS) 409–36
 - anti-ischemic therapy 420–2
 - antithrombotic therapy 422–31, 1145–7
 - biomarkers 415–17, 1143–4
 - case history 1142, 1143, 1147–8, 1149
 - cell protection 433
 - clinical diagnosis 410–11
 - clinical features 410, 413
 - coronary reperfusion procedures 431–3
 - definitions 409–10
 - diabetes mellitus 413–14, 1148–9
 - early invasive vs. conservative management 431–3, 1144–5
 - ECG features 410, 411, 414–15
 - incidence, natural history and prognosis 411–13
 - initial management 419–20
 - management 419–35, 1142–9
 - pathophysiology 418–19
 - plaque passivation 433–5
 - renal dysfunction 414, 1113, 1115
 - risk scores 417–18
 - risk stratification 413, 1142–3
 - secondary prevention 1148–9, 1157–61
 - subacute therapy 435
 - see also* myocardial infarction, non-ST segment elevation; unstable angina
 - ST segment elevation *see* myocardial infarction (MI), ST segment elevation
- acute ischemic stroke *see* stroke, acute
- acute limb ischemia (ALI) 1063
- acute myocardial infarction *see* myocardial infarction (MI), acute
- Acute Myocardial Infarction-Streptokinase (AMI-SK) trial 485
- acute rejection, cardiac allografts 1104, Plate 68.1, Plate 68.2
- acute renal failure 1114
- ACUTE study 590
- adenosine
 - atrial fibrillation 556
 - NSTEMI acute coronary syndrome 433
 - supraventricular tachycardia 607–8, 609, 612, 613
- adenosine antagonists, heart failure 760
- adenosine triphosphate (ATP) test, syncope 681–2
- adenovirus-related myocarditis 808
- ADEPT trial 649
- adherence *see* compliance
- ADMIRAL study 480
- ADMIT study 158
- adolescents
 - atherosclerosis development 258–9
 - pacemaker therapy 641
- ADONIS study 551, 552, 553, 557
- ADP receptor antagonists
 - NSTEMI acute coronary syndrome 423–5
 - see also* thienopyridines
- adrenaline, cardiac arrest 697
- advanced cardiac life support (ACLS) units 447, 450
- advanced glycation endproducts (AGE) 183–4
- advanced life support 695–8
- ADVANCE trial 185, 186
- Adventist Health Study 316
- Aerobics Center Study 192, 193
- AFASAK trial 581–2
- AFASAK 2 trial 583, 584
- AFCAPS/TexCAPS trial 158
- AF CHF study *see* Atrial Fibrillation Congestive Heart Failure study
- AFFECT trial 73
- AFFIRM study 532–3, 535, 550, 558, 559, 596
 - anticoagulation 533, 588–9
 - mortality statistics 532, 536
 - sotalol vs. other antiarrhythmics 546, 547
- Africa, sub-Saharan 95, 96, 250–1, 740
- African Americans 251–2, 761
- age
 - cardiogenic shock and 499
 - cardiovascular deaths in developing countries 96
 - coronary artery disease and 17
 - hypertension and 165–6
 - peripheral arterial disease and 1051, 1052
 - venous thromboembolism and 1032
 - see also* children; elderly patients
- aggregation bias 33–4
- aging, population 100
- AIDS *see* HIV infection
- AIM-HIGH study 160
- AIRE trial 518, 762
- airway
 - advanced life support 697
 - basic life support 693
- albumin, urinary excretion 1111–12
- cardiovascular risk 1112, 1113
- see also* microalbuminuria
- alcohol consumption 317
 - coronary artery disease 317, 347
 - ethnic populations 243, 244
 - heart failure 743
 - hypertension and 168, 169
- alcohol septal ablation, percutaneous 803–4
- Aldactone *see* spironolactone
- aldosterone receptor blockers (aldosterone antagonists)
 - acute myocarditis 789
 - asymptomatic left ventricular systolic dysfunction 749–50

Index

- aldosterone receptor blockers (*cont.*)
heart failure 758–9, 1166
hypertension 174
postinfarction 497–8, 519
renal insufficiency 1114
ALIVE study 550, 620
allele frequency, effect size and 269
allergic reactions, acute STEMI 1154, 1155
ALLHAT study 172, 173, 174, 744, 745
allopurinol, Chagas' disease 831
allostatic load 215
ALOX5AP gene 273
alpha-2 agonists, perioperative 56–7
alpha-blockers
heart failure prevention 744
hypertension 172, 174
ALSPAC study 262
alteplase 458
acute MI 459, 462, 463
adjunctive anticoagulants 482, 485, 487
adjunctive Gp IIb/IIIa antagonists 478–9
adverse effects 461
see also tissue plasminogen activator
American College of Cardiology, NCDR-ACTION registry 409
American College of Cardiology/American Heart Association (ACC/AHA) guidelines
acute STEMI
prehospital care 444, 448, 450, 451, 460
reperfusion strategies 450, 451, 463, 466, 469
aortic regurgitation 889, 891
aortic stenosis 1187, 1188
aortic valve replacement 886, 897
atrial fibrillation 589
CABG 379, 381
cardiac transplantation 1100–1
heart failure 740–1
infective endocarditis 945, 946–50, 953
NSTE acute coronary syndrome 409, 430–1, 1144
pacemaker implantation 636, 637–41
percutaneous balloon mitral valvuloplasty 914, 915, 916, 917, 921
perioperative cardiac risk 1068, 1073, 1183–4
peripheral arterial disease 1052, 1061
valve replacement surgery 935, 936
valvular heart disease 878, 879–80
American College of Chest Physicians (ACCP)
anticoagulation in pregnancy 1001
atrial fibrillation 589
Americas 249
amiloride, hypertension 174
aminophylline, cardiac arrest 698
aminorex fumarate 1118
amiodarone
adverse effects 532, 551
analogs 553
arrhythmogenic right ventricular cardiomyopathy 726
atrial fibrillation
acute cardioversion 537, 538, 540–1
after cardiac surgery 560
after left atrial ablation 554
case history 1172
postinfarction 506
prophylactic use 548–9, 550–1
rate control 555, 557, 558
vs. ablation therapy 598–9
vs. rate control 533, 536
atrial tachycardia 610
atrioventricular reciprocating tachycardia 613
automatic junctional tachycardia 612
beta-blocker interaction 620
cardiac arrest 697
Chagas' cardiomyopathy 832
hypertrophic cardiomyopathy 714
ICD recipients 626
paroxysmal supraventricular tachycardia 608
postinfarction patients 504–5
pregnancy 1000
sudden cardiac death prevention 620, 621, 625
AMIOVIRT trial 625, 626
amlodipine
acute myocarditis 789
chronic stable angina 349
heart failure prevention 744, 745
heart failure therapy 761
hypertension 171, 172–4
NSTE acute coronary syndrome 421
ampicillin, infective endocarditis 948, 949
ampicillin-sulbactam, infective endocarditis 948, 949
AMPK gene 292
amputation 1050, 1055
amyloidosis 812–14
AL 812–13
familial 813–14
senile cardiac (SCA) 814
analgesia
acute MI 448–9
non-ST segment elevation ACS 419–20
Andersen-Tawil syndrome 711
Anderson-Fabry disease (AFD) 816
ANDROMEDA study 552, 553
anemia
Eisenmenger's syndrome 1024
non-cardiac surgery and 1070
aneurysms
aortic *see* aortic aneurysms
intracranial 278–9
left ventricular *see* left ventricular aneurysms
angina
aortic regurgitation 888
atypical 15, 346
chronic stable 345–53
CABG 351–2, 380–2
CABG vs. medical therapy 380–2, 392–3, 394
CABG vs. PCI 398–400
case history 1138–40
definition 345–6
epidemiology 345
medical management 346–51, 369–73
myocardial revascularization 351–2, 353, 402
non-pharmacologic strategies 351
optimal medical therapy (OMT) 352–3
percutaneous intervention 351–2, 359–73, 374, 393–7
pharmacologic therapy 345, 347–51
recommended initial management 352–3
treatment choices 1138–40
classic (typical) 15, 345–6
classification 346
demand 346
equivalents 346
increasing (crescendo) 410
new-onset 410
non-cardiac surgery 1072
pathophysiology 346
post revascularization 345
refractory 414–15, 433, 1147
rest 410
unstable *see* unstable angina
variable threshold 346
variant 421
vasospastic (Prinzmetal's) 349
angiography
cardiac *see* cardiac catheterization
peripheral arterial disease 1055
see also coronary angiography; pulmonary angiography
angiotensin-converting enzyme inhibitors (ACEIs)
acute myocarditis 787–8
aortic disease 1085
aortic regurgitation 888–9
aortic stenosis 881
asymptomatic left ventricular systolic dysfunction 748
atrial fibrillation prophylaxis 568–72
Chagas' cardiomyopathy 834
chronic stable angina 347
cost effectiveness 44
heart failure 761–3, 768, 772, 1165
atrial fibrillation prevention 569–71
cost-effectiveness 763
prevention 744–5, 746, 762–3
hypertension 171, 172, 173, 174
atrial fibrillation prevention 571
heart failure prevention 744–6
obese patients 225
peripheral arterial disease 1057–8
NSTE acute coronary syndrome 435, 1149
pregnancy 1001
renal disease 1114
STEMI 498, 518, 521
arrhythmia prevention 519
heart failure 498
heart failure prevention 746
stroke prevention 980
sudden cardiac death prevention 622
angiotensin receptor blockers (ARBs)
acute myocarditis 787–8
aortic disease 1085
asymptomatic left ventricular systolic dysfunction 748, 749
atrial fibrillation prophylaxis 568–72
chronic stable angina 347
heart failure 763–4, 772, 1166
atrial fibrillation prevention 569–71
prevention 745
hypertension 171, 172, 173
atrial fibrillation prevention 571
heart failure prevention 745
obese patients 225
NSTE acute coronary syndrome 435, 1149
pregnancy 1001
renal disease 1114
STEMI 518, 521
stroke prevention 980
sudden cardiac death prevention 622
angiotensin type 1 receptor (AGTR1) gene polymorphism 276
Anglo-Scandinavian Study of Early Thrombolysis (ASSET) 459
animal models 304
anisoylated plasminogen streptokinase activator complex (APSAC) (anistreplase), acute STEMI 462, 482
ankle brachial index (ABI) 1053, 1054
ankyrin-B mutations 711
ANRIL gene 279
antepartum management, women with heart disease 999–1001
anterior spinal artery damage 1092
anthracycline cardiomyopathy 743, 747
antianginal therapy *see* anti-ischemic therapy
antiarrhythmic drugs (AADs)
acute myocarditis 790–1
atrial fibrillation *see under* atrial fibrillation
atrial flutter 611
atrial tachycardia 610
atrioventricular nodal re-entrant tachycardia 612
atrioventricular reciprocating tachycardia 614
cardiac arrest 697
Chagas' cardiomyopathy 832–4
class IA, atrial fibrillation 537
class IC, atrial fibrillation 546
class III, atrial fibrillation 548–9
heart failure 769
ICD recipients 626–9
paroxysmal supraventricular tachycardia 608
postinfarction 7, 504–5, 519
pregnancy 1000
sudden cardiac death prevention 619–21
antibiotics
group A streptococcal pharyngitis 862–4
infective endocarditis prophylaxis 953
labor and delivery 1001–2
infective endocarditis therapy 944–5, 946–50
pericarditis 849
rheumatic carditis 811–12, 864
rheumatic fever 864

- antibody-mediated rejection, cardiac allografts 1104, Plate 68.2
- anticoagulation
 aircraft pilots 81, 87
 atrial fibrillation *see under* atrial fibrillation
 atrial flutter 591, 611
 Chagas' cardiomyopathy 836
 Eisenmenger syndrome 1024
 infective endocarditis 952
 left atrial thrombus 917
 mechanisms of action 428, 476
 mitral stenosis 921
 NSTEMI acute coronary syndrome 427–31, 1145–6
 PCI 368–9
 portopulmonary hypertension 1128
 pregnant women 1000–1
 prosthetic valve recipients 959–60
 bioprosthetic valves 964–5
 mechanical valves 961–4
 starting dose 959–60
 young women 875
 pulmonary hypertension 1127
 renal insufficiency 1115
 rheumatic carditis 864
 secondary stroke prevention 982–3
 STEMI
 acute 449, 481–90
 intracavitary thrombus 502, 1154
 long-term 521
 stroke
 acute 977, 978
 secondary prevention 982–3
 venous thromboembolism 1039–41
see also heparin; oral anticoagulants; warfarin
- antidepressants
 postinfarction patients 206, 507
 smoking cessation 132, 133
- anti-HLA antibodies, heart transplantation 1102, 1104
- antihypertensive agents 169–74
 active-controlled trials 171–4
 acute stroke 974
 aortic disease 1085
 cost effectiveness 175
 heart failure prevention 744–6
 newer agents 174
 obesity 225
 peripheral arterial disease 1057–8
 placebo-controlled trials 169–71
 pregnancy 1001
 stroke prevention 979–80
 treatment goals 165
- anti-interleukin-6 (IL6) antibody therapy 1105–6
- anti-ischemic therapy
 chronic stable angina 346, 347–50
 combinations 350
 newer agents 350–1
 NSTEMI acute coronary syndrome 420–2
- antiobesity drugs 226–7
- antioxidants 310–11
- ANTIPAF trial 572
- antiplatelet therapy
 acute STEMI 449, 475–81
 acute stroke 977
 atrial fibrillation 582–5
 chronic stable angina 347
 heart failure prevention 747
 infective endocarditis 952–3
 NSTEMI acute coronary syndrome 422–7, 430–1, 1145, 1149
 PCI 365–6
 perioperative 57
 peripheral arterial disease 1058–60
 postinfarction, long-term 521
 prosthetic valve recipients 962, 963–5
 renal insufficiency 1115
 secondary stroke prevention 981–2
 sites of action 476
 Antiplatelet Trialists' Collaboration 422–3, 1058, 1059
- antipyretic agents, acute stroke 973–4
- antiretroviral therapy, highly active (HAART) 1161
- anti-T cell receptor monoclonal antibody OKT3 1102, 1104
- antithrombin III (AT III) 481
 deficiency 1035
- antithrombotic therapy
 acute STEMI 475–91, 1153
 prehospital 449
 safety 461, 475
 atrial fibrillation 581–92
 atrial flutter 591, 611
 mechanisms of action 476
 NSTEMI acute coronary syndrome 422–31, 1145–7
 PCI 365–9
 prosthetic valve recipients 957
see also anticoagulation; antiplatelet therapy
- antithymocyte globulin 1102
- anti-TNF therapy, heart failure 769–70
- antituberculosis chemotherapy 850–2
- antiviral treatment, acute myocarditis 789
- anxiety
 coronary artery disease and 203, 205
 interventions 205
- aorta
 coarctation of *see* coarctation of aorta
 ectasia 1080
 intramural hematoma *see* intramural hematoma (IMH) of thoracic aorta
 penetrating atherosclerotic ulcer *see* penetrating atherosclerotic ulcer (PAU) of thoracic aorta
 traumatic transection 1089–90
- aortic aneurysms
 abdominal
 genetic factors 278
 serum cholesterol and 142
 acute presentation *see* acute aortic syndromes
 ascending thoracic
 aortic valve-sparing operations 928–9, 1088
 bicuspid aortic valve and *see under* bicuspid aortic valve
 management 1087–8, 1089, 1090–1
 Sundt classification 1080, 1081
 chronic, management 1090–3
 congenital causes 1082, 1084
 degenerative 1079–80
 descending thoracic
 management 1089, 1091–3
 Safi classification 1080, 1081
 etiology 1079–80
 familial thoracic 289, 1085
 management 1087, 1090–1
 pathophysiology 1086
 thoracic 1079–94
 diagnosis 1086
 diameter 1079, 1084–5
 incidence 1082–4
 management 1086–9, 1090–3
 natural history and prognosis 1084–6
 nomenclature and definitions 1079–82
 pathophysiology 1085–6
 prevention of rupture 1085
 thoracoabdominal
 Crawford classification 1080, 1082
 management 1089, 1091–3
- aortic annulus dilation 929
- aortic arch surgery
 acute disease 1087–8, 1089
 chronic disease 1090–1, 1092
- aortic cusp repair 927
- aortic disease 1079–94
 acute *see* acute aortic syndromes
 chronic 1090–3
 diagnosis 1086
 genetics 289
 incidence 1082–4
 management 1086–93
 natural history and prognosis 1084–6
- nomenclature and definitions 1079–82
 pregnancy and 994–5
 subacute 1090
 aortic dissection 1079, 1080–2
 acute 1081
 management 1087, 1088, 1089, 1089
 bicuspid aortic valve and 1086
 chronic 1080
 management 1090–3
 DeBakey or Stanford classification 1081, 1083
 diagnosis 1086
 incidence 1084
 non-communicating 1082
 pathogenesis 1080–1, 1083
 pregnancy 994–5
 variant forms 1081–2
- aortic insufficiency (AI) *see* aortic regurgitation
- aortic pseudoaneurysms, traumatic 1079–80, 1089–90
- aortic regurgitation (AR)
 acute 888
 aortic valve repair 889, 891, 927–9
 asymptomatic 886, 891
 chronic 885–91
 etiology 885
 management 888–9
 medical management 888–9
 natural history 885–8
 surgical management 889–91, 892
 infective endocarditis 945
 mitral balloon valvuloplasty and 916
 paravalvular (PVAR), transcatheter prosthetic valves 905, 906, 907–8
 pregnancy and 994
 rheumatic 886–7
 syphilitic 886
- aortic root 927
 aneurysms/dissection
 management 928, 1087–8, 1090–1
 pregnancy 994–5
 replacement 928, 934, 1079, 1087–8
 and valve, composite graft replacement 928, 929, 1087–8
 valve-sparing operations 928, 1088
- aortic stenosis (AS) 878–85
 aircraft pilots 81, 82
 asymptomatic 884–5, 1187–9
 calcific (degenerative) 878, 896
 congenital valvar 878, 1012
 management 927, 1013–14
 outcomes and complications 1014
 endocarditis prophylaxis 881, 1188
 etiology 878
 grading 878–9
 low gradient 884, 885
 management 881–5
 medical management 881
 mild 879, 880
 moderate 879, 880
 natural history 880–1, 896–7
 non-cardiac surgery 1070–1
 non-surgical valve therapy 896–909
 pathophysiology 896
 pregnancy and 994, 996
 severe 879–80
 subvalvar (SAS) 1012, 1013, 1014
 supravalvar (SVAS) 1012, 1013
 surgical management 881–5, 886, 896
 syncope 679
 timing of surgery 1187–9
- aortic valve
 area 879
 bicuspid *see* bicuspid aortic valve
 disease 878–92
 endocarditis 952
 homograft bioprosthetic valve 934
 non-surgical therapy 896–909
 stenosis *see* aortic stenosis
- aortic valve repair 927–9
 aortic regurgitation 889, 891, 927–9
 aortic valve-sparing operations with 928–9

Index

- aortic valve replacement (AVR)
aortic aneurysm repair with 928, 1087–8
aortic regurgitation 889–91
asymptomatic patients 891
guidelines 891, 892
aortic stenosis 881–5
asymptomatic patients 884–5, 1187–9
with heart failure 882–3, 884
indications and risk 897–8
low gradient 884, 885
recommendations 886, 897, 909
balloon valvuloplasty as bridge to 883, 904
choice of valve 931–5
non-surgical alternatives 896–909
transcatheter *see* transcatheter aortic valve replacement
aortic valve-sparing operations 928–9, 1088
aortic valvuloplasty, percutaneous balloon *see* percutaneous balloon aortic valvuloplasty
aorto-atrial fistulas, infective endocarditis 952
aorto-bifemoral bypass surgery 1062
aorto-ostial lesions, PCI 373
aortopathies *see* aortic disease
aortoplasty procedures 1087
aorto-ventricular fistulas, infective endocarditis 952
APAF study 598–9
apixaban, atrial fibrillation 586
apolipoprotein A-I (Apo A-I) 143, 270
deficiency (*APOA1* mutations) 270, 271
drugs increasing production 1160–1
Milano 155, 270–2, 1160
proteoliposomes, intravenous injection 1160
apolipoprotein B (Apo B) 138, 150
familial defective 270, 271
gene polymorphism 276
apolipoprotein B:apolipoprotein A1 ratio 148
apolipoprotein E (Apo E) epsilon-2/3/4 isoform polymorphisms 275, 276
Appropriate Blood Pressure Control in Diabetes trial 1057
Arab populations 244–6
ARCH study 560
AREVA trial 962
ARGAMI-2 study 487–8, 489
argatroban
acute STEMI 487–8
NSTEMI acute coronary syndrome 430
L-arginine 1124
ARGMI-2 Trial 742
ARH gene mutations 271
ARMYDA-2 trial 366
ARMYDA-3 trial 575
arrhythmias
adult congenital heart disease 1024–5
amyloidosis 812–13
Chagas' disease 830, 832–4
dietary influences 307–8, 314
heart transplant recipients 1104–5
monogenic disorders 706–15
postinfarction 504–5
management 504–5
prevention 519–20, 522
risk factors 519
pregnant women with heart disease 993, 994, 996, 1000
syncope 676, 677, 678–9, 685
see also specific arrhythmias
arrhythmogenic right ventricular cardiomyopathy (ARVC) 714–15, 721–7
clinical features 724
diagnosis 724–6
epidemiology 722
future directions 727
genetics 289, 295–6, 710, 714–15, 722–3
history 721–2
ICD therapy 629, 715, 726–7
management 715, 726–7
natural history 723–4
pathology 722
arterial calcification, genetic factors 268
arterial grafts, CABG 384–6
Arterial Revascularization Therapy Study *see* ARTS
ARTS 345, 398
ARTS-II 399–400
ARVC *see* arrhythmogenic right ventricular cardiomyopathy
ascorbic acid 310
ASCOT study 172–4
ASPEN study 159
ASPIRE trial 369
aspirin (acetylsalicylic acid; ASA)
acute pericarditis 847
acute STEMI 448, 449, 476–7, 1152–3
acute stroke 972, 977, 979
aircraft pilots 87
atrial fibrillation 582–5, 589, 591
chronic stable angina 347
heart failure prevention 747
infective endocarditis 952–3
NSTEMI acute coronary syndrome 422–3, 430, 431, 1145
longer term 435, 1149
PCI 365, 366
perioperative 57
peripheral arterial disease 1059, 1060
postinfarction pericarditis 501–2
pregnancy 1001
prosthetic valve recipients 962, 963–4, 965
resistance 423
rheumatic fever 864–5
STEMI long-term 521
stroke prevention 28, 981–2
venous thromboprophylaxis 1033, 1043
ASSENT-II study 462, 463
ASSENT-3 trial 479, 485
ASSENT-PLUS trial 484
ASSET study 459
A-STAR study 550
asthma 578
asymmetric dimethylarginin (ADMA) 1114
Asymptomatic Cardiac Ischemia Pilot study *see* ACIP study
asystole, transcatheter pacing 699
ATACS trial 430
atenolol
atrial fibrillation 558, 560
chronic stable angina 349
hypertension 172, 173, 175
perioperative 55, 1073
ATHENA study 552, 553, 557
atherectomy
percutaneous coronary 363
peripheral arterial disease 1062
atherosclerosis
acute coronary syndromes and 418
aortic valve stenosis 878
carotid arteries 984
development in youth 258–9
exercise benefits 197
fetal/childhood health and 260
genetic factors 268, 278, 297, 298
heart failure prevention 746–7
pathophysiology of angina 346
peripheral arterial disease 1050
prevention *see* prevention of cardiovascular disease
psychosocial influences 202
risk factors *see* risk factors, cardiovascular
smoking-related 126
Atherosclerosis Risk in Communities (ARIC) study 216, 315
atherosclerotic plaque
culprit lesions, acute coronary syndromes 418
passivation therapies 433–5
ruptured or fissured 409, 418
athletes, sinus bradycardia 644, 1179
ATLAS trial 762
atorvastatin 150, 151
animal model of hypertrophic cardiomyopathy 300
atrial fibrillation prevention 572–4, 575
cholesterol-lowering efficacy 144
combination therapy 157
cost-effectiveness 160
diabetes mellitus 159
elderly 158
heart failure prevention 745, 746
NSTEMI acute coronary syndrome 433–5, 1149
perioperative 57, 1076, 1184
secondary prevention of MI 1157–8
secondary stroke prevention 983
ATP binding cassette transporter (ABCA1) gene 271, 297
Atrial arrhythmia Conversion Trials (ACT) 542, 543
atrial fibrillation (AF) 531–61
ablation therapy 532, 596–603
ablate and pace strategy 599–600, 650
antiarrhythmic drug use 554
anticoagulation 591, 592–3
case history 1172
complications 601–3
non-randomized trials in patient subgroups 600–1
principle 597, Plate 38.1
randomized controlled trials 597–600, 601
statins after 575
after cardiac surgery 557–61
corticosteroid prophylaxis 576, 577
pharmacologic prevention 559–61
prevalence and risk factors 559
rate vs. rhythm control 559
statins for prevention 575
aircraft pilots 85–7, 88
antiarrhythmic agents
acute cardioversion 537–42
after cardiac surgery 561
after left atrial ablation 554
with electrical cardioversion 541
prophylactic 542–53
rate control 557
site of initiation 554
vs. ablation therapy 597–600
vs. rate control strategies 532–7, 596–7
anticoagulation 581–2, 592–3
adjusted dose 584–5
after stroke 587, 982
cardioversion 590–1
case history 1171, 1172
evidence-based decision making 4, 5
gaps in implementing evidence 64, 65
hemorrhage risk 587–8
postinfarction 591
rate vs. rhythm control 588–9
surgical procedures 591–2
vs. aspirin 582–4
antiplatelet therapy 582–5, 592
antithrombotic therapy 581–92
cardioversion 590–1
coronary artery disease 591
decision aids 10–11
evidence-based decision making 4, 5–6, 8–9, 10–11
hemorrhage risk 587–8
recommendations 589–90
risk stratification 586–8
cardioversion
antiarrhythmic drugs after 542–4
antiarrhythmic drugs with 542
antithrombotic therapy 590–1, 592
pharmacologic 537–42
statins after 574–5
case history 1170–3
CHADS₂ index 587, 592
congenital heart disease 1025
coronary artery disease and 572–4, 591
corticosteroids and 576, 577–8
device-based therapy 597

- familial 291–2, **707**, 708–9
genetics 708–9
heart failure with *see under* heart failure
HEMORR₂HAGES scheme 588
hypertrophic cardiomyopathy 587, 600–1, 802
lifetime risk 531
lone
 monogenic forms 708
 prophylactic antiarrhythmics 544, 545
 stroke risk 581
mitral regurgitation 872
mitral stenosis 917
 balloon mitral valvuloplasty 914–15, 916, 921
 non-rheumatic 581
 non-valvular (NVAf) 581
pacemaker therapy 597, **639**, 653
 ablate and pace strategy 599–600, 650
 preventive role 646–8
paroxysmal 531, 581
 antithrombotic therapy 581–92
 “pill in the pocket” approach 537
 prophylactic ACEIs and ARBs 572
 prophylactic antiarrhythmics 542–53
 rate control 556–7
 rate vs. rhythm control 532–3
 stroke risk 587
permanent 531, 581
 rate control 557–9
persistent 531, 581
 antithrombotic therapy 581–92
 corticosteroids **576**, 577–8
 prophylactic ACEIs and ARBs 571–2
 prophylactic antiarrhythmics 542–53
 rate control 556–7
 rate vs. rhythm control 533–6
 stroke risk 587
postinfarction 505–6, 591, 593
pregnant women with heart disease 996, 1000
primary prevention 531–2
principles of therapy 531–2
rate control 554–9
 acute 554–6
 after cardiac surgery 559
 long-term 557–9
 vs. rhythm control 532–7, 588–9
recent (new)-onset, anticoagulation 587, 592
recurrent 581, 587
rhythm control 532, 537–42
 advantages 596–7
 after cardiac surgery 559
 catheter-based *see* atrial fibrillation (AF),
 ablation therapy
 inadequacy of non-ablative 597
 pharmacologic cardioversion 537–42
 prophylactic antiarrhythmics 542–53
 vs. rate control 532–7, 588–9
secondary prevention 531–2
stroke risk 86–7, 581, 586–7
 see also under stroke
upstream therapies 531–2, 568–78
Atrial Fibrillation Congestive Heart Failure (AF
 CHF) study **535**, 536–7
Atrial Fibrillation Investigators 582, 586–7
atrial flutter 610–12
 acute cardioversion 539, 611
 after oral cardioversion of AF 539
 antithrombotic therapy 591, 611
 atypical, after left atrial ablation 602, 603,
 Plate 38.2, Plate 38.3
 case history 1171
 genetic factors 709
 long-term management 611–12
atrial natriuretic peptide, STEMI 518
atrial septal defect (ASD) 1007–9
 after balloon mitral valvuloplasty 921
 diagnostic evaluation 1008
 management 1008–9
 outcomes and complications 1009
 pregnancy 993
atrial septostomy, pulmonary hypertension 1126
atrial standstill, inherited 707
atrial switch procedures (Senning and Mustard)
 1020
 late complications **1021**, 1024, 1025
 pregnancy after 995–6
atrial tachyarrhythmias, genetics **707**, 708–11
atrial tachycardia 609–10
 focal 609
 multifocal 610
 non-paroxysmal 606
 paroxysmal 610
 re-entrant 610
atrio-esophageal fistula, left atrial ablation 602
atrioventricular (AV) block 642–4
 complete (CHB) (third degree)
 case history 1179–80, 1181
 congenital **641**, 643, 678
 congenital heart disease 1025
 pacing **637–8**, 642–3
 first degree **637**, 642
 new paradigm for physiologic pacing 648–9
 pacemaker mode selection 644–8, 650, 1179–81
 postinfarction 506, **638**, 643–4
 second degree **637**, 642
 syncope 676, 678
atrioventricular nodal re-entrant tachycardia
 (AVNRT) 606, 612
 ablation therapy 609, 612
 acute management 607–8, 612
 evaluation 607
atrioventricular reciprocating tachycardia 613–14
 antidromic 613
 orthodromic 613
 permanent junctional 613
atrioventricular re-entrant tachycardia
 (AVRT) 606, 607–9, 614
atrioventricular septal defect (AVSD) 1010–12, 1025
 management 1011–12
 pregnancy 993–4
atropine, cardiac arrest 698
attitudes, barriers to changing 67
audit, and data feedback systems 69–70, 71
Australia, cardiovascular mortality 95
Australia-New Zealand Heart Failure Trial 749
autoimmune disease
 acute pericarditis 846
 Chagas’ cardiomyopathy 828–9
 myocarditis **785**, 786
automatic junctional tachycardia (AJT) 612–13
autonomic dysfunction
 benefits of exercise 196
 Chagas’ disease 827–8, 830
 syncope 678
autosomal dominant inheritance 289
autosomal recessive inheritance 289–90
AVERT study 150, 370
aviation 79–90
 1% rule and best evidence 81–3
 accidents due to medical cause 80–1
 atrial fibrillation 85–7, 88
 cardiology workshops 81
 cardiovascular disease prevention 83–4
 coronary artery disease 84–5, 86
 environment 80
 health maintenance 83
 regulatory control 79–80
 regulatory orphans/long QT syndrome 87–9
AVID study 505, 625–6
AWESOME study 399
axillary artery cannulation, aortic arch surgery 1091
azimilide
 atrial fibrillation 550
 ICD recipients 626–7
 sudden cardiac death prevention 620
BAATAF trial 581–2, **583**
babesiosis 792
bacteremia 942
bacterial endocarditis *see* infective endocarditis
bacterial myocarditis 810–12
bacterial pericarditis 849–50
BAFTA trial 584, 588
Bahrain 246
balloon angioplasty *see* percutaneous transluminal
 coronary angioplasty
Baltimore Longitudinal Study of Ageing (BLSA)
 315
BARI trial 398, 400, 401
BARI 2D trial 373, 380, 401
bariatric surgery 227–30
Barlow’s disease of mitral valve 930
basic life support, adult 692–5
BASIL study 1062
Batista’s surgery 834–5
Bayesian risk models 17–18, 19, 48
bedrest
 acute coronary syndromes 419
 acute pericarditis 847
 rheumatic fever 864
beedie smoking 243
behavior, barriers to changing 67
Behavioral Risk Factor Surveillance System
 (BRFSS) 249–50
behavioral therapy, obesity 224
Belgian Salt Intervention Trial 312
benazepril, hypertension **173**, 174
bendroflumethiazide, hypertension 172–4
BENEFIT study 630
BENESTENT-1 trial 359
benzathine penicillin G
 group A streptococcal pharyngitis 862–3, **866**
 rheumatic carditis 864, **866**
benznidazole, Chagas’ disease 830, 831, 832, 833
beraprost
 intermittent claudication 1061
 pulmonary hypertension 1126
BEST trial 767
beta-1 adrenergic receptor gene polymorphisms
 767
Beta Blocker Heart Attack Trial 213
beta-blockers
 acute myocarditis 788–9
 amiodarone interaction 620
 aortic disease 1085, 1087, 1092
 asymptomatic left ventricular systolic
 dysfunction 748–9
 atrial fibrillation 541, 544
 acute rate control 554–5
 after cardiac surgery 559–60
 long-term rate control 556, 558–9
 postinfarction 506
 atrial tachycardia 609–10
 atrioventricular nodal re-entrant
 tachycardia 612
 atrioventricular reciprocating tachycardia 613
 automatic junctional tachycardia 612
 catecholaminergic polymorphic ventricular
 tachycardia 713
 Chagas’ cardiomyopathy 834
 chronic stable angina 348–9
 cost effectiveness **44**
 heart failure 765–8, 769, 1166
 prevention **744**, 768
 hypertension 169–70, 172, **173**
 obesity 225
 pharmacogenetics 174–5
 hypertrophic cardiomyopathy 799
 ICD recipients 626
 long QT syndrome 711–12
 non-paroxysmal junctional tachycardia 613
 NSTEMI acute coronary syndrome 420–1, 433,
 435, 1149
 paroxysmal supraventricular tachycardia 608
 perioperative 54–6, 1073–5, **1077**, 1183–4
 pregnant women 994, 995, 997, 1000
 renal insufficiency 1115
 sinus tachycardia 609
STEMI
 acute phase **448**, 449
 heart failure prevention **744**, 768
 long-term use 521, 621
 prevention of arrhythmias 504, 505, 519
 prevention of remodeling 518

Index

- beta-blockers (*cont.*)
sudden cardiac death prevention 621
vasodilator, hypertension 174
vasovagal syncope 684
- beta-type natriuretic peptides *see* brain natriuretic peptide
- bezafibrate 143
peripheral arterial disease 1058
secondary prevention of MI 1159
- bicuspid aortic valve (BAV) 878, 1012–14
aortic aneurysmal disease 1080, 1086, 1087
coarctation of aorta and 1014
pregnancy and 994, 995, 1000
prophylactic replacement of ascending aorta 1086
timing of surgery 1187–9
transmission to offspring 999
- bifascicular block, pacing indications 638, 643
- bile acid sequestrants (resins) 152, 153–4
combination therapy 156–7, 157
- biliopancreatic diversion 228, 229
- biochemical markers, cardiac *see* biomarkers, cardiac
- biologic aortic root prostheses 1088
- BIOMACS-II study 484
- biomarkers, cardiac
acute myocarditis 786
incremental prognostic value 21
NSTE acute coronary syndrome 410–11, 415–17
postinfarction left ventricular dysfunction 497
postoperative monitoring 53
- bioprosthetic heart valves 931, 958–9, 960
aortic homograft 934
balloon valvuloplasty 921
bovine pericardial 959
new developments 931–5
porcine 959
pregnancy and 875, 994
pulmonary autograft 934–5
selection 935, 936
stentless xenograft 934
structural deterioration 929, 933
thromboembolism risk 960
thrombogenicity 958–9
vs. mechanical 931, 932
young women 875
- birth weight
adult cardiovascular disease and 259–60
cardiovascular risk factors and 260–1, 262, 263
- bisoprolol
atrial fibrillation 558
heart failure 766, 768
perioperative 55, 1073
- bivalirudin
acute STEMI 487, 488
comparative properties 484
NSTE acute coronary syndrome 429–30, 431, 1146–7
PCI 368–9
- Bjork–Shiley valve 931, 934, 958
- black African populations 250–1
see also Africa, sub-Saharan; African Americans
- Blalock–Taussig shunt 1022
- bleeding/hemorrhage
antithrombotic therapy-associated
atrial fibrillation 582, 583–4, 587–8
NSTE acute coronary syndrome 425, 427, 430, 1148
prosthetic valve recipients 962–3
stroke 981
venous thromboembolism 1041
defined 928
fibrinolytic therapy-associated 461, 975
valve replacement surgery 931, 932
- bleomycin, intrapericardial 854
- blinding, treatment allocation and outcome assessment 27
- BLOCK-HF trial 650
- blood cultures, infective endocarditis 942–3, 945
- blood letting 3
- blood pressure (BP) 165–75
calcium and magnesium intake and 313
classification 165, 166
continuum of risk 102–4
definitions 165
diastolic (DBP) 165
fetal determinants 260–1, 262
fruit and vegetable consumption and 314
management 168–74
acute stroke 974
after STEMI 520
multiple risk factor interventions 332, 335–6
secondary stroke prevention 979–80
see also antihypertensive agents
natural history 166–8
potassium intake and 312
sodium intake and 311–12, 319
systolic (SBP) 165
see also hypertension; hypotension
- Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTCC) 744–5
- blood transfusion, preoperative 1070
- BLOS study 559
- BNP *see* brain natriuretic peptide
- body composition, early influences 261, 262, 263
- body mass index (BMI) 221, 222
- body size, early influences 262, 263
- bone morphogenetic protein receptor II (BMPRII) mutations 1123
- bosentan
Eisenmenger syndrome 1024
heart failure 770
pulmonary hypertension 1124, 1127
- Boston–Irish Diet Heart Study 101
- brachial flow-mediated dilation (FMD), children and adolescents 258–9
- brachiocephalic perfusion, aortic arch surgery 1091
- brachytherapy, coronary in-stent thrombosis 1155
- bradyarrhythmias/bradycardia
pacemaker therapy 642, 644, 834, 1178–81
postcardiac transplantation 654
- bradykinin, pulmonary hypertension 1126
- brain death 1101
- brain natriuretic peptide (BNP)
aortic stenosis 879
heart failure 760, 773
incremental prognostic value 21
NSTE acute coronary syndrome 416–17
postinfarction left ventricular dysfunction 497
preoperative risk estimation 51–2
prohormone N-terminal fragment (NT-proBNP) NSTE acute coronary syndrome 416–17
preoperative risk estimation 51–2
therapy *see* nesiritide
- breast-fed infants 262, 263
- BRIGHT study 174
- British Regional Heart Study 193, 194, 212–13
- Bromley Heart Failure study 742
- Brugada syndrome 713–14
genetics 289, 291, 707, 710
ICD therapy 630, 713–14
syncope 675
- bruits, arterial 1053
- bucindolol, heart failure 767
- budiodarone, atrial fibrillation 553
- buffers, cardiac arrest 698
- bufomedil, intermittent claudication 1061
- bundle branch block
postinfarction 506, 643–4
see also left bundle branch block; right bundle branch block
- bupropion, smoking cessation 119, 132, 133, 1055–6
- Bypass Angioplasty Revascularization Investigation trial *see* BARI trial
- CABG *see* coronary artery bypass grafting
- CABG-Patch trial 520, 623
- CACAF study 598
- CAD *see* coronary artery disease
- CADILLAC study 480–1
- CAFA trial 581–2, 583
- calcium, dietary intake 313
- calcium channel blockers (CCBs)
acute myocarditis 789
aortic disease 1085
atrial fibrillation
cardioversion 541, 542
rate control 554–5, 556, 558–9
atrial tachycardia 609, 610
atrioventricular nodal re-entrant tachycardia 612
chronic stable angina 349
heart failure prevention 744, 745
heart failure therapy 761
hypertension 171, 172–4
intermittent claudication 1061
NSTE acute coronary syndrome 420–1, 435
paroxysmal supraventricular tachycardia 607
pulmonary hypertension 1126, 1127, 1128
sinus tachycardia 609
- calf vein thrombosis 1032, 1036
- Calgary Syncope Score 1179
- California Tobacco Control Program 117, 118
- caloric restriction 224
- calsequestrin 2 mutations 713
- CAMIAT study 504–5, 620
- Canada 238
Aboriginal populations 248–50
cardiovascular mortality 95
tobacco control 122
see also European populations
- Canadian Cardiovascular Classification 411
- Canadian Implantable Defibrillator Study (CIDS) 505, 625–6
- Canadian Multicenter Trial 422
- Canadian Registry of Atrial Fibrillation (CARAF) 531
- Canadian Trial of Atrial Fibrillation (CTAF) 546, 547, 548–9, 550
- Canadian Trial of Physiologic Pacing (CTOPP) 645, 646, 1180
- cancer
heart transplant recipients 1105–6
pericardial disease 853–4
treatment, cardiomyopathy after 743
venous thromboembolism 1041
- candesartan
acute myocarditis 788
atrial fibrillation prevention 572
heart failure 571, 763–4, 772
- candidate gene–association studies 275–6
- cangrelor 423
- capadenoson, atrial fibrillation 556
- CAPRICORN study 519, 749, 768
- CAPRIE study 347, 423, 981, 1059
- captopril
acute coronary syndromes 1149
acute myocarditis 787–8
aortic regurgitation 888
heart failure 762, 763, 1165
hypertension 571
- Captopril-Digoxin Multicenter Research Group trial 756–7
- Captopril Prevention Project (CAPPP) trial 27, 570, 571
- CAPTURE trial 416, 425
- carbohydrates, dietary 308–9
- carboplatin, intrapericardial 854
- carboxyhemoglobin 126
- cardiac arrest 692
drugs for management 697–8
recognition 692–3
see also cardiopulmonary resuscitation; sudden cardiac death
- Cardiac Arrest Study Hamburg (CASH) 505, 625–6
- cardiac biomarkers *see* biomarkers, cardiac
- cardiac catheterization (and angiography)
aortic stenosis 878–9, 1188
atrioventricular septal defect 1011
coarctation of aorta 1015

- Eisenmenger syndrome 1024
 left ventricular outflow tract obstruction 1013
 mitral regurgitation 872
 mitral stenosis 916–17
 patent ductus arteriosus 1016
 pulmonary hypertension 1120, 1123
 tetralogy of Fallot 1019
 ventricular septal defect 1010
- cardiac glycosides
 heart failure 756–7
see also digoxin
- cardiac rehabilitation *see* rehabilitation, cardiac
- cardiac resynchronization therapy (CRT) 655–61, 771, 1167
 atrial fibrillation 656, 657–9, 661
 Chagas' cardiomyopathy 835
 class I or II heart failure 660
 ICD with (CRT-D) 631–2, 656–7, 660–1
 indications 640
 narrow QRS complexes and 659–60
 non-responders 659
 randomized trials 655–7, 658
 STEMI 519
- cardiac revascularization *see* myocardial revascularization
- Cardiac Risk Index
 Modified 48–9
 Original (Goldman) 48–9
 Revised 48–50, 51, 1068
- cardiac surgery
 atrial fibrillation after 559–61, 575
 during pregnancy 994
see also specific procedures
- cardiac transplantation 1099–107
 Chagas' cardiomyopathy 835
 complications 1103–6
 contraindications 1101
 donor selection 1101–2
 Fontan circulation 1023
 historical perspective 1099
 indications 1099, 1100–1
 myocarditis 791
 operative details 1102, 1103
 outcomes 1099–100, 1101
 pacemaker therapy after 640, 654
 postoperative course 1102–4
- cardiogenic shock 498–9
 aortic stenosis with 883
 mitral regurgitation 503
 reperfusion therapy 451, 464, 469, 499
 RV infarction 499–500
 ventricular septal rupture 503–4
- cardiomyopathies
 causes 743
 drug-induced 743, 747
 epidemiologic transition 97
 infective 808–12
 infiltrative 812–16
 peripartum 996–7
 sudden cardiac death prevention 629–30
 tachycardia-mediated 606
see also specific cardiomyopathies
- Cardiomyopathy Trial (CAT) 624–5, 626
- cardiopulmonary bypass (CPB), CABG with 379, 382
- cardiopulmonary resuscitation (CPR) 692–700
 active compression decompression (ACD) 699
 adult basic life support 692–5
 advanced life support 695–8
 airway and ventilation 693
 chest compression-only 694–5
 chest compressions 693–5
 compression/ventilation ratio 694
 before defibrillation 695
 establishing evidence base 692
 load-distributing band 699
 Lund University Cardiac Arrest System (LUCAS) device 699
 mechanical (piston) 699
 prompt devices 699
 techniques and devices assisting 695–6
- cardiovascular disease (CVD)
 epidemic *see* epidemic of cardiovascular disease
 global perspective 95–107
 global projections 98–9
 mortality *see* mortality
 prevention *see* prevention of cardiovascular disease
 resource utilization 38–9
 syncope 679
- Cardiovascular Health Study 575–7
- cardiovascular reactivity, psychosocial influences 202
- cardioversion
 atrial fibrillation *see under* atrial fibrillation
 atrial flutter 539, 611
 atrial tachycardia 609–10, 611
 atrioventricular reciprocating tachycardia 613
 electrical *see* electrical (DC) cardioversion
- CARDS trial 159
- CARE-HF study 632, 657, 660–1, 1167
- CARE study 150, 157, 158–9, 521, 745, 746
- CARISA trial 350
- CARMEN trial 749
- carotid artery angioplasty and stenting 985
- carotid artery stenosis 984–5
- carotid endarterectomy 984–5
- carotid intima-media thickness (cIMT)
 children and adolescents 258–9
 fetal/childhood health and 260
 genetic factors 268
- carotid revascularization 984–5
- carotid sinus massage (CSM) 678, 680
- carotid sinus syndrome (CSS)
 diagnosis 677–8
 pacing indications 639, 651
 syncope 675
 treatment 684–5
- Carpentier–Edwards bovine pericardial valve 960
- Carpentier–Edwards porcine valve 931, 933, 934
- carteolol, acute myocarditis 788
- carvedilol
 asymptomatic left ventricular systolic dysfunction 749
 atrial fibrillation 544, 558
 Chagas' cardiomyopathy 834
 chronic stable angina 349
 heart failure 766, 767, 768, 1166
 STEMI 519
- cascade screening, familial hypercholesterolemia 281
- CASCADE study 621
- case–control studies 35
- case management 70–1, 106
- CASS *see* Coronary Artery Surgery Study
- CAST study 619–20, 769, 977
- catecholaminergic polymorphic ventricular tachycardia (CPVT) 630, 713
 genetics 707, 710, 713
- catheter ablation
 arrhythmogenic right ventricular cardiomyopathy 726
 atrial fibrillation *see* atrial fibrillation (AF), ablation therapy
 atrial flutter 611–12, 1171
 atrial tachycardia 610
 atrioventricular nodal re-entrant tachycardia 609, 612
 atrioventricular reciprocating tachycardia 613–14
 automatic junctional tachycardia 612
 cost effectiveness 44
 inter-atrial re-entrant tachycardia 1025
 paroxysmal supraventricular tachycardia 609
 sinus tachycardia 609
- CAVATAS 985
- CDKN2A gene 278, 279
- CDKN2B gene 278, 279
- cefazolin, infective endocarditis 950
- cefibuten, group A streptococcal pharyngitis 863
- ceftriaxone, infective endocarditis 946, 947
- celivarone, atrial fibrillation 553
- Centers for Medicare & Medicaid Services (CMS) 71
- Central Europe 96
- central nervous system modulators, heart failure 768–9
- central obesity *see* obesity, abdominal
- cephalosporins, group A streptococcal pharyngitis 863
- cerebellar infarction, surgical intervention 978
- cerebral edema, acute ischemic stroke 978
- cerebral infarction
 imaging 973
 malignant 972, 978
see also stroke
- cerebral thromboembolism *see* stroke, ischemic
- cerebrovascular accident *see* stroke
- cerebrovascular disease (CbVD)
 ethnic groups 238, 242, 246, 247
 mortality 95–6
 smoking-related risks 113, 114
 syncope 679
see also stroke
- cervastatin 149, 151
- certificate-of-need (CON) programs 72
- CETP *see* cholesteryl ester transfer protein
- CHADS₂ index 587, 592
- Chagas' cardiomyopathy (CCC) 792, 823–37
 arrhythmias 830, 832–4
 clinical features 829–30
 device therapy 629–30, 832–4
 epidemiology 824
 heart failure 743, 829, 830
 prognosis 825, 826
 treatment 834, 835
 management 830–6
 natural history 825
 pathogenesis 827–9
 prevention 747, 836–7
 prognosis 826–7
 thromboembolism 830, 835–6
- Chagas' disease 823–37
 acute phase 823, 825, 829, 831
 chronic phase 823, 829, 831–2
see also Chagas' cardiomyopathy
 classification of heart involvement 829
 definitions 823–4
 indeterminate form 823, 825–6, 827, 829
 natural history and prognosis 825–7
 trypanocidal therapy 830–2, 833
- Chagas' myocarditis 792, 825, 827, 829
- CHAMPION trials 423
- channelopathies 706–15
 atrial arrhythmias 707, 708–11
 ICD therapy 630
 sudden cardiac death 629
 syncope 675, 679
 ventricular arrhythmias 710, 711–14
- CHARISMA trial 347, 1059, 1149
- CHARITY study 630, 834
- CHARM study 570, 571, 739, 742–3, 763–4
- CHD *see* congenital heart disease; coronary artery disease
- chest compressions
 basic life support 693–5
 devices aiding 699
- chest pain
 angina 345–6
 Chagas' disease 830
 clinical assessment 15
 ECG recording during 414–15
 prehospital management 450
- chest radiography
 atrial septal defect 1008
 atrioventricular septal defect 1011
 coarctation of aorta 1014
 Ebstein anomaly 1018
 Eisenmenger syndrome 1023
 left ventricular outflow tract obstruction 1013
 mitral regurgitation 871
 patent ductus arteriosus 1016
 pulmonary hypertension 1122

Index

- chest radiography (*cont.*)
pulmonary valve stenosis 1017
tetralogy of Fallot 1019
tuberculous pericarditis 850
ventricular septal defect 1010
Cheyne–Stokes breathing 1165
CHF-STAT study 541, **548–9**, 550, 557
children
atherosclerosis development 258–9
determinants of CVD development 262–4
pacemaker therapy **641**
pulmonary arterial hypertension 1126–7
China 98, 240–2
cardiovascular disease epidemic 100, 240
cardiovascular mortality 95, 96, 240
healthcare expenditure 107
migrants from 241–2
prevention strategies 106, 242
risk factors 240–1
tobacco use 112, **113**, 114, 117, 240, 241
Chinese Acute Stroke Trial 587
chlorthalidone
heart failure prevention 744, **745**
hypertension 172, **173**, 174
chocolate 310
cholesterol 306
absorption inhibitors, selective **152**, 155
dietary intake 306
lowering therapy *see* lipid-lowering therapy
serum 138–43, 306
abdominal aortic aneurysm and 142
average concentrations 138
classification **148**
dietary carbohydrates and 308–9
dietary fats and 140–1, 306–7
dietary fiber and 309–10
effects of lipid-lowering agents 140, 150, 152, 153
ethnic variations 240
foods influencing 316
genetic influences 279, **280**
ischemic heart disease and 102–4, 138–40
management policy 144
peripheral arterial disease and 142, 1052
safety of reducing 142–3
as screening test 144
stroke and 141–2, 983
total 138
treatment targets 147–8, **149**
trends over time 333–4
see also high-density lipoprotein (HDL)
cholesterol; low-density lipoprotein (LDL)
cholesterol
Cholesterol Treatment Trialists' collaboration 33
cholesteryl ester transfer protein (CETP) 1160
gene polymorphism 276
inhibitors 155, 1158, 1160
cholestyramine **152**, 153
combination therapy **157**
chordae tendinae
importance of preserving 871, 930
spontaneous rupture 869, 870
chromosomal abnormalities 288
chromosome 9p21 locus 276–9, 281, 297–8
chronic non-communicable diseases 96, 97, 98–9, 235
see also epidemiologic transition
chronic obstructive pulmonary disease (COPD) 578, 1119
chronotropic incompetence **639**, 644, 650, 1179
cibenzoline, atrial fibrillation 546
CIBIS studies 766, 767, 768
ciclosporin
giant cell myocarditis 791
heart transplant recipients 1099, 1102–4
cigarettes
advertising/promotion bans 117–19
smoking *see* smoking
taxation/price increases 116, 120
cilostazol, intermittent claudication 1060–1
cisplatin, intrapericardial **854**
Civil Aviation Authority (CAA) 79, 85
CK1827452, heart failure 760
CLARITY-TIMI-28 trial 477
CLASSICS trial 365
CLEAR PLATELETS 1b trial 368
Clinical and Translational Science Awards (CTSAs) 74–5
clinical applications of evidence 1135–7
clinical assessment 14, 15–17
diagnosis of CAD 15–16
diagnosis of severe CAD 17
prediction of patient outcome 17
clinical expertise 9, 1136
clinical guidelines
barriers to implementing 66–8
improving implementation 68–72
clinical practice
gaps in implementing evidence 63–6
strategies for improving 68–72
clinical prediction tools 5
clinical significance, diagnostic testing 21–3
clinical state/circumstances, decisions based on 5
clinical trials 26–31, 304
avoiding bias 26–8
avoiding random errors 29–30
observational 26, 34–5
see also randomized controlled trials
clofibrate 154
clonidine
atrial fibrillation 556
perioperative 56–7
smoking cessation 133
clopidogrel
atrial fibrillation 585, 591
chronic stable angina 347
heart failure prevention **745**, 747
NSTEMI acute coronary syndrome 423–4, 425, 431, 1145
longer term 435, 1149
PCI 365–6, 368, 477–8
peripheral arterial disease 1059, 1060
renal insufficiency 1115
resistance 425
secondary stroke prevention 981
STEMI 449, 477–8, 521
CLOUT trial 364
coagulase-negative staphylococci 942
coagulation cascade
as therapeutic target 428, 481
thrombus formation 418, 476
coagulation status, psychosocial influences 202, 215
coarctation of aorta 1014–15
management 1015
pregnancy and 994, 1000
cocaine abuse 997
Cochrane Collaboration, Effective Practice and Organization of Care (EPOC) group 69
Cockcroft–Gault (CG) formula 1110–11
cognitive-behavioral therapy 206
cognitive function, after CABG 383
cohort studies 35
colchicine, pericarditis 845, 847, 848
colesevelam 153, 154
combination therapy 156–7
colestipol **152**, 153
combination therapy 156, **157**
COMET trial 767–8
COMMIT/CCS-2 trial 477
COMMIT-metoprolol trial 449
COMMIT trial 55
common disease–common variant hypothesis 273–4
community, simplified model 212
COMPANION trial 631–2, 657, 660–1, 1167
Comparative Risk Assessment (CRA) project 331
COMPASS-HF trial 773
complex (polygenic) disorders 288, 296–9
compliance (adherence)
biased analysis in clinical trials 27–8
long-term rates 63
study power and 30
compression stockings, graduated (GCS) **1042**, 1043
computed tomography (CT)
acute stroke 973
aortic disease 1086
aortic stenosis 879
incremental value 21
infective endocarditis 944
pericardial disease 850, 852
venography 1036–7
computed tomography angiography (CTA)
congenital heart disease 1015, 1016, 1023
peripheral arterial disease 1055
computed tomography pulmonary angiography (CTPA)
pulmonary embolism 1037–8, **1039**
pulmonary hypertension 1122, 1123
conduction disorders
familial **289**
indications for pacing **637–41**
postinfarction 506, 643–4
progressive **707**
syncope 678
confounding 31
congenital heart disease (CHD) 1006–25
arrhythmias 1024–5
cyanotic, pregnancy 995, 998
etiology 1006–7
exercise-related cardiac events 195
genetics 999, 1006–7
non-inherited risk factors 1007
pacemaker therapy **641**, 1025
pregnancy 993–6, 998, 999
prevalence/incidence 1006, **1007**
pulmonary hypertension 1120
connective tissue disease
aortic aneurysms 1080, 1091
pericarditis 848
pulmonary hypertension 1118
connexin 40 gene mutations 292
consensus statements 69
CONSENSUS trial 762
CONTAK CD study 656–7, 660
continuous quality improvement (CQI) 69
convenience stores 216
COPERNICUS trial 767
COPE study 847
COPPA II study 561
copy number variation (CNV) 297
CORE study 848
CoreValve ReValving™ System 907, **909**
coronary allograft vasculopathy (CAV),
transplanted hearts 1105
coronary angiography
economic analysis 39–40
heart donors 1101
heart transplant recipients 1105
incremental value 18–19
infective endocarditis 944
mitral stenosis 916–17
NSTEMI acute coronary syndrome 431–3
pregnant women 997
preoperative, non-cardiac surgery **1072**
STEMI, after fibrinolysis 516–17
coronary angioplasty, percutaneous transluminal
see percutaneous transluminal coronary
angioplasty
coronary arteries
calcification, psychosocial influences 202
exercise-associated structural changes 195
patency rates
after fibrinolytic therapy 458–9
after primary PCI 464
physiologic measurements 364–5
thrombus within *see* intracoronary thrombus
vasomotor control 346
coronary artery bypass grafting (CABG) 379–86
acute MI 468–9
aircraft pilots 84–5
aortic valve replacement with 882
chronic stable angina 351–2, 380–2, 402

- conduits 384–6
 cost effectiveness 44
 diabetes mellitus 400–2
 endarterectomy with 386
 historical overview 379
 indications 381
 left anterior small thoracotomy (LAST)
 procedure 384
 minimally invasive (MIDCAB) 384
 NSTEMI acute coronary syndrome 432
 off-pump (OPCAB) 382–4
 on-pump (ONCAB) 382–4
 peripheral artery disease 1185
 prior to non-cardiac surgery 58, 1076
 quality improvement strategies 70, 71, 72
 robotics 384
 target lesions 379, 380
 techniques 382–6
 totally endoscopic (TEACAB) 384
 vs. medical management 379–82, 392–3, 394,
 1138–40
 vs. PCI 398–402, 1138–40
 coronary artery disease (CAD; coronary heart
 disease; CHD)
 acute syndromes *see* acute coronary syndromes
 aircraft pilots 84–5, 86
 aortic stenosis with 882
 atrial fibrillation and 572–4, 591
 autosomal dominant 272
 bifurcation 373, 374
 CABG *see* coronary artery bypass grafting
 cholesterol and 138–40
 chronic total occlusions (CTOs) 358, 373, 374
 diabetes mellitus 400
 diagnosis
 clinical 15–17
 clinical significance 21–2
 incremental value of tests 17–21
 nomograms for predicting probability 15, 16,
 17
 non-invasive screening for severe 17, 19, 20,
 22–3
 dysglycemia-related risk 181–3
 epidemiologic transition 97–8
 ethnic variations 238–51
 exercise-related cardiac events 195
 exercise training 193–4
 fetal origins 258–64
 gaps in implementing evidence 64, 65
 genetics 268–83, 296, 297–8
 genetic testing 280–2
 global burden 495
 global mortality 95–6
 global projections 98–9
 HDL cholesterol and 143–4
 heart failure
 epidemiology 742
 prevention 745, 746–7
 ICD therapy 623–4, 1174–6
 left anterior descending *see* left anterior
 descending (LAD) coronary artery disease
 left main *see* left main coronary artery disease
 left main equivalent, CABG 381
 microvascular *see* coronary microvascular
 disturbances
 multivessel
 CABG 381
 CABG vs. medical therapy 380, 392–3, 394
 CABG vs. PCI 399
 PCI 373, 374, 517
 recommendations for revascularization 402
 non-cardiac surgery 1070, 1071–2, 1077
 percutaneous intervention *see* percutaneous
 coronary intervention
 peripheral arterial disease and 1051, 1052,
 1183–5
 prediction of outcome 17, 19–21, 23
 psychosocial factors 204–5
 pregnancy 997
 prevention *see* prevention of cardiovascular
 disease
 psychosocial interventions 205–6
 psychosocial risk factors 202–4
 rehabilitation *see* rehabilitation, cardiac
 risk factors *see* risk factors, cardiovascular
 single vessel
 CABG vs. medical therapy 380, 392–3, 394
 CABG vs. PCI 399
 indications for CABG 381
 indications for PCI 373, 374
 recommendations for revascularization 402
 smoking-related risk 113, 114
 stable
 CABG 351–2, 380–2
 medical management 345–53, 369–73
 non-cardiac surgery 1070, 1071–2
 optimal medical therapy (OMT) 352–3
 PCI 359–73, 374, 393–7
 treatment choices 1138–40
 see also angina, chronic stable
 triglycerides and 143
see also angina; myocardial infarction;
 myocardial ischemia
 Coronary Artery Revascularization Prophylaxis
 (CARP) trial 53, 58, 1184
 Coronary Artery Revitalization in Diabetes
 (CARDIA) trial 401
 Coronary Artery Surgery Study (CASS) 380, 392–3
 coronary atherosclerosis *see* atherosclerosis
 coronary blood flow (CBF) 346
 Coronary Drug Project 28, 1159
 coronary endarterectomy 386
 coronary flow reserve (CFR) 357
 coronary flow velocity reserve, psychosocial
 factors 202
 coronary fractional flow reserve (FFR) 364–5
 coronary intervention, percutaneous *see*
 percutaneous coronary intervention
 coronary microvascular disturbances
 angina 346
 Chagas' cardiomyopathy 828
 hypertrophic cardiomyopathy 797
 coronary reperfusion therapy *see under*
 reperfusion therapy
 coronary restenosis 374
 bare metal stents 359, 361
 clinical presentations 395–6
 drug-eluting stents 361–2, 363
 risk factors 362
 coronary revascularization *see* myocardial
 revascularization
 coronary stents 357–8
 adjunctive pharmacologic therapy 365–9
 bare metal (BMS) 357–8, 359–60
 effectiveness 359–60, 360–1, 395, 397
 vs. CABG 398–9
 challenging anatomic lesions 373–4
 diabetic patients 401
 drug-eluting (DES) 357–8, 361–3
 acute STEMI 467, 1153
 diabetic patients 401
 effectiveness 361–3, 395–6, 397
 safety 396–7
 thrombotic restenosis 1154–5
 vs. CABG 399–400
 intravascular ultrasound guidance 364
 late thrombosis 362–3, 366, 396–7
 NSTEMI acute coronary syndromes 432, 1147, 1149
 primary, in acute MI 466–7
 vs. CABG 398–400
see also percutaneous coronary intervention
 CORONA trial 770
 Corpus Christi Heart Project (CCHP) 247
 corticosteroids
 acute pericarditis 845, 847
 atrial fibrillation prevention 569, 576, 577–8
 cardiac sarcoidosis 815
 myocarditis 789–90, 810, 811
 recurrent pericarditis 848
 rheumatic fever 864–5
 tuberculous pericarditis 852–3
 cortisone, rheumatic fever 865
 CORYFREE study 553
Corynebacterium diphtheriae myocarditis 810
 cost-benefit analysis 42
 cost effectiveness (CE) 42–5
 analysis 42–5
 antihypertensive therapy 175
 calculation 43–4
 diagnostic testing 21–3, 45
 lipid-lowering therapy 159–60
 patient selection and 45
 prevention strategies 106–7
 ratio 43–5
 selected therapies 44
 smoking cessation interventions 1056
 syncope management 686
 tobacco control interventions 119–21
 cost-minimization analysis 42
 costs
 average 40
 cost-effectiveness analysis 42–3
 determination 39–40
 discounting 43
 estimation methods 40–1
 healthcare *see* healthcare expenditure
 marginal 40
 patient out-of-pocket 67, 72
 per case 40
 counseling, smoking cessation 129–30
 COURAGE trial 85, 351–2, 372, 395, 1140, 1184
Coxiella burnetii 812, 846
 Cox linear proportional hazards model 19
 coxsackie B virus-induced myocarditis (CVB) 786,
 788, 808
 C-reactive protein (CRP)
 atrial fibrillation risk and 577
 effects of lipid-lowering agents 149, 348
 incremental prognostic value 21
 NSTEMI acute coronary syndrome 416
 postinfarction left ventricular dysfunction 497
 psychosocial influences 215
 CREATE trial 65–6, 484–5, 486
 creatine kinase (CK/CK-MB)
 NSTEMI acute coronary syndrome 415, 1143
 postinfarction left ventricular dysfunction 497
 creatinine, serum 1110–11
 CREDO trial 365, 477, 478
 CRESCENDO trial 227, 230
 critical limb ischemia 1050, 1063
 CRP *see* C-reactive protein
 CRRAFT study 535
 CRT *see* cardiac resynchronization therapy
 CRUSADE registry 72, 409, 427, 1144
 alphaB-crystallin mutations 294, 295
 CT *see* computed tomography
 CTT study 150, 158, 159
 CURE trial 424, 745, 1145, 1149
 methodological aspects 30
 PCI arm 365, 424, 477–8, 1153
 CURRENT trial 365, 366, 424
 cyanosis, pulmonary hypertension 1122
 cyanotic congenital heart disease, pregnancy in
 995, 998
 CYBA gene 297
 cyclic GMP (cGMP) 1124
 CYP2C9 genotype 282
 cystathionine beta-synthase 272
 cystatin C, serum 1111
 cytosine 132
 cytomegalovirus (CMV) infection, heart transplant
 recipients 1105, 1106
 cytotoxic agents, intrapericardial 853, 854
 DAAF study 541
 dabigatran, atrial fibrillation 586
 Dacron grafts, aortic disease 1087–8, 1092, 1093
 DAFNE study 552
 dairy products 317
 dalteparin
 acute STEMI 484
 NSTEMI acute coronary syndrome 429, 430
 venous thromboembolism prophylaxis 1043

Index

- DANAMI I trial 516
DANAMI II trial 449, 465–6
Danish Diet, Cancer and Health Study 576, 577
Danish pacemaker mode selection trial 644–5, 647
Danon disease 816
DANPACE trial 646, 648, 1180
DASH diet and trial 312, 314, 317, 319–20
Data Monitoring Committee (DMC) 31
David procedure, aortic root aneurysm 928, 1088
DAVID trial 648
DAVIT trial 421
DDAFS study 548–9
D-dimer blood testing 1037, 1038, 1039
decision aids 9, 10–11
decision analytic modeling 6
decision making 1136–7
 evidence-based *see* evidence-based clinical decision making
 patient preferences and 5–6, 1136–7
 shared 9–10
decision support tools 69, 70
decompressive hemicraniectomy, acute stroke 972, 978
DEDICATION trial 468
deep vein thrombosis (DVT) 1032
 diagnosis 1036–7
 distal 1032
 natural history and prognosis 1032–5
 postoperative 1042
 prevention 1033
 proximal 1032
 recurrent 1037, 1041
 treatment 1033–4, 1039–42
 see also venous thromboembolism
DEFER study 364–5
defibrillation 695–7
 CPR before 695
 first shock energy levels 696
 prehospital settings 448, 692
 procedures before 695
 second and subsequent shocks 696
 second and third shock success rate 696–7
 waveform analysis 695–6
defibrillators
 electrode–patient interface 695
 shock waveform 696
DEFINITE study 625, 626, 750
demand–control model 214, 215
demographic changes 99–100
demographic transition 96–7
Department of Veterans Affairs Trial 931
depression
 coronary artery disease and 203, 204–5
 exercise 196
 interventions 205, 206
 postinfarction 506, 507
 smoking cessation and 129–30, 132
DESIRE study 660
desmin mutations 294, 295
desmoglein 2 (DSG2) mutations 295–6
desmoplakin (DSP) mutations 295–6, 723
desmosomal gene mutations 295–6, 714–15, 723, 726
desmoteplase, acute stroke 976
developed countries *see* high-income countries
developing countries *see* low- and middle-income countries
device infections 941
Diabetes Control and Complications Trial 185
diabetes mellitus (DM) 179–87
 acute coronary syndromes 1142
 antihypertensive therapy 171, 172, 173
 associated risk factors 185
 CABG vs. PCI 400–2
 cardiovascular disease mechanisms 183–5
 cardiovascular disease risk 181–2, 183
 chronic complications 179, 180
 coronary artery disease outcomes 400
 diagnosis 179, 180
 etiological classification 180–1
 gestational 180, 181
 glycemic control *see* glycemic control
 heart failure
 case history 1164–7
 epidemiology 742–3
 prevention 744, 745, 747
 lipid-lowering therapy 158–9, 160–1
 myocardial revascularization
 recommendations 402
 non-cardiac surgery 1069–70, 1071
 NSTE acute coronary syndrome 413–14, 426, 435, 1148–9
 peripheral arterial disease 1052, 1057, 1184–5
 postinfarction management 520–1
 during pregnancy, effect on offspring 261, 262, 263
 prevalence 180, 333–4
 type 1 180, 181
 glucose-lowering trials 185
 type 2 180, 181
 Aboriginal populations 250
 African Americans 251
 Arab populations 246
 early life influences 261, 262
 exercise 196
 genetic factors 278
 glucose-lowering trials 185–6
 Japanese 239–40
 obesity and 222, 224, 225
 South Asians 242, 243, 244
 weight loss 225
 Diabetes Prevention Program 196, 225
 diagnostic tests 14–23
 clinical significance 21–3
 coronary artery disease 17–19, 21–2
 cost effectiveness 21–3, 45
 incremental value 17–21
 non-invasive screening for severe CAD 19, 20, 20, 22–3
 prediction of patient outcome 19–21, 23
 reference (gold standard) 18–19
 DIAMOND studies 540, 547–50, 620
 diet 304–21
 blood pressure management 168, 169, 319–20
 epidemiologic transition 97–8, 100
 ethnic diversity 238, 239–40
 exposure variables 305
 as independent variable 306
 Japanese traditional 240, 319
 lag time effects 305
 Mediterranean 211, 307, 308, 318
 methods of studying causal associations 304–6
 outcome variables 304–5
 patterns and composite interventions 318–20
 policy implications 320–1
 prudent vs. Western 319
 recommendations 320
 serum lipids and 140–1, 306–7, 308–10
 social determinants 216–17
 study designs 304
 vegetarian 318
 weight-reducing 223, 224
 see also specific nutrients
 Diet, Exercise, and Weight Loss Intervention Trial (DEW-IT) 312
 Diet and Reinforcement Trials (DART) 314, 622
 Dietary Approaches to Stop Hypertension *see* DASH
 DiGeorge syndrome 289, 1006–7
 digitalis *see* digoxin
 Digitalis Investigators Group (DIG) study 757, 772
 digoxin
 acute myocarditis 789
 atrial fibrillation
 acute cardioversion 541
 acute rate control 555
 long-term rate control 556–7, 558–9
 postinfarction 506
 atrial flutter 611
 atrial tachycardia 610
 atrioventricular nodal re-entrant tachycardia 612
 heart failure 756–7, 772, 1166–7
 non-randomized studies 34–5
 pregnancy 1000
 toxicity 610
 DIG study *see* Digitalis Investigators Group (DIG) study
dilated cardiomyopathy (DCM) 294–5, 784–93
 acute, management 787–91
 clinical presentation 786
 diagnosis 786–7
 genetics 289, 294, 295, 786
 ICD therapy 625
 mitral regurgitation 874
 non-cardiac surgery 1070
 non-ischemic, ICD therapy 624–5
 pathogenesis 294–5
 see also myocarditis
diltiazem
 atrial fibrillation 533, 541, 542, 554–5, 558–9
 atrial flutter 611
 atrioventricular reciprocating tachycardia 613
 chronic stable angina 349
 heart failure prevention 744
 heart failure therapy 761
 NSTE acute coronary syndrome 421
 paroxysmal supraventricular tachycardia 607
DINAMIT trial 520, 624, 626, 1175
DIONYSOS trial 551–3
DIPOM trial 55
dipyridamole
 peripheral arterial disease 1059, 1060
 prosthetic valve recipients 962
 pulmonary hypertension 1127
 secondary stroke prevention 981–2
direct thrombin inhibitors (DTIs)
 acute STEMI 487–8, 489
 NSTE acute coronary syndrome 429–30, 1146–7
 primary PCI 488
Direct Thrombin Inhibitor Trialists' Collaborative Group 488
disability, smoking-related 112–13
disability-adjusted life years (DALYs)
 cardiovascular disease 95, 98–9
 coronary heart disease 495
 smoking 113, 114
 stroke 971
disease management programs 70–1
disopyramide
 atrial fibrillation 541, 545
 atrioventricular reciprocating tachycardia 614
 hypertrophic cardiomyopathy 799
DISPERSE trials 423
diuretics
 heart failure prevention 744, 745
 heart failure therapy 757–8, 759, 772, 1165
 hypertension 170–1, 172, 225
 postinfarction 497, 498
 pregnant women 1000, 1001
 renal insufficiency 1114–15
divorce 212–13
dobutamine
 aortic stenosis 884
 heart failure 764–5
dobutamine stress echocardiography (DSE), preoperative 1184, 1185
docosahexaenoic acid (DHA) 307, 575–7
doctors *see* physicians
dofetilide
 atrial fibrillation
 acute cardioversion 537, 538, 540
 after cardiac surgery 560
 long-term prophylaxis 547–50
 paroxysmal supraventricular tachycardia 608
 sudden cardiac death prevention 620
dopamine, heart failure 765
Doppler ultrasound
 ankle brachial index 1053, 1054
 pulmonary hypertension 1122–3
Down syndrome, congenital heart lesions 1011

- doxazosin
heart failure prevention 744
hypertension 172, 173, 174
- doxycycline, intrapericardial 854
- D-Phe-Pro-Arg-CH₂Cl, acute STEMI 487–8
- Dressler's syndrome 502
- driving, medical fitness 79
- dronedaron, atrial fibrillation 551–3, 557
- DU-176b, atrial fibrillation 586
- ductus arteriosus 1015, 1016
see also patent ductus arteriosus
- dumping syndrome 230
- duteplase
acute MI 462
see also tissue plasminogen activator
- dysglycemia 179–87
associated risk factors 185
cardiovascular disease mechanisms 183–5
cardiovascular disease risk 181–3
early life influences 261, 262, 263
exercise 196
glucose-lowering trials 185–6
in pregnancy, effect on offspring 261
see also diabetes mellitus; impaired fasting glucose; impaired glucose tolerance
- dyslipidemia
African Americans 251
heart failure prevention 745
HIV infection 1161
obesity 225–6
peripheral arterial disease and 1051–2
see also lipids, serum
- dysphagia lusoria 1082
- dystrophin mutations 294, 295
- EARLY-ACS trial 427
- Eastbourne Syncope Assessment (EaSyAS) trial 682
- Eastern Europe 96, 97, 98, 237–8
- Ebstein anomaly 1017–18
arrhythmias 1025
pregnancy and 994
- ECASS-3 trial 975–6
- echocardiography
acute myocarditis 786–7, 808–9
aortic disease 1086
aortic stenosis 878–9
arrhythmogenic right ventricular cardiomyopathy 724–5
atrial septal defect 1008
atrioventricular septal defect 1011
coarctation of aorta 1015
Ebstein anomaly 1018
Eisenmenger syndrome 1023
infective endocarditis 944
left ventricular outflow tract obstruction 1013
mitral regurgitation 871–2
patent ductus arteriosus 1016
percutaneous balloon mitral valvuloplasty 918
pericardial disease 850, 852
pulmonary hypertension 1120, 1121, 1122–3
pulmonary valve stenosis 1017
syncope 680–1, 682
tetralogy of Fallot 1019
ventricular septal defect 1010
see also ultrasound imaging
- Echo-CRT trial 660
- ecologic bias 33–4
- economics, health 38–46
general concepts 38–9
international perspectives 41–2
see also cost effectiveness; costs
- edema, heart failure 758
- edifoligide 386
- Edinburgh Heart Valve Trial 931
- education
early symptoms of acute MI 446–7
patient 70
provider 69, 70, 75
- efavirenz 1161
- efegatran, acute STEMI 487–8
- effectiveness
measuring 43
see also cost effectiveness
- effect size, allele frequency and 269
- EFFECT study 66, 739
- effort–reward imbalance model 214, 215
- eggs 317–18
- EGSYS-2 study 683
- Egypt 246
- ehrlichiosis 792
- eicosapentaenoic acid (EPA) 307, 575–7
- Eisenmenger syndrome 1023–4
arrhythmias 1025
atrioventricular septal defect 1011
complications 1024
diagnostic evaluation 1023–4
management 1024
patent ductus arteriosus 1015
pregnancy 995, 1001, 1002, 1024, 1127
ventricular septal defect 1009
- ejection fraction, left ventricular *see* left ventricular ejection fraction
- elderly patients
acute coronary syndromes 1142
acute MI
adjunctive Gp IIb/IIIa antagonists 480
delay in presentation 444–6
fibrinolysis 463
angina management 380
aortic valve replacement 882, 897–8
atrial fibrillation 584, 592
cardiac amyloidosis 814
Gp IIb/IIIa antagonists 427
hypertension management 169, 173, 174, 312
ICD therapy 630–1
lipid-lowering therapy 157–8
mitral valve surgery 873
pacemaker therapy 644, 645, 646–7
- electrical (DC) cardioversion
atrial fibrillation 542, 544, 574–5
atrial tachycardia 609, 611
atrioventricular reciprocating tachycardia 613
see also cardioversion
- electrocardiogram (ECG)
acute myocarditis 786
acute STEMI 1153, 1154, 1155
arrhythmogenic right ventricular cardiomyopathy 725, 727
atrial septal defect 1008
atrioventricular septal defect 1011
Ebstein anomaly 1017
Eisenmenger syndrome 1023
incremental prognostic value 20
infective endocarditis 943
left ventricular outflow tract obstruction 1013
NSTE acute coronary syndrome 410, 411, 414–15
patent ductus arteriosus 1016
pericardial disease 850, 852
perioperative 1071, 1077
prehospital 447
pulmonary hypertension 1122
pulmonary valve stenosis 1017
signal-averaged (SAECG) 682
arrhythmogenic right ventricular cardiomyopathy 725
supraventricular tachycardia 606–7
syncope 680, 681–2
tetralogy of Fallot 1019
tuberculous pericarditis 850
ventricular septal defect 1009–10
- electroencephalography (EEG), syncope 683
- electrophysiologic testing (EPS)
arrhythmogenic right ventricular cardiomyopathy 727
Brugada syndrome 714
syncope 682–3
- elephant trunk technique, aortic arch surgery 1091, 1092
- ELITE-II trial 763
- embolectomy, acute limb ischemia 1063
- embolism 1032
defined 928
infective endocarditis 942, 945, 952–3
paradoxical 993
systemic, Chagas' cardiomyopathy 830, 835–6
see also pulmonary embolism; thromboembolism
- embolization protection devices, primary PCI in acute MI 468
- EMERALD trial 468, 540, 548–9
- EMERAS collaborative group 460
- emergency medical systems (EMS), prehospital activation in acute MI 444, 446–7
activation in acute stroke 973
diagnosis of acute MI 447
expediting reperfusion therapy 449–50
see also prehospital settings
- emergency surgery, cardiac risk 1071–3
- EMIAT study 504–5, 620
- Emory Angioplasty Versus Surgery Trial (EAST) 401
- employment *see* work
- employment fitness standards
aviation industry 79–90
regulatory process 79–80
- ENACT registry 411
- enalapril
aortic disease 1085
aortic regurgitation 888–9
asymptomatic left ventricular systolic dysfunction 748
Chagas' cardiomyopathy 834
heart failure 569, 762, 763, 768
hypertension 571
- encainide
postinfarction therapy 7
sudden cardiac death prevention 619–20
- encephalomyocarditis virus (ECMV) myocarditis 786
- ENDEAVOR-3 trial 362
- endocannabinoid receptor CB1 antagonists 1160
see also rimonabant
- endocarditis
infective *see* infective endocarditis
non-bacterial thrombotic 942
- endomyocardial biopsy (EMB)
arrhythmogenic right ventricular cardiomyopathy 724
cardiac allografts 1104
clinical role 787, 788
myocarditis 787, 809
- endothelial dysfunction
benefits of exercise 196–7
coronary artery disease 346
psychosocial factors 202, 215
pulmonary arterial hypertension 1120, 1123
renal disease 1113–14
- endothelin-1
cardiac arrest 697
pulmonary hypertension 1124
- endothelin receptor antagonists
Eisenmenger's syndrome 1024
heart failure 770
pulmonary hypertension 1124, 1125, 1126, 1127, 1128
- endovascular therapy
acute stroke 976–7
aortic disease 1089, 1090, 1093
carotid stenosis 985
peripheral arterial disease 1061–2
- endpoints *see* outcomes
- enhanced external counterpulsation (EECP) 351
- ENHANCE study 155
- enoxaparin
acute STEMI 485–7
NSTE acute coronary syndrome 429, 430–1, 1146, 1147
PCI 368, 369
prosthetic valve recipients 961–2
venous thromboprophylaxis 1043
- enoximone, heart failure 765

Index

- ENRICH study 206
enterococcal endocarditis 942, **948–9**
enteroviruses 808
environmental factors
 ethnic and regional differences 252
 genetic disorders 288
 migrant studies 101–2, 236
enzymes, cardiac *see* biomarkers, cardiac
eosinophilic myocarditis 792
EPHESUS study 497–8, 519, 622, 749
EPICA study 735
EPIC study 309, 367
epidemic of cardiovascular disease
 dietary interventions 320–1
 ethnic groups 238, 240
 evolution 96–8
 mechanisms 99–102
 strategies for tackling 102–7
epidemiologic transition 96–8, 740
 arrested 98
 CVD profiles during 97
 demographic changes due to 99–100
 early and late adopters 98
 variations 97–8
epidural analgesia
 labor, maternal heart disease 1002
 postoperative, prevention of vascular events 58
epilepsy, vs. syncope 679, 680
EPILOG study 367
epinephrine, cardiac arrest 697
EPISTENT study 367
eplerenone
 asymptomatic left ventricular systolic dysfunction 749–50
 heart failure 759, 1166
 postinfarction 497–8, 519
 renal insufficiency 1114
 sudden cardiac death prevention 622
epoprostenol
 heart failure 761
 pulmonary hypertension 1126, 1127, 1128
Epstein-Barr virus (EBV) 1105
eptifibatid
 acute STEMI 478–9, 481
 coronary in-stent thrombosis 1154
 NSTE acute coronary syndrome 425, 426, 431, 435, 1145
 PCI 366–8
equivalence studies 29
ERACI-II trial 398
ERAFT trial 545–6
ERATO study 552, 557
erythromycin
 group A streptococcal pharyngitis 863, **866**
 rheumatic carditis 864
 rheumatic fever 864, **866**
ESC *see* European Society of Cardiology
ESCAPE trial 772
ESCAT trials 963
esmolol
 atrial fibrillation 554–5
 paroxysmal supraventricular tachycardia 608
esophageal injury, left atrial ablation 602
ESPRIT trial 367, 426, 1154
ESSENCE trial 429
ESTEEM-CRT trial 659–60
ESVEM study 620–1
etanercept, heart failure 769–70
ethnic groups 235–52
 cardiovascular disease rates 101–2
 defining 235
 disease profiles in specific 236–52
 environmental influences on risk 252
 genetic influences on risk 252
 hypertension 166, 239, **244**, 246, 250, 251
 interpretation of studies in 235
 stroke etiology 979
 studies of multiple 252
 see also migrants; *specific populations*
EURIDIS study 551, **552**, 553, 557
EUROACTION project 336–7, **338**, 341
EUROASPIRE surveys 333–4, **335**, 336
EuroHeart Failure Survey 738, 739
Euro Heart Survey 881–2
EUROPA trial 498, **745**, 746
European Atrial Fibrillation Trial (EAFT) 582, 583, 587
European Aviation Safety Agency (EASA) 79, 80, 83, 84
European Carotid Surgery Trial (ECST) 984
European Coronary Surgery Study (ECSS) 380, 392–3
European populations 211, 237–9
 disease burden 95, 96, 237–8
 epidemiologic transition 97–8
 prevention approaches 238–9
 risk factors 238
European Society of Cardiology (ESC) guidelines
 acute coronary syndromes 409, 431
 anticoagulation in pregnancy 1001
 aortic valve surgery **886**, **892**
 atrial fibrillation 589
 infective endocarditis 945, **946–50**
 valvular heart disease 878
European System for Cardiac Operative Risk Evaluation (EuroSCORE) 898
EVA-AMI trial 481
EVENT registry 396–7
EVEREST study 770
everolimus
 -eluting coronary stents 361
 heart transplant recipients 1105
evidence 6–9
 clinical applicability 8–9, 10–11, 1135–7
 contradictory 7–8
 defined 6
 hierarchy 6–7
 interpretation 8
 recognizing limitations 1135–6
evidence-based clinical decision making 4–12
 defined 4
 external influences 12
 model 4–9
 recommended approach 9–10, 1136–7
evidence-based medicine 3–4
 barriers to implementing 66–8
 defined 4
 employment fitness standards 79–90
 implementation in cardiology 63–75
 practice gaps 63, 64–6
 quality improvement strategies 68–72
 vs. patient-centered medicine 1135–6
exercise (training) 190–8
 blood pressure lowering 168, **169**, 195–6
 chronic stable angina 347
 definition 190
 Eisenmenger syndrome 1024
 heart failure 194–5, 770, 1165
 mechanisms of cardioprotective effect 195–7
 myocarditis 791
 obesity 196, 224
 peripheral arterial disease 1056–7
 postinfarction 506–7, 520, 521–2
 primary prevention 191–2
 recommendations 197–8, 224
 related cardiac events 195
 secondary prevention/rehabilitation 193–4, 332–3
 see also physical activity
exercise (stress) testing
 aircraft pilots 81, 84
 aortic stenosis 885, 1188
 atrial septal defect 1008
 cost effectiveness 44
 Eisenmenger syndrome 1023
 incremental value 18–19, 20, **21–2**
 left ventricular outflow tract obstruction 1013
 mitral regurgitation 873
 peripheral arterial disease 1053–4
 preoperative, non-cardiac surgery 1069, **1071–2**
 pulmonary hypertension 1120
 syncope 682
 tetralogy of Fallot 1019
EXTRACT-TIMI 25 trial 448–9, 485–6
ExTraMATCH 194
ezetimibe **152**, **155**
 chronic stable angina 347
 combination therapy 156, **157**
 secondary prevention of MI 1157, 1158
factorial study designs 30
factor V Leiden **276**, 1035
factor Xa 481
factor Xa inhibitors 429
 acute STEMI 488–90
 atrial fibrillation 586
 see also fondaparinux; low molecular weight heparin
fainting *see* syncope
Fallot's tetralogy *see* tetralogy of Fallot
falls, carotid sinus syndrome 651
false negatives 18, 29–30
false positives 18
FAME study 365
familial hypercholesterolemia (FH) 270, **271**, 281
familial Mediterranean fever 848
family-based linkage analysis 272–3
family history 290
family networks 212–13
FAMIS study 518
fascicular block, pacing indications **638**, **643**
fast-food outlets 216
fasudil
 chronic stable angina 351
 pulmonary hypertension 1126
fat, visceral *see* obesity, abdominal
fats, dietary 306–8
 epidemiologic transition 97–8, 100
 serum lipids and 140–1, 306–7, 308
fatty acids 306–8
 monounsaturated (MUFA) 307, 308
 polyunsaturated (PUFAs) *see* polyunsaturated fatty acids
 saturated (SFAs) 141, 306–8
 trans (t-FAs) 141, 307, 308
 unsaturated 141, 307–8
fatty streaks 258
felodipine, heart failure 761
fenofibrate **152**, 154–5
 combination therapy **157**
 diabetes mellitus 159
 secondary prevention of MI 1157, 1158, 1159
fetal complications, maternal heart disease 999
fetal origins hypothesis 101, 258–64
 postnatal factors and 264
 prevention implications 264
 prospective cohort studies 261–2, **263**
 retrospective studies 259–61
 underlying mechanisms 259, 264
fever, acute stroke 973–4
FFAACs study 585
fiber, dietary 309–10
fibrin acid derivatives (fibrates) **152**, 154–5
 combination therapy **157**
 peripheral arterial disease 1058
 secondary prevention of MI 1158, 1159
fibrillin alterations 1085
fibrinogen, plasma 280
fibrinolytic therapy 457–8
 acute limb ischemia 1063
 acute MI 457–63
 adjunctive anticoagulants 482–3, 484–6, 487–90
 adjunctive antiplatelet agents 477, 478–80
 adjunctive antithrombotics 461, 475, 490
 bolus injections 463
 case history 1152–3
 comparative trials 462–3
 at early presentation 463
 efficacy 458–60
 elderly 463
 gaps in clinical practice 65
 historic perspective 456–7
 left ventricular function after 497

- PCI after 516–17
 prehospital 448, 450–1
 recommendations 466
 risks 461–2
 trial methodologies 28, 29, 30–1
 vs. primary PCI 464, 465
- acute stroke 972, 974–6
 intra-arterial delivery 976–7
 intravenous delivery 974–6
- approved agents 458
 cardiac arrest 698
 cardiogenic shock 499
 intrapericardial
 purulent pericarditis 849
 tuberculous pericarditis 851
 mechanisms of action 457
 pulmonary embolism 1041–2
- Fibrinolytic Therapy Trialists' (FTT) Collaborative Group 459–60, 463
- FIELD trial 159, 1159
- financial quality improvement interventions 70, 71–2
- FINESSE trial 480
- Finland 105–6, 238–9
- fish consumption 307, 314, 577
- fish oils 307, 314
 atrial fibrillation prevention 575, 577
 ICD recipients 627–8
 sudden cardiac death prevention 622
- fistula formation, infective endocarditis 952
- fitness, cardiorespiratory 190, 192–3
- 5A study 554
- flavonoids 310
- flecainide
 atrial fibrillation 537–9, 542, 545–6
 atrial tachycardia 610
 atrioventricular nodal re-entrant tachycardia 612
 atrioventricular reciprocating tachycardia 614
 long QT syndrome 711–12
 paroxysmal supraventricular tachycardia 608
 postinfarction therapy 7
 sudden cardiac death prevention 619–20
- Flecainide Atrial Fibrillation study 546
- Flecainide Multicenter Atrial Fibrillation Study 546
- flosequinin, heart failure 761
- fludrocortisone, vasovagal syncope 684
- fluid retention, heart failure 757–8
- fluidione 585
- fluoxetine, pulmonary hypertension 1126
- fluvastatin 150, 151
 cost-effectiveness 160
 perioperative 57
- folate 311
- folic acid 311
- fondaparinux
 acute STEMI 488–90
 comparative properties 484
 NSTEMI acute coronary syndrome 429, 431, 435, 1146
 PCI 369, 490
 venous thromboembolism 1033, 1039, 1040
 venous thromboprophylaxis 1033, 1042
- Fontan procedure 1021–3
 clinical presentation 1022
 late complications 1022–3, 1024, 1025
 pregnancy after 996
- foods
 consumption data collection 305
 specific, and CVD risk 313–18
- Forrester classification 496
- foscarnet 1106
- 4S *see* Scandinavian Simvastatin Survival Study
- fractional flow reserve (FFR), coronary 364–5
- Framingham Heart Study
 atrial fibrillation 574
 heart failure 736, 738, 739, 743
- Framingham Offspring Study 203, 268
- Framingham risk score, incremental value of
 diagnostic tests 20–1
- Framingham Study
 atrial fibrillation 581
 cardiovascular risk factors 103, 104
 heart failure 739, 742
 syncope 674
- FRAMI study 484
- France 95, 96, 237–8
- FREEDOM study 401
- French paradox 310
- FRISC-II study 430, 432, 1144
- FRISC study 413, 415, 428
- fruit and vegetables 313–14, 315
 antioxidants 310–11
 differences in access 216
 hypertension prevention 168, 314, 319
- functional capacity
 preoperative evaluation 1069, 1070
 pulmonary arterial hypertension 1120, 1121
 sudden cardiac death and 619
see also New York Heart Association (NYHA)
- functional capacity
- fungal infections 812
 endocarditis 942, 951
 pericarditis 849
- furosemide
 heart failure 758, 1165
 postinfarction 497
- galectin 2 (LGALS2) 276
- ganciclovir 1106
- garlic 316–17
- gastric banding 228, 229, 230
- gastroepiploic artery (GEA) grafts 385–6
- gastrointestinal bleeding, patient information 11
- gastroplasty, vertical-banded 228, 229
- GELIA trial 962–3
- gemfibrozil 152, 154–5
 combination therapy 157
 cost-effectiveness 160
 heart failure prevention 745, 746
 secondary prevention of MI 1159
- gender differences
 hypertension 165–6
 peripheral arterial disease 1050, 1051, 1052
 smoking prevalence 111, 112
 smoking-related mortality and disability 112–13
 venous thromboembolism recurrence 1041
see also women
- gene chips 275, 279
- gene–environment interactions 288
- ethnic groups 252
 migrant groups 101–2, 236
- general practice, preventive cardiology program 336–7
- Genetic Association Database 275
- genetic counseling 290, 999
- genetics
 clinical role 296
 coronary heart disease 268–83, 296, 297–8
 candidate–gene association studies 275–6, 297
 chromosome 9p21 locus 276–9, 297–8
 evidence for 268
 genome-wide association studies 276–7, 297
 genome-wide linkage analysis 272–3
 low-frequency intermediate penetrance (LFIP) variants 282
 “Mendelian randomization” studies 279–80
 number of effects/effect sizes 268–70
 single nucleotide polymorphisms 273–5, 276–7
 ethnic and regional differences 252
 future therapy and 299–300
 glossary of terms 283–4
 hypertension 174, 298–9
 molecular 288–300
 new technology 297
 polygenic disorders 288, 296–9
 single gene disorders *see* single gene disorders
- genetic testing 280–2, 296
- GENIHUSS study 174
- genome-wide association (GWA) studies 273, 274–5, 297
 coronary heart disease 276–7, 297
 plasma lipids 279, 280
- genome-wide case–control association studies 296–7
- genome-wide linkage analysis 272–3
- gentamicin, infective endocarditis 946, 947, 948, 949, 950
- geographic patterns of disease 236
- ghrelin, pulmonary hypertension 1126
- giant cell arteritis, aortic aneurysms 1080
- GISSI-1 study 28, 29, 307, 459
- GISSI-2 study 462, 482
- GISSI-Atrial Fibrillation trial 572
- GISSI-Prevenzione trial 622
- Glenn shunt 1022, 1025
- Global Burden of Disease study 98–9, 242, 245
- global perspectives 95–107
- Global Use of Streptokinase and tPA for Occluded Coronary Arteries *see* GUSTO
- glomerular filtration rate (GFR) 1110–11
 cardiovascular risk and 1112
 estimated (eGFR) 1110–11
 indications for measuring 1112
 pathophysiologic effects of low 1113–14
 therapeutic implications of low 1113–15
- glucose
 lowering therapy 185–6
 plasma
 acute stroke 974
 cardiovascular disease risk and 182–3
 diabetic complications and 179, 180
 diagnostic thresholds 179, 180
 toxic effects 183–4
 see also dysglycemia; impaired fasting glucose; impaired glucose tolerance
- glycation, protein 183–4
- glycemic control, diabetic
 cardiovascular outcomes and 185–6
 non-cardiac surgery 1069–70
 peripheral arterial disease 1057
- glycemic index 309
- glycemic load 309
- glyceryl trinitrate *see* nitroglycerin
- glycogen storage diseases 815–16
 type IIa (Pompe) 816
 type IIb (Danon) 816
 type III 816
- glycoprotein IIb/IIIa receptor blockers (GPI)
 acute STEMI 478–81
 coronary in-stent thrombosis 1154
 NSTEMI acute coronary syndrome 425–7, 431, 435, 1145, 1147
 oral 427
 PCI 366–8
- Goldman (Original) Cardiac Risk Index 48–9
- gold standard test 18–19
- GRACE registry 106, 411, 414, 427
- GRACE score 417, 418
- graduated compression stockings (GCS) 1042, 1043
- graft failure, primary cardiac 1104
- graft rejection, cardiac 1104, Plate 68.1, Plate 68.2
- granulocyte colony-stimulating factor (G-CSF), STEMI 518–19
- greater saphenous vein grafts *see* saphenous vein grafts
- Greece 96, 211
- green tea 310
- group A streptococcal (GAS) pharyngitis 810–11, 861–2
 prevention of rheumatic fever 862–4, 866
- Gruppo Italiano per lo Studio della Streptochinasi nell' Infarto Miocardico *see* GISSI
- GUSTO-I study 461, 462, 505
- GUSTO-II study 412, 413, 414
- GUSTO-IIb study 429, 487, 489
- GUSTO-III study 462, 463
- GUSTO-IV study 416–17, 426
- GUSTO-V study 479, 485

Index

- GUSTO angiographic study 459
GUSTO score 417
- Hancock valves 931, **933**, **934**, 959
haplotype map (HapMap), human 274–5
HART-II trial 485
Harvard Alumni Study 191–2, 193, 195–6
HAS study 369
head tilt–chin lift method, airway opening 693
healthcare expenditure 38, **39**, 106–7
healthcare insurance 72
healthcare providers *see* providers, healthcare
health economics *see* economics, health
Health Food Shoppers Study **315**
Health Professionals' Follow-up Study (HPS) 309, 313–14, **315**, 319
health transition 96–7, 98
healthy migrant effect 248
heart block
 familial **289**
 indications for pacing 637–8
 postinfarction 506
 see also atrioventricular (AV) block; bundle branch block
heart failure (HF) 735–50
 acute myocarditis 787–9
 adjunctive therapies 770–1, 1166–7
 amyloidosis 812, 813
 aortic regurgitation 886, 888
 aortic stenosis 882–3, 884
 atrial fibrillation and
 ablation therapy 600
 ACEIs and ARBs for prevention 569–71
 antiarrhythmics for prevention 544, **552**, 553
 cardiac resynchronization therapy 656, 657–9, 661
 rate vs. rhythm control 536–7
 statins for prevention 574
 biventricular pacing 649–50, 655
 cardiac resynchronization therapy *see* cardiac resynchronization therapy
 cardiac transplantation *see* cardiac transplantation
 Chagas' disease *see under* Chagas' cardiomyopathy
 clinical trial designs 772
 developing world 739–40
 device-based therapy 771, 1167
 diabetes and *see under* diabetes mellitus
 epidemiology 735–40
 etiology 740–3
 exercise training 194–5, 770, 1165
 hospitalization rates 738–9
 hypertension-related risk 166, 167, 742
 hypertrophic cardiomyopathy 798, 799–800
 infective endocarditis 945, 951, 952, 953
 left ventricular assist devices (LVADs) 771, 1106–7
 lifestyle modification 770, 1165
 management 756–73, 1164–7
 gaps in implementing evidence 64, 65
 recommendations 773
 structured programs 70–1, 771, 1166
 mitral regurgitation 870, 872–4
 monitoring 772–3
 mortality 739
 non-cardiac surgery 1070, **1071**
 performance measures 773
 pharmacologic therapy 756–70, 1165–7
 postinfarction 496–8
 epidemiology 742
 management 497–8, 759, 769, 1176
 pathophysiology 496
 prevention 746–7
 prognostic markers 496–7
 reperfusion therapy 451, 497
 pregnant women with heart disease 994, 996
 with preserved systolic function (HF-PSF)
 incidence 738
 management 771–2
 prognosis 739
 preventive strategies 743–8
 renal dysfunction and 743, 1114–15, 1165
 risk factors 741, 742–3
 sudden cardiac death prevention 620, 621, 623–5, 769
 symptomatic
 incidence 736–8
 prevalence 735, **736**, 736
 transposition of great arteries 1021
 weight loss 230
 see also left ventricular dysfunction; left ventricular systolic dysfunction
Heartmate XVE® device 1106–7
Heart of Soweto Study 740
Heart Outcomes Prevention and Evaluation trial *see* HOPE trial
Heart Protection Study (HPS) 157, 435, 521
 adverse events 151
 design 30
 patient subgroups 158, 159
 peripheral arterial disease 1058
 stroke prevention 983
HEARTSCORE 330
heart transplantation *see* cardiac transplantation
HELP AMI trial 517
Helsinki Heart Study 154
HELVITCA trial 369
hematoma, intramural, of thoracic aorta *see* intramural hematoma (IMH) of thoracic aorta
hemochromatosis, hereditary 815
hemodynamic monitoring
 heart failure 772, 773
 non-cardiac surgery **1077**
 peripartum, maternal heart disease 1001
hemodynamic therapy, acute MI 497–8
hemoglobin, glycosylated (HbA1c)
 cardiovascular disease and 181–2, 183, 185, 186
 peripheral arterial disease 1057
HEMORR₂HAGES scheme 588
hemorrhage *see* bleeding/hemorrhage
heparin
 low molecular weight *see* low molecular weight heparin
 postinfarction thromboembolism 502
 unfractionated (UFH)
 acute ischemic stroke 977, 978
 acute STEMI 481–3
 atrial fibrillation 587
 NSTE acute coronary syndrome 427–9, 430–1, 435, 1146
 PCI 368, **369**
 during pregnancy 1000–1
 prosthetic valve recipients 961–2, 964, 965
 sites of action 427, 429
 venous thromboembolism **1033**, 1039–40
 venous thromboprophylaxis **1033**, 1042, 1043
 vs. other anticoagulants **484**
 heparin-induced thrombocytopenia (HIT) 1035, 1040
 hepatopulmonary syndrome 1127–8
 HERO-1 trial 487, 489
 HERO-2 trial 479, **485**, 487, 488, 489
 HF *see* heart failure
 HF ACTION trial 195, 770
 hibernating myocardium 380–2, 497
 high blood pressure *see* hypertension
 high-density lipoprotein (HDL), reconstituted 155–6
 high-density lipoprotein (HDL) cholesterol 143–4
 approaches to raising 1157, 1158–61
 classification **148**
 dietary fats and 306, 307
 effects of lipid-lowering agents 150, 152, 153, 155, 156–7, 1158–60
 ethnic variations 250
 genetic influences 279, **280**
 treatment targets 147–8, 347
 high-income countries (HIC)
 cardiovascular disease projections 99
 cardiovascular mortality 95–6, 235–6
 epidemiologic transition 97–8
 healthcare expenditure 106–7
 prevention strategies 105–6
 smoking trends 111–12
 tobacco control interventions 116–19, **120**
 tobacco-related deaths 113–14, **115**
 highly active antiretroviral therapy (HAART) 1161
 high-risk individuals
 cholesterol-lowering therapy 144
 EUROACTION program 336–7, **338**
 identification 104, 105, 329–31
 preventive strategies targeting 104, 106
 see also risk stratification
HINT study 421
Hippocrates 221
hirudin
 acute STEMI 487, 488
 NSTE acute coronary syndrome 429–30
 PCI 368–9
Hirudin for the Improvement of Thrombolysis (HIT)-4 study 487, 489
Hispanics 246–8
HIV infection
 Chagas' disease co-infection 831
 dyslipidemia 1161
 myocarditis 792, 808
 pulmonary hypertension 1120, 1128
 tuberculous pericarditis 850, 853
HLA haplotypes, rheumatic fever risk 862
HMG-CoA reductase inhibitors *see* statins
HOBIPACE trial 650
Holt–Oram syndrome **289**
homocysteine (HCY) 311
homocystinuria **272**
HOPE trial 347, 498
 atrial fibrillation **570**
 heart failure 743, 745, 746
 sudden cardiac death 622
 vitamin E supplements 310
HOPE PAD trial 1057–8
HORIZONS AMI trial 481, 488
hormone replacement therapy 158
hospitals
 gaps in implementing evidence 64–5
 preventive cardiology program 336–7
 regional cardiac destination 450
 report cards 73
 smoking cessation programs 130, **131**
 see also prehospital settings; providers, healthcare
hostility 202–3, 205
HOT CAFÉ study 533–6
HPS *see* Heart Protection Study
Human Genome Project 273, 297
human immunodeficiency virus infection *see* HIV infection
hydralazine
 aortic regurgitation 888
 heart failure 760–1, 1166
hydrochlorothiazide, hypertension 170, **173**, 174
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors *see* statins
hyperacute rejection, cardiac allografts 1104
hypercholesterolemia
 autosomal dominant 3 (PCSK9 mutations) 270, **271**, 282
 autosomal recessive **271**
 familial (FH) 270, **271**, 281
 see also cholesterol, serum
hypercoagulability 1035
HyperGEN 174
hyperglycemia
 acute stroke 974
 see also dysglycemia
hyperhomocystinemia 1035
hyperkalemia 1114
hyperlipidemia
 familial combined 154
 see also dyslipidemia

- hypertension 165–75
 aortic aneurysms 1080
 atrial fibrillation prevention 571
 burden 168
 cardiovascular risk 102–4, 166, 167
 cardiovascular risk stratification 165, 166
 classification 165, 166
 definition 165
 dietary management 168, 169, 319–20
 drug treatment 169–74
 see also antihypertensive agents
 epidemiologic transition 97, 100
 ethnic populations 166, 239, 244, 246, 250, 251
 exercise 168, 169, 195–6
 fetal determinants 260–1, 262, 263
 gaps in implementing evidence 64
 genetics 174, 298–9
 gestational *see* pre-eclampsia
 heart failure prevention 744–6
 heart failure risk 166, 167, 742
 immunotherapy 175
 isolated systolic (ISH) 165
 drug treatment 169, 171
 natural history 166–8
 multiple risk factor interventions 332, 335–6
 natural history 166–8
 non-cardiac surgery 1070
 non-pharmacologic approaches 168–9, 319–20
 obesity and 222, 224–5, 227
 peripheral arterial disease and 1051–2
 pharmacogenetics 174–5
 potassium supplementation 168, 169, 312
 pregnancy 1001
 prevalence 165–6, 333–4
 prevention 168–9, 319–20
 sodium intake and 311
 sodium restriction 168, 169, 312, 319
 stroke 974, 979–80
 thrifty gene hypothesis 101
 weight loss 168, 169, 224–5
- Hypertension Detection and Follow-up Program (HDFP) study 170
- hypertriglyceridemia
 treatment 152, 154–5
see also triglycerides (TGs), serum
- hypertrophic cardiomyopathy (HCM) 796–804
 atrial arrhythmia subset 710–11
 atrial fibrillation 587, 600–1
 case history 1170–3
 management 802
 definition and nomenclature 796–7
 epidemiology 796
 familial (FHCM) 292–4, 714, 797–8
 animal models 299–300
 future therapy 300
 genotype/phenotype correlations 292–3, 799
 molecular genetics 289, 292, 293
 pathogenesis 288, 293–4
 genetics 797–8
 heart failure 798, 799–800
 histopathology 797
 ICD therapy 629, 714, 800–2
 LV hypertrophy 797
 LV outflow obstruction 797
 management 799–804
 natural history 798
 non-cardiac surgery 1070
 pacemaker therapy 640, 652–3, 803
 preclinical diagnosis 300
 pregnancy 997
 risk stratification 714, 799
 screening of relatives 296
 sporadic 292
 sudden cardiac death 292, 293, 714, 798–9
 prevention 629, 800–2
 surgical procedures 802–3
 symptoms 798
 syncope 679, 685
- hyperventilation, cardiopulmonary resuscitation 693, 694
- hypobetalipoproteinemia, familial 142–3
- hypotension
 nitroglycerin-induced 420
 orthostatic 680
 perioperative, risks 52, 55
 syncope 676
 transient postural 676
- hypothalamic-pituitary-adrenal axis 215
- hypothyroidism, pericarditis 846
- ibuprofen
 acute pericarditis 847
 atrial fibrillation 585
- ibutilide
 atrial fibrillation 538, 539–40, 542
 after cardiac surgery 560
 atrial flutter 611
- Ibutilide Repeat Dose Study 548–9
- Ibutilide/Sotalol Comparator Study (ISCS) 548–9
- ICDs *see* implantable cardioverter defibrillators
- ICTUS study 432, 1144–5
- IDEAL study 521
- idaraparinux, venous thromboembolism 1040
- iliac artery angioplasty and stenting 1061
- iloprost
 critical limb ischemia 1063
 pulmonary hypertension 1126
- imaging
 acute stroke 973
 arrhythmic right ventricular cardiomyopathy 724–5
 carotid arteries 984
 infective endocarditis 944
 peripheral arterial disease 1054–5
 tuberculous pericarditis 850
see also specific modalities
- imatinib, pulmonary hypertension 1126
- immune-mediated cardiac damage, Chagas' disease 828–9
- immunosuppressive therapy
 heart transplant recipients 1102–4
 myocarditis 789–90, 791, 810, 811
- immunotherapy
 cardiomyopathy risk 743
 myocarditis 809–10
 post-transplant lymphoproliferative disorder 1105–6
- IMPACT study 619
- IMPACT-II study 367
- IMPACT-AMI study 478–80
- impaired fasting glucose (IFG) 179, 180
 cardiovascular disease risk 182–3
 glucose-lowering trials 186
- impaired glucose tolerance (IGT) 179, 180
 cardiovascular disease risk 182–3
 glucose-lowering trials 186
 of pregnancy, effect on offspring 261
- impedance during inspiration device (ITD) 685
- implantable cardioverter defibrillators (ICD) 623–32
 adjunctive antiarrhythmic drugs 626–9
 arrhythmic right ventricular cardiomyopathy 629, 715, 726–7
 asymptomatic left ventricular systolic dysfunction 748, 750
 Brugada syndrome 630, 713–14
 cardiac resynchronization therapy with (CRT-D) 631–2, 656–7, 660–1
 catecholaminergic polymorphic ventricular tachycardia 713
 Chagas' cardiomyopathy 629–30, 832–4
 coronary artery disease 623–4, 1174–6
 cost effectiveness 44
 dilated cardiomyopathy 625
 heart failure 771, 1167
 hypertrophic cardiomyopathy 629, 714, 800–2
 ischemic cardiomyopathy 623–4
 less common conditions 629–30
 long QT syndrome 630, 712
 myocarditis 790–1
 non-ischemic dilated cardiomyopathy 624–5
 pacing strategies 648
- postinfarction 505, 520, 623–4, 1174–6
 pregnancy and 1000
 recommended use 631
 secondary prevention of sudden cardiac death 625–6
 short QT syndrome 712–13
 syncope 675, 685
 under-represented populations 630–1
- implantable loop recorders (ILRs), syncope 681–2
- implementation science/research 64
- IMPROVE-IT trial 347
- INCREMENTAL study 659
- India
 cardiovascular disease epidemic 100
 cardiovascular mortality 95, 96, 242
 epidemiologic transition 98
 migrants 243, 245
 risk factors 242–3, 244
 tobacco use 112, 113, 114, 116, 242
- India Multi-center Study 315
- The Indian Polypill Study (TIPS) 339
- indometacin, acute pericarditis 847
- industrialized countries *see* high-income countries
- infections
 cardiac device 941
 heart transplant recipients 1106
- infective cardiomyopathies 808–12
- infective endocarditis (IE) 941–53
 acute 941
 antibiotic therapy 944–5, 946–50
 complications and outcome 951–3
 diagnosis 942–4
 Duke Criteria 943–4
 epidemiology 941–2
 mitral valve repair 930
 native valve 941
 antibiotic therapy 946, 948, 950
 mortality 953
 surgical treatment 945, 951
 nomenclature 941
 nosocomial 941
 operated valvular, defined 928
 pathogenesis 942, Plate 59.1
 prevention 953
 aortic stenosis 881, 1188
 labor and delivery 1001–2
 prosthetic valve *see* prosthetic valve endocarditis
 subacute 941
 surgical treatment 945–51
- inferior vena cava (IVC) filters 1034, 1041
- infiltrative cardiomyopathies 812–16
- inflammatory markers
 NSTE acute coronary syndrome 415–16
 psychosocial influences 202, 215
 statin actions 149
- influximab, heart failure 770
- influenza vaccination 521
- infrainguinal bypass procedures 1062
- inheritance, patterns of 289–90
- INIGHT study 744
- INITIATIVE study 351
- INJECT study 463
- injuries, syncope 675
- inogatran, acute STEMI 487–8
- inotropic drugs
 cardiogenic shock 499
 heart failure 764–5, 766
 RV infarction 500
- Inoue balloon 913, 914, 918, 919
- Institute for Healthcare Improvement 73
- insulin
 acute stroke 974
 insufficient effect 184–5
 intensive therapy 185
 non-cardiac surgery 1069–70
- insulin resistance
 cardiovascular disease risk 184
 early life influences 262, 263
 exercise 196
 obesity 224
 syndrome *see* metabolic syndrome

Index

- insurance, healthcare 72
intention-to-treat analysis 27–8
interferon-alpha, acute myocarditis 789
Inter-Health Program 251
INTERHEART study 236–7
 cardiovascular risk factors 102, 148, 236–7
 fruit and vegetables 315
 genetic factors 268
 psychosocial stress 203, 211–12
 specific ethnic groups 240–1, 242–3, 244, 248, 250, 251
interim analyses 31
interleukin 6 215, 416
intermittent claudication
 diagnosis 1052–3
 incidence 1050
 lifestyle measures 1055–7
 pharmacologic therapy 1058, 1059, 1060–1
 surgical treatment 1061–2
 see also peripheral arterial disease
internal mammary artery (IMA) grafts *see* internal thoracic artery grafts
internal thoracic artery (ITA) grafts 384–5
 bilateral (BITA) 385
 diabetic patients 401
 history 379
 left (LITA) 384
 minimally invasive CABG 384
 right (RITA) 384–5
International Civil Aviation Organization (ICAO) 80–1
International Haplotype Map (HapMap) Project 274–5
International Liaison Committee on Resuscitation (ILCOR) 692, 695, 696–7
international normalized ratio (INR)
 bioprosthetic valve recipients 965
 mechanical valve recipients 961, 964
 prosthetic valve recipients 959–60
 secondary stroke prevention 982, 983
International Society for Heart and Lung Transplantation (ISHLT) 1099–100, 1104, 1105
International Stroke Trial (IST) 587, 974, 977
International Study of Infarct Survival *see* ISIS
INTERSALT study 311, 312
interventricular septal rupture, postinfarction 503–4
In-TIME-II study 462
intra-aortic balloon pumping
 cardiogenic shock 499
 non-cardiac surgery 1070
intra-arterial thrombolysis, acute stroke 976–7
intra-atrial re-entrant tachycardia (IART) 610, 1024–5
intracerebral hemorrhage (ICH) 972, 979
 acute ischemic stroke 978
 antiplatelet therapy and 981
intracoronary thrombus
 fibrinolysis *see* fibrinolytic therapy, acute MI
 NSTEMI acute coronary syndrome 409, 418–19
 percutaneous aspiration/thrombectomy 467–8
 STEMI 456, 475–6
intracranial aneurysms, genetic factors 278–9
intracranial hemorrhage (ICH)
 fibrinolytic therapy-associated 461
 prasugrel-associated 425
 warfarin-treated patients 582, 583–4, 588
intramural hematoma (IMH) of thoracic aorta 1081–2
 incidence 1084
 management 1087, 1089, 1090, 1092
intravascular ultrasound (IVUS)
 heart transplant recipients 1105
 PCI 363–4
intravenous immunoglobulin (IVIG)
 myocarditis 790, 809–10
 rheumatic fever 865
INTRO-AMI study 479
ion channelopathies *see* channelopathies
irbesartan
 atrial fibrillation prevention 571–2
 heart failure prevention 745
 hypertension 171, 172
Irbesartan Diabetic Nephropathy Trial (IDNT) 171, 172, 173, 745
iron deficiency, Eisenmenger's syndrome 1024
ISAR-COOL study 432, 1144
ISAR-REACT trial 365–6, 368, 1145
ischemic cardiomyopathy
 ICD therapy 623–4
 non-cardiac surgery 1070
ischemic heart disease (IHD) *see* coronary artery disease
ischemic penumbra, cerebral 974
ISIS-2 trial 29, 459, 476, 483
ISIS-3 trial 461, 462, 482
ISIS-4 trial 32
isoflavones 316
isoproterenol, tilt-table testing 682
isosorbide dinitrate
 chronic stable angina 349, 350
 heart failure 760–1, 1166
 NSTEMI acute coronary syndrome 421
isosorbide mononitrate, chronic stable angina 349, 350
ISSUE 2 study 681–2, 685
Italy 96, 238
ivabradine, chronic stable angina 351
Janeway lesions 942
Japanese 239–40
 cardiovascular mortality 95, 239
 epidemiologic transition 98
 migrants 101, 236, 240
 prevention approaches 240
 risk factors 239–40
 traditional diet 240, 319
Jatene procedure *see* arterial switch operation
Jervell–Lang–Nielsen syndrome (JLN) 291, 710, 711
 treatment 712
Jikei heart study 745
job strain 203, 205, 214–15
Joint Aviation Authorities (JAA) 80
Joint European Societies' guidelines 329, 330–1
Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7) 165, 166, 170
JTT705 1160
junctional tachycardia
 automatic 612–13
 non-paroxysmal 612–13
JUPITER trial 416
Karasek job strain model 203
Kawasaki's disease, pregnancy and 997
KCNA5 gene 708
KCNE1 gene 709, 711
KCNE2 gene 708, 711
KCNH2 gene 711
KCNJ11 gene 279
KCNQ1 gene 708, 711
Kenyan Luo Migration study 311
ketorolac, acute pericarditis 847
kidney disease *see* renal disease
Killip classification 496
knowledge, improving 66–7
knowledge translation 64
 barriers 66–8
 future directions 74
 strategies to promote 69
Komo-Ise Study 213
Kuopio Ischemic Heart Disease Study (KIHD) 315
Kussmaul's sign 500
labeling dilemma 1135–6
labor management, maternal heart disease 1001–2
LADIP trial 611
lamin A/C mutations 294, 295, 707, 708–9
Late Assessment of Thrombolytic Efficacy (LATE) 460
Latin America 248, 249
 cardiovascular mortality 95
 Chagas' disease 824
 latrofiban 427
"law of diminishing returns" 39
league tables, cost-effectiveness ratios 44–5
left anterior descending (LAD) coronary artery disease
 arterial grafts 384–5
 CABG vs. medical therapy 380, 392–3, 394
 CABG vs. PCI 399
 indications for CABG 381
 indications for PCI 373, 374
 recommendations for revascularization 402
left anterior hemiblock
 pacing 643
 postinfarction 506
left anterior small thoracotomy (LAST) procedure, CABG 384
left atrial ablation, atrial fibrillation *see* atrial fibrillation, ablation therapy
left atrial isomerism 1025
left atrial tachyarrhythmia, organized *see* organized left atrial tachyarrhythmia
left atrial thrombus, mitral stenosis 916, 917
left bundle branch block (LBBB)
 acute coronary syndromes 414
 pacing indications 643, 644
 postinfarction 506
left cardiac sympathetic denervation (LCSD), long QT syndrome 712
left main coronary artery disease
 CABG 381, 392–3
 indications for PCI 373, 374
 recommendations for revascularization 402
left posterior hemiblock, pacing 643
left-to-right shunts
 atrioventricular septal defects 1011
 pregnancy and 993–4
 ventricular septal defect 1009, 1010
left ventricular aneurysms
 Chagas' cardiomyopathy 830
 postinfarction 500–1, 1153–4
left ventricular assist devices (LVADs)
 acute myocarditis 791
 end-stage heart failure 771, 1106–7
left ventricular dilation, aortic regurgitation 889, 891
left ventricular (LV) dysfunction
 CABG 380–2, 393, 394
 diabetic patients 401
 mitral regurgitation 870, 872–4
 mitral stenosis 874
 postinfarction 496–8
 ICD therapy 505, 623–4
 management 497–8, 748–50
 pathophysiology 496
 prevention 517–19
 prognostic markers 496–7
 ventricular aneurysms and 500–1
 see also cardiomyopathies; heart failure; left ventricular systolic dysfunction
left ventricular ejection fraction (LVEF)
 aortic regurgitation 889, 891
 aortic stenosis 883, 884
 ICD therapy and 623–5, 626, 1175–6
 mitral regurgitation 871, 872–3
 mitral stenosis 874
 postinfarction 496, 519
 sudden cardiac death risk stratification 619, 623
left ventricular end-diastolic dimension, aortic regurgitation 891
left ventricular end-systolic dimension, mitral regurgitation 873
left ventricular free wall rupture 501
left ventricular function
 assessment
 mitral regurgitation 872–3
 postinfarction 496
 preoperative, non-cardiac surgery 1071
 mitral regurgitation 870–1

- left ventricular hypertrophy
 aortic stenosis 882, 896
 hypertrophic cardiomyopathy 797
 sodium intake and 312
- left ventricular outflow tract obstruction (LVOTO)
 1012–14
 clinical presentation 1012
 diagnostic evaluation 1013
 management 1013–14
 outcomes and complications 1014
 pregnancy and 994, 997
 transposition of great arteries 1020
 see also aortic stenosis
- left ventricular pseudoaneurysms 501
- left ventricular remodeling
 heart failure 742
 postinfarction 496
 markers 496–7
 prevention 517–19, 522
- left ventricular systolic dysfunction (LVSD)
 735–50
 aortic regurgitation 886, 889
 aortic stenosis 882–3, 884
 asymptomatic (ALVSD)
 aortic regurgitation 886
 epidemiology 740
 management 748–50
 prognosis 740
 drug-induced 747
 peripartum cardiomyopathy 996–7
 postinfarction *see under* left ventricular (LV)
 dysfunction
 prevalence 735, 737
 see also heart failure
- left ventricular (LV) thrombus, postinfarction 502,
 1153–4
- Leriche's syndrome 1061
- levosimendan
 cardiogenic shock 499
 heart failure 765
 postinfarction heart failure 497, 498
- lidocaine (lignocaine), postinfarction 504
- LIFE study 570, 571, 745
- lifestyle
 epidemiologic transition and 97–8, 100
 sedentary 190
- lifestyle modification
 chronic stable angina 346–7
 coronary artery disease 332–4
 diabetes 225
 heart failure 770, 1165
 hypertension 165, 168–9
 integrated approach 337, 339–40
 NSTE acute coronary syndromes 1148, 1157,
 1158
 obesity 223, 224
 peripheral arterial disease 1055–7
 STEMI 520
 see also diet; exercise; smoking cessation; weight
 loss
- LIFE trial 172, 173
- LIMIT-2 32
- linear proportional hazards model 19
- linkage analysis, genetic 272–3, 296
- linkage disequilibrium 274
- alpha-linolenic acid 307
- lipid-lowering therapy 147–61
 chronic stable angina 346–7
 clinical use 161
 combination 156–7
 costs and cost effectiveness 159–60
 diabetes mellitus 158–9, 160–1
 elderly 157–8
 future directions 160–1
 heart failure prevention 744, 745, 746
 non-statin agents 152
 novel agents 155–6
 perioperative 57–8, 1075–6
 peripheral arterial disease 159, 1058
 secondary MI prevention 1157–60
 secondary stroke prevention 983–4
- STEMI 521
 treatment goals 147–8, 149
 women 158
 see also specific agents/groups of agents
- lipids, serum 138–45
 classification 148
 dietary carbohydrates and 308–9
 dietary fats and 140–1, 306–7, 308
 dietary fiber and 309–10
 effects of therapy 150–1, 152
 exercise benefits 196
 foods influencing 316
 genetic studies 279, 280, 297, 298
 heart failure risk and 743
 ischemic heart disease and 138–40, 143–4
 management policy 144
 multiple risk factor interventions 332, 335–6
 as screening tests 144
 treatment targets 147–8, 149
 see also cholesterol; dyslipidemia; fats, dietary;
 fatty acids; triglycerides
- LIPID study 150, 521
- lipoprotein (a) (Lp(a)) 150, 152
 African Americans 251
 genetic influences 280
- 5-lipoxygenase activating protein (FLAP) 273
- lisinopril
 heart failure 569, 762
 heart failure prevention 745
 hypertension 173, 571
- liver disease, chronic 1127–8
- liver transplantation 1128
- lixivaptan, heart failure 770
- LMWH *see* low molecular weight heparin
- Loeys–Dietz syndrome 1086
- logistic regression analysis 19, 20
- long QT syndrome (LQTS)
 aircraft pilots 87–9
 congenital 706, 710, 711–12
 heterogeneity 707
 molecular genetics 289, 291
 ICD therapy 630, 712
 non-pharmacologic therapy 712
 pacemaker therapy 653–4
 pharmacologic therapy 711–12
 syncope 675
- Look AHEAD trial 225, 230
- loop diuretics
 heart failure 757–8, 1165
 renal insufficiency 1114
- losartan
 animal model of hypertrophic cardiomyopathy
 299
 aortic disease 1085
 asymptomatic left ventricular systolic
 dysfunction 749
 heart failure 763
 heart failure prevention 745
 hypertension 171, 172, 174, 571
 STEMI 518
- Louis, Pierre 3
- lovastatin 149
 combination therapy 156–7
 cost-effectiveness 160
 women 158
- low- and middle-income countries (LMIC)
 cardiovascular disease epidemic 99–102
 cardiovascular disease projections 98–9
 cardiovascular mortality 95, 96, 235
 early age of cardiovascular deaths 96
 epidemiologic transition 96, 97, 98
 gaps in implementing evidence 65–6
 healthcare expenditure 107
 heart failure epidemiology 739–40
 prevention strategies 105–6
 smoking trends 111, 112
 tobacco control interventions 116, 117, 120–1
 tobacco-related deaths 113–14, 115
- low birth weight *see* birth weight
- low-calorie diets (LCDs) 224
- low-density lipoprotein (LDL), oxidation 310
- low-density lipoprotein (LDL) cholesterol 138
 benefits of lowering 147
 classification 148
 dietary fats and 306, 307
 dietary fiber and 309–10
 effects of therapy 140, 150, 152, 153, 156–7
 genetic influences 279, 280
 secondary prevention strategies 1157, 1158
 small dense particles 159
 treatment recommendations 147–8, 149, 151
 treatment targets 347, 521
- low-density lipoprotein receptor adapter protein 1
 (LDLRAP1) 271
- low-density lipoprotein receptor (LDLR) gene
 mutations 270
- low-density lipoprotein (LDL) receptor related
 protein 6 (LRP6) 272
- lower extremity arterial bypass surgery 1062
- antiplatelet therapy 1058, 1059, 1060
 smoking and outcome 1055, 1062
- low-frequency intermediate penetrance (LFIP)
 variants 282
- low molecular weight heparin (LMWH)
 acute STEMI 483–7
 acute stroke 977, 978, 982
 NSTE acute coronary syndrome 427–9, 430,
 431, 435, 1146
 PCI 368, 369
 pregnancy 1001
 prosthetic valve recipients 961–2, 964, 965
 sites of action 427, 429
 venous thromboembolism 1033, 1034, 1039,
 1040
 venous thromboprophylaxis 1042–3
- Lp(a) *see* lipoprotein (a)
- LRP6 gene mutations 272
- Lund University Cardiac Arrest System (LUCAS)
 device 699
- lung function tests 1123
- lung transplantation, pulmonary
 hypertension 1122, 1126, 1128
- LVADs *see* left ventricular assist devices
- lycopene 310–11
- Lyme myocarditis 792, 812
- lymphotoxin-alpha (LTA) 276
- Lyon Diet Heart Study 305, 307
- lysosomal storage disorders (LSD) 815–16
- MADIT trial 505, 520, 623, 626
- MADIT II trial 505, 520, 623–4, 626, 648, 750
- MADIT-CRT trial 660
- MAGIC trial 32
- magnesium, dietary intake 313
- magnesium (sulfate) therapy
 acute MI
 unreliable meta-analyses 32, 33
 VF prophylaxis 504
 atrial fibrillation 541, 556, 560–1
 cardiac arrest 698
- magnetic resonance angiography (MRA)
 peripheral arterial disease 1055
 pulmonary embolism 1038
- magnetic resonance imaging (MRI)
 acute myocarditis 787, 809
 acute stroke 973, 976
 aortic disease 1086
 aortic stenosis 879
 arrhythmic right ventricular
 cardiomyopathy 725
 atrial septal defect 1008
 coarctation of aorta 1015
 Eisenmenger's syndrome 1023
 hypertrophic cardiomyopathy 796–7
 infective endocarditis 944
 left ventricular outflow tract obstruction 1013
 patent ductus arteriosus 1016
 pericardial disease 850, 852
 tetralogy of Fallot 1019
- magnetic resonance (MR) venography 1036–7
- MAIA study 553
- malignant disease *see* cancer

Index

- Marfan syndrome
aortic valve-sparing operations 928, 929
genetics 289, 999
management of aortic disease 1087, 1090–1
pathophysiology of aortic disease 1085–6
pregnancy and 994–5, 1000
marital status 212–13
marital stress 205
MASS-2 study 372
MASTER trial 58
MAST study 977
Mauritius 106
MAZE procedure
adult congenital heart disease 1018, 1023, 1025
hypertrophic cardiomyopathy 802
mecamylamine, smoking cessation 133
mechanical prosthetic valves 931, 957–8, 959
antithrombotic therapy 961–4
bileaflet 958
caged-ball 957, 958
new developments 931–4
pregnancy and 875, 994, 1000–1
selection 935, 936
single leaflet/tilting disk 957–8
thromboembolism risk 960
thrombogenicity 957–8
vs. biologic 931, 932
young women 875
Medicine, Angioplasty or Surgery Study-II (MASS-II) 398
Medi-RIVAGE study 318
Mediterranean diet 211, 307, 308, 318
Medtronic porcine valves 933, 960
Medtronic tilting disk valve 958
MEF2A gene 272
MELT trial 976
Mendelian disorders *see* single gene disorders
“Mendelian randomization” studies 279–80, 304
Merci Retriever device, acute stroke 976
MERIT-HF trial 766–7
MERLIN trial 351, 422
mesothelioma 853
meta-analyses 26, 31–4
fixed-effect vs. random-effects methods 33
heterogeneity between trial results 33–4
individual patient data (IPD) 34
sources of bias 31–3
metabolic equivalents (METs) 1070
metabolic storage diseases 815–16
metabolic syndrome (insulin resistance syndrome)
case history 1138
ethnic populations 242
exercise 196
lipid-lowering therapy 147–8
obesity 225–6
small dense LDL-C particles 159
see also insulin resistance
meta-regression 33–4
metformin 225, 1164
methicillin-resistant *Staphylococcus aureus* (MRSA)
endocarditis 950
methylene tetrahydrofolate reductase (MTHFR)
gene polymorphism 276
alpha-methyl noradrenaline, cardiac arrest 697
methylprednisolone
atrial fibrillation prevention 577
NSTE acute coronary syndrome 433
metoprolol
acute myocarditis 788
acute STEMI 449
atrial fibrillation 544, 555, 558, 559–60
chronic stable angina 349
heart failure 766–8
NSTE acute coronary syndrome 421
paroxysmal supraventricular tachycardia 608
perioperative 54–6, 1073–5, 1183–4
Metoprolol in Dilated Cardiomyopathy (MDC)
study 766
mevastatin 149
Mexican Americans 246–8
mexiletine
long QT syndrome 711
prevention of ventricular arrhythmias 619
microalbuminuria 1112
cardiovascular risk 1112–13
heart failure risk 743
see also proteinuria
microvascular coronary disturbances *see* coronary
microvascular disturbances
middle cerebral artery (MCA) infarct,
malignant 972, 978
midodrine, vasovagal syncope 684
migrants 101–2, 236
Chinese 241–2
Hispanic 247–8
Japanese 101, 236, 240
Kenyan Luo 311
South Asian 243, 245
milk and milk products 317
milrinone, heart failure 765
MIND-IT study 206
mineralocorticoid receptor mutations 299
minerals 311–13
minocycline, intrapericardial 854
MIRACLE study 656
MIRACLE ICD study 656
MIRACLE ICD II study 656, 660
MIRACL study 150, 433, 572–4, 1149
mitochondrial cardiomyopathies 289
mitochondrial inheritance 289, 290
mitomycin C, intrapericardial 854
mitoxantrone, intrapericardial 854
mitral commissurotomy
closed surgical 913, 919–20
open 875, 913, 919–20
percutaneous balloon *see* percutaneous balloon
mitral valvuloplasty
restenosis after 920
mitral insufficiency (MI) *see* mitral regurgitation
mitral regurgitation (MR) 869–74
acute
hemodynamics 870
management 872
postinfarction 503
assessing symptom status 873
asymptomatic 873
balloon mitral valvuloplasty and 916, 917, 921
cardiomyopathic 874
chronic 872–3
hemodynamics 870
etiologic 869
far advanced 873–4
functional 874
indications for surgery 871–4
infective endocarditis 945
ischemic 503, 874, 929
valve repair 930
medical therapy 874
mitral valve repair 929–31
non-ischemic 930–1
pathophysiology 870–1
pregnancy and 994
severity assessment 871–2
mitral stenosis (MS) 874–5
etiologic and pathophysiology 874–5
indications for surgery 875
mitral valve repair 929–30
percutaneous balloon valvuloplasty 913–22
pregnancy 996, 1000
rheumatic 929–30
severity assessment 917
Wilkins–Weyman (MGH) scoring system
915–16
mitral valve
Barlow’s disease 930
endocarditis 930
severe calcification 917
mitral valve annuloplasty, undersized 930
mitral valve disease 869–75
myxomatous or degenerative 930
rheumatic 929–30
mitral valve repair 869, 929–31
guidelines 935
indications 872–3
infective endocarditis 945
vs. replacement 871
mitral valve replacement (MVR) 913
Chagas’ cardiomyopathy 835
choice of valve 931–5, 936
importance of chordal preservation 871, 930
indications 873, 875
vs. repair 930
mitral valve surgery
indications 871–3
postinfarction 503
timing 869, 875
young women 875
mitral valvotomy
closed 913
percutaneous balloon *see* percutaneous balloon
mitral valvuloplasty
mitral valvulotome, percutaneous metallic 919
mobile cardiac outpatient telemetry (MCOT) 681, 682
Modification of Diet in Renal Disease (MDRD)
formula 1111
molecular genetics 288–300
MONICA project 211, 213, 236, 735, 742
monogenic disorders *see* single gene disorders
monounsaturated fatty acids (MUFA) 307, 308
Montreal Heart Attack Readjustment Trial
(M-HART) 507
Montreal Study 422
mood disorders, smoking cessation and 129–30, 132
morcinizine, sudden cardiac death prevention
619–20
morphine
acute STEMI 448
non-ST segment elevation ACS 419–20
Morrow procedure 803
mortality
cost-effectiveness analysis 43
ethnic variations 237–51
global cardiovascular 95–6, 98–9, 235–6, 495
operative, defined 928
risk scores 330–1
MOST trial 645–6, 647, 648, 1180
moxonidine, heart failure 768–9
MRI *see* magnetic resonance imaging
MTAP gene 279
mucopolysaccharidoses (MPS) 816
Multicenter Diltiazem Post-infarction Trial 213
Multiple Risk Factor Intervention Trial (MRFIT)
102–3, 104, 168, 203, 212–13
MULTISTRATEGY trial 467, 481
Mustard operation 1020
late complications 1021, 1024, 1025
pregnancy after 995–6
MUSTIC trial 656
MUSTT trial 520, 623, 626
MWNAF trial 584
mycophenolate, heart transplant recipients 1103–4
myocardial infarction (MI)
acute (AMI) 1152–6
ACE inhibitors 498
antithrombotic therapies 449, 475–91
CABG 468–9
clinical decision-making 1152–6
clinical diagnosis 410–11
fibrinolytic therapy *see* fibrinolytic therapy,
acute MI
hemodynamic therapy 497–8
new definition 495
patient delay 444–7
PCI *see* percutaneous coronary intervention
(PCI), primary
prehospital diagnosis 447
prehospital management 447–52
reperfusion therapy *see under* reperfusion
therapy
sinus tachycardia 609
symptoms 447

- complications 495–507
 atrial fibrillation 505–6, 591, 593
 case history 1153–4
 conduction disturbances 506, 638, 643–4
 heart failure *see* heart failure (HF),
 postinfarction
 see also specific complications
 diabetes-related risk 181, 182
 exercise-related 195
 expansion 495
 extension 495
 Forrester classification 496
 gaps in implementing evidence 65
 hypertension-related risk 166, 167
 ICD therapy after 505, 520, 623–4, 1174–6
 Killip classification 496
 management after early phase 516–22, 1155
 evidence-based integrated approach 522
 ICD therapy 505, 520, 623–4
 invasive evaluation and PCI 516–17
 preventing arrhythmias 519–20, 619–22
 preventing cardiac remodeling 517–19
 secondary prevention 520–2
 non-cardiac surgery after 1070, 1072
 non-ST segment elevation (NSTEMI) 409
 biomarkers 416
 clinical diagnosis 410, 411
 diabetes mellitus 413–14
 incidence, natural history and
 prognosis 411–13
 management 419–35
 reinfarction 495, 496
 secondary prevention strategies 1157–61
 see also acute coronary syndromes
 perioperative 52–4, 1077
 benefits of surveillance 53–4
 clinical significance 53
 diagnosis 53
 pathophysiology 52–3
 prevention 54–8
 pregnancy 997
 prevention *see* prevention
 prognostic markers 496–7
 recurrent (reinfarction) 495–6
 after fibrinolysis 462
 right ventricular 499–500
 silent 447
 smoking-related risk 112, 113
 ST segment elevation (STEMI) 409
 acute *see* myocardial infarction (MI), acute
 clinical diagnosis 410, 411
 discharge after 520
 incidence 411
 management after early phase 516–22
 natural history and prognosis 412
 pathophysiology 456
 reinfarction 495–6
 sudden cardiac death prevention 619–20
 syncope 679
 myocardial ischemia
 asymptomatic
 diabetic patients 400–1
 management guidelines 373, 381
 Chagas' cardiomyopathy 828
 early postinfarction 410
 exercise benefits 197
 medical management 346–51
 pathophysiology 346, 357
 postinfarction, management 516–17
 refractory 414–15, 433, 1147
 silent 346
 syncope 679
 see also angina
 myocardial necrosis 456
 myocardial reperfusion therapy *see under*
 reperfusion therapy
 myocardial revascularization
 aircraft pilots 84–5
 broad indications 392
 chronic stable angina 351–2, 353, 402
 diabetic patients 400–2
 individual decision-making 400
 NSTEMI acute coronary syndrome 431–3, 434
 peripheral artery disease 1184, 1185
 prior to non-cardiac surgery 58, 1184
 see also coronary artery bypass grafting;
 percutaneous coronary intervention;
 reperfusion therapy
 myocarditis 784–93
 acute 784–93
 clinical presentation 784, 786
 diagnosis 786–7
 heart failure therapy 787–9
 incidence 784–5
 natural history and prognosis 785–6
 specific therapy 789–91
 acute necrotizing eosinophilic 785, 792
 autoimmune 785, 786
 bacterial 810–12
 Chagas' 792, 825, 827
 chronic 786
 Dallas criteria 784, 787
 definition 784
 eosinophilic 792
 etiologies 784, 785
 fulminant 785, 787
 giant cell (GCM) 785, 791, Plate 48.2
 HIV 792, 808
 hypersensitivity 785, 791–2
 infectious 785, 808–12
 Lyme 792
 lymphocytic 785, Plate 48.1
 management 787–91
 pathogenesis 786
 prevention 791
 subacute 786
 viral 784, 785, 808–10
 clinical presentation and diagnosis 808–9
 management 789, 790, 809–10, 811
 pathogenesis 786
 prevention 791
 see also dilated cardiomyopathy
 Myocarditis Treatment Trial 784–5, 786, 787, 790,
 810
 myocardium
 free wall rupture 501
 hibernating 497
 stunned 497
 Trypanosoma cruzi-induced damage 828
 myoglobin, NSTEMI acute coronary syndrome 415
 myosin-binding protein C mutations 293, 798
 myosin heavy chain (MHC) mutations 293, 294,
 295, 299, 798
 myosin light chain mutations 293
 myozenin 2 (MYOZ2) gene 292, 293

 n-3 fatty acids *see* omega-3 polyunsaturated fatty
 acids
 n-6 fatty acids 307
 NADPH oxidase 297
 nadroparin
 NSTEMI acute coronary syndrome 429
 prosthetic valve recipients 961–2
 nafcillin, infective endocarditis 950
 naftidrofuryl, intermittent claudication 1060, 1061
 narrow QRS complexes, cardiac resynchronization
 therapy 659–60
 NASCET trial 984
 NAS-PAEF study 585
 nateglinide 186
 National Cardiovascular Data Registry (NCDR)
 70
 National Cholesterol Education Program (NCEP),
 Adult Treatment Panels (ATP) 147–8, 149,
 158, 226
 National Health and Nutrition Examination
 Survey (NHANES) 315, 318
 National Health Interview Survey (NHIS) 247
 National Heart Attack Alert Working Group 463
 National Heart Foundation of Australia 309, 313
 National Institute of Neurologic Disease and
 Stroke (NINDS) tPA Stroke Study 974–5

 National Institutes of Health Stroke Scale (NIHSS)
 975
 National Longitudinal Mortality Study 247
 National Millennium Project of Japan 174
 Native Americans 248–50
 natriuretic peptides, beta-type *see* brain natriuretic
 peptide
 NAVIGATOR trial 186
 Naxos disease 296, 714, 722
 pathogenesis 723
 nebivolol, heart failure 767, 768
Neisseria meningitidis pericarditis 849
 neonates
 mothers with heart disease 999
 persistent pulmonary hypertension 1127
 nesiritide
 cardiogenic shock 499
 heart failure 760
 postinfarction heart failure 497, 498
 Netherlands, cardiovascular mortality 96
 neuraxial blockade, perioperative vascular events
 and 58
 neurologic disorders
 acute ischemic stroke 978
 syncope 679
 neurologic studies, syncope 683
 neuroprotective therapy
 acute stroke 977
 aortic surgery 1091, 1093
 nevirapine 1161
 New York Heart Association (NYHA) functional
 capacity
 aortic valve disease 889, 890, 900
 biventricular pacing 650
 CRT 640, 655–6, 659, 660
 CRT plus ICD therapy 660–1
 ICD therapy 505, 625, 631
 mitral stenosis 875
 pulmonary hypertension 1120
 sudden cardiac death and 619
 niacin *see* nicotinic acid
 NICE-1 trial 368
 nicorandil, chronic stable angina 351
 nicotine 126
 addiction 128–9
 vaccine 134
 withdrawal symptoms 128, 130–2
 see also smoking; tobacco
 nicotine replacement therapy (NRT) 119, 130–2,
 133
 cost effectiveness 119–21
 peripheral arterial disease 1055–6
 nicotinic acetylcholine receptors (nAChR) 128
 nicotinic acid (niacin) 151–3
 chronic stable angina 347
 combination therapy 156, 157
 diabetes mellitus 158
 peripheral arterial disease 1058
 secondary prevention of MI 1157–8, 1159–60
 nifedipine
 aortic regurgitation 888–9
 chronic stable angina 349
 heart failure 761
 heart failure prevention 744
 NSTEMI acute coronary syndrome 421
 nifurtimox, Chagas' disease 830
 Ni-Ho-San study 101, 236
 nitrates
 acute STEMI 449
 chronic stable angina 349, 350
 heart failure 759–61, 1166
 NSTEMI acute coronary syndrome 420, 421
 phosphodiesterase-5 inhibitor interactions
 420
 postinfarction 497, 498
 nitrendipine 171, 745
 nitric oxide (NO)
 pulmonary hypertension 1124, 1125, 1127
 smoking-related effects 126
 nitric oxide synthase, endothelial (eNOS), gene
 polymorphism 276

Index

- nitroglycerin (NTG)
 - acute STEMI 448, 449
 - chronic stable angina 349, 350
 - heart failure 759–60
 - intraoperative 1077
 - NSTE acute coronary syndrome 420, 435, 1147
 - phosphodiesterase-5 inhibitor interactions 420
 - tilt-table testing 682
 - nitroprusside
 - aortic stenosis 882–3
 - heart failure 760
 - non-communicable diseases *see* chronic non-communicable diseases
 - non-exercise activity thermogenesis (NEAT) 190
 - non-inferiority trials 29
 - non-steroidal anti-inflammatory drugs (NSAIDs)
 - acute MI 448–9
 - acute pericarditis 845, 847
 - myocarditis 790
 - postinfarction pericarditis 501–2, 1154
 - recurrent pericarditis 848
 - renin system inhibition and 1114
 - rheumatic fever 865
 - non-ST segment elevation acute coronary syndromes *see* acute coronary syndromes (ACS), non-ST segment elevation
 - non-ST segment elevation myocardial infarction *see* myocardial infarction (MI), non-ST segment elevation
 - Noonan syndrome 289
 - NORDIC trial 374
 - NORDIL trial 744
 - North American Aboriginal populations 248–50
 - North American Symptomatic Carotid Endarterectomy Trial (NASCET) 984
 - North Karelia Project 105–6, 239
 - nortriptyline, smoking cessation 133
 - Norway, cardiovascular mortality 96
 - Norwegian Vitamin Trial (NORVIT) 311
 - NSTEMI *see* myocardial infarction (MI), non-ST segment elevation
 - Nurses' Health Study (NHS)
 - diet 306–7, 309, 315
 - physical activity 192, 196
 - nursing interventions, postinfarction 507
 - nutrients, cardiovascular disease and 306–11
 - nuts 316
 - NXY-059, acute stroke 977

 - OASIS-2 trial 429, 430
 - OASIS-5 trial 369, 429, 489, 1146
 - OASIS-6 trial 489–90
 - OASIS-7 trial 365, 366
 - OASIS pilot study 429, 430
 - OASIS registry 412
 - OAT trial 517
 - obesity 221–31
 - abdominal (central) 221
 - ethnic variations 242
 - fetal programming 261
 - temporal trends 333–4
 - cardiovascular benefits of weight loss 230
 - classification 221–2
 - definitions 221, 222
 - diabetes 222, 224, 225
 - dyslipidemia 225–6
 - early life influences 261, 262, 263, 264
 - epidemiologic transition 97, 100
 - ethnic populations 239–40, 243, 244, 246, 250
 - exercise 196, 224
 - health hazards 222
 - heart failure prevention 744, 747
 - heart failure risk 743
 - hypertension 222, 224–5, 227
 - management 223, 224–30
 - maternal, effects on offspring 262, 263
 - natural history 222
 - pathophysiology 222–4
 - pharmacotherapy 226–7
 - social determinants 216–17
 - surgery 227–30
 - temporal trends 222, 333–4
 - thrifty gene hypothesis 101
 - weight reduction 223, 224–6
- obesogenic environment 217
- O'Brien–Fleming rule 31
- observational studies 26, 34–5
- occupational physical activity 191
- Octopus study 383
- Odyssey study 315
- Ohsaki study 310
- Okinawa diet 240
- OKT3 monoclonal antibody 1102, 1104
- older patients *see* elderly patients
- olive oil 318
- olmesartan, atrial fibrillation prevention 572
- Olmsted County Study 736, 738, 739
- omega-3 (n-3) polyunsaturated fatty acids 307, 314
 - atrial fibrillation prevention 575–7
 - ICD recipients 627–8
 - sudden cardiac death prevention 622
- omega-6 (n-6) polyunsaturated fatty acids 307
- ONTARGET trial 980, 1149
- ON-TIME 2 study 481
- on treatment analysis 28
- OPPOSITE trial 600
- OPTIC trial 620, 626
- OPTIMAAL study 518, 749
- oral anticoagulants (OAC)
 - atrial fibrillation 581–5, 591
 - peripheral arterial disease 1059, 1060
 - prosthetic valve recipients 959–60, 961–5
 - self-monitoring 963
 - venous thromboembolism 1033, 1034, 1040–1*see also* anticoagulation; warfarin
- orbofiban 427
- organizational quality improvement interventions 69–71
- organized left atrial tachyarrhythmia (OLAT), after left atrial ablation 602, 603, Plate 38.2, Plate 38.3
- ORIGIN trial 186
- orlistat 226–7
- orthopedic surgery, venous thromboprophylaxis 1043
- Osler nodes 942
- Ottawa Heart Genome Study 298
- outcomes (endpoints)
 - blinding of assessment 27
 - clinical assessment for predicting 17
 - cost-effectiveness analysis 43
 - dietary studies 304–5
 - public reporting 71, 72
- outpatient settings, gaps in implementing evidence 65, 66
- overweight
 - cardiovascular benefits of weight loss 230
 - classification 221, 222
 - fetal influences 261, 262
 - management 223, 224–30*see also* obesity
- oxacillin, infective endocarditis 950
- Oxford Vascular Study (OXVASC) 971, 972
- oxygen administration
 - acute MI 448
 - acute stroke 973
 - Eisenmenger syndrome 1024
 - portopulmonary hypertension 1128
-
- p22^{phox} protein 297
- PABA-CHF trial 597, 600
- PAC-A-TACH trial 646
- Pacemaker Selection in the Elderly (PASE) study 645, 646, 647, 1180
- pacemaker syndrome 644
- pacemaker therapy
 - acute myocarditis 790
 - alternative site and multisite pacing 649–50
 - atrial fibrillation 597, 639, 653
 - ablate and pace strategy 599–600, 650
 - atrial flutter 611
-
- biventricular pacing 649–50
- cardiac arrest 699
- case histories 1178–81
- Chagas' cardiomyopathy 834
- congenital heart disease 641, 1025
- current practice 636
- future perspectives 661
- goals 636
- heart transplant recipients 1104–5
- hypertrophic cardiomyopathy 640, 652–3, 803
- indications
 - ACC/AHA guidelines 637–41
 - conventional 642–4
 - new 650–4
- mode selection in AV block/sinus node disease 644–8, 1179–81
- new paradigm for physiologic 648–9
- postinfarction 500, 506, 519
- statin therapy with 574
- syncope 684–5
- ventricular dyssynchrony 649
- see also*
- cardiac resynchronization therapy
- PACE trial 650
- paclitaxel-coated balloons, peripheral arterial disease 1062
- paclitaxel-eluting coronary stents 361, 362–3
 - acute STEMI 467
 - safety 396–7
- PAF 2 study 535
- PAFAC study 544–5, 546, 547, 548–9
- PAMI trial 464
- PAMI-2 trial 469
- Pamplona Hospital Study 315
- panel-reactive antibodies (PRA), heart donor selection 1102
- PAPABEAR study 560
- Papa India aircraft disaster 80–1
- paradoxical embolization 993
- PARAGON-A study 414
- paraoxonase gene polymorphism 276
- paraplegia, after thoracoabdominal aortic repair 1092–3
- parasitic infections 812
- paravalvular abscess 952
- Paroxysmal Supraventricular Tachycardia (PSVT) trial 545
- PARTNER trial 906
- parvovirus B19 myocarditis 808
- PASSION trial 467
- PATAF trial 583, 584
- patent ductus arteriosus (PDA) 1015–16
 - management 1016
 - pregnancy 993
- PATH-CHF trial 655
- PATH-CHF II trial 655–6
- Pathobiological Determinants of Atherosclerosis in Youth (PDAY) 258
- patient-centered medicine 1135, 1136
- patient–physician interface 3–12
- patients
 - actions, driving decision making 6
 - applicability of evidence to 8–9, 10–11
 - communication with 9
 - education 70
 - implementing evidence-based cardiology and 67
 - preferences, driving decision making 5–6, 1136–7
 - responses to symptoms, acute coronary syndromes 419, 444–7
 - shared decision making 9–10
- PAVE trial 600, 650
- pay-for-performance programs 71–2
- PBAV *see* percutaneous balloon aortic valvuloplasty
- PBMV *see* percutaneous balloon mitral valvuloplasty
- PCI *see* percutaneous coronary intervention
- PCI-CLARITY trial 477–8
- PCI-CURE trial 365, 424, 477–8, 1153
- PCSK9 gene 270, 271, 282
- PEACE trial 347, 498, 745, 746

- penetrance 296
penetrating atherosclerotic ulcer (PAU) of thoracic aorta 1081, 1082
incidence 1084
management 1087, 1089
penicillin
group A streptococcal pharyngitis 862–3, 866
infective endocarditis 946, 947, 948, 949
pregnant women 1000
rheumatic carditis 811–12, 864
rheumatic fever 864, 866
PENTALYSE study 488–9
pentoxifylline
intermittent claudication 1060, 1061
prosthetic valve recipients 962
Penumbra System aspiration catheter, acute stroke 976
PEP-CHF study 772
percutaneous balloon aortic valvuloplasty (PBAV) 896, 898–904
as bridge to replacement 883, 904
complications 899, 901
effectiveness 898–901, 902–3
factors affecting outcome 901
pregnancy and 994
repeat 902–3, 904
therapeutic role 904, 909
vs. transcatheter aortic valve replacement 908, 909
percutaneous balloon mitral valvuloplasty (PBMV) 913–22
alternative techniques 913, 918–19
bioprosthetic valves 921
complications 921
contraindications 917
cylindrical balloon technique 918, 919
indications 875, 914–15
Inoue technique 913–14, 917–18
vs. cylindrical balloon technique 919, 921
mechanism and pathophysiology 914
postprocedure management 921
pregnancy 920, 996
preprocedure evaluation 915–17
procedure 917–18
prognostic scoring systems 915–16
pulmonary hypertension 920
restenosis 920
tricuspid insufficiency 920
vs. open and closed surgical commissurotomy 919–20
percutaneous balloon pulmonary valvuloplasty 1017
percutaneous coronary intervention (PCI) 357–74
aircraft pilots 84–5
atherectomy 363
atrial fibrillation and 591, 593
cardiogenic shock 499
challenging anatomic lesions 373–4
diabetes mellitus 400–2
early routine, STEMI 516–17
elective postinfarction 517
facilitated, STEMI 451, 480, 1153
gaps in implementing evidence 65
intravascular ultrasound 363–4
NSTEMI acute coronary syndrome 431–3, 434, 1147
pregnant women 997
pressure wire 364–5
primary (direct) 449, 451, 464–8
adjunctive anticoagulants 483, 486–7, 488, 490
adjunctive antiplatelet agents 477–8, 480–1
adjunctive antithrombotic therapy 475, 490
case history 1152–3
coronary stents 466–7
door-to-balloon time 464–6
embolization protection devices 468
historic perspective 457
intracoronary aspiration/thrombectomy devices 467–8
management of multivessel disease after 517
recommendations 466
technology trials 466–8
vs. fibrinolysis 464, 465
principles and historic overview 357–8
prior to non-cardiac surgery 58
quality improvement strategies 70, 72
renal insufficiency 1115
rescue, STEMI 451
stable coronary artery disease 359–73, 393–7, 402
adjunctive pharmacology trials 365–9
indications 373, 374
technology trials 359–65
STEMI after early phase 516–17, 522
target lesions 379, 380
technology 358
vascular access 358–9
vs. CABG 398–402, 1138–40
vs. medical therapy 351–2, 369–73, 395, 396, 1138–40
see also coronary stents; percutaneous transluminal coronary angioplasty
percutaneous transluminal angioplasty
carotid artery stenosis 985
coarctation of aorta 1015
peripheral arterial disease 1061–2
antiplatelet therapy 1058, 1059, 1060
percutaneous transluminal coronary angioplasty (PTCA) (balloon angioplasty) 357
alone vs. PTCA with coronary stenting 359–60, 360–1, 395
applications 358
intravascular ultrasound guidance 364
vs. CABG 398
vs. medical therapy 369–72, 393–5
pericardial biopsy
neoplastic pericarditis 853
tuberculosis 850, 851
pericardial calcification 852
pericardial disease 845–54
primary acute 846–7
pericardial effusion
causes 846
chronic idiopathic 845, 848
neoplastic 853–4
postinfarction 502
tuberculous 850–3
pericardiectomy
chronic idiopathic pericardial effusion 849
purulent pericarditis 849–50
tuberculous constrictive pericarditis 852
pericardiocentesis
diagnostic 846, 849, 851, 853
therapeutic 849, 851, 853
pericardiotomy 849, 851, 853–4
pericarditis
acute 845, 846–7
autoimmune 848
causes 846
constrictive, tuberculous 851–2
effusive constrictive tuberculous 852
neoplastic 845, 853–4
postinfarction 501–2, 1153–4
purulent 845, 849–50
recurrent 848
tuberculous 845, 850–3
perindopril
heart failure 772
heart failure prevention 745, 746
hypertension 171, 172–4
postinfarction 498
PeriOperative ISchemic Evaluation trial see POISE trial
peripartum cardiomyopathy 996–7
peripheral arterial disease (PAD) 1050–63
coronary artery disease and 1051, 1052, 1183–5
diagnosis 1052–5
epidemiology and natural history 1050–1
lipid-lowering therapy 159, 1058
risk factors 142, 1051–2
Rutherford staging 1053
treatment 1055–62
lifestyle modification 1055–7
secondary event prevention 1057–60
surgery 1061–2
targeting circulatory disease 1060–2
see also critical limb ischemia; intermittent claudication
pexelizumab 433
pharmacogenetics
cardiovascular disease 282–3
hypertension 174–5
Phase A to Z trial 521
phenprocoumon 959
phlebotomy, Eisenmenger's syndrome 1024
phosphatidylinositol, oral supplements 1160
phosphodiesterase-5 inhibitors
Eisenmenger syndrome 1024
nitroglycerin interaction 420
pulmonary hypertension 1124, 1126, 1127
phospholipids, oral supplements 1160
phrenic nerve injury, after left atrial ablation 603
physical activity 190–8
cardioprotective effects 191–2
definition 190
ethnic variations 244, 246
obesity 196, 224
occupational 191
postinfarction 521–2
recommendations 197–8, 224
social determinants 216
see also exercise
Physical Counter-pressure Maneuver (PCM) trial 684
physicians
barriers to changing practice 67, 68
individual preferences 4
quality improvement interventions 69–70, 71–2, 75
Physician's Health Study (PHS) 315, 576, 577
PIAF study 533, 534, 536
pilsicainide, atrial fibrillation 546
Pima Indians 261
pioglitazone 185
plakoglobin (JUP) mutations 295–6, 722, 723
plakophilin 2 (PKP2) mutations 295–6
plaque, atherosclerotic see atherosclerotic plaque
plasmin 457
plasminogen activator inhibitor (PAI-1) gene polymorphism 276
plasminogen activators 457
platelet-derived growth factor (PDGF) 1126
platelets
NSTEMI acute coronary syndrome 418–19
psychosocial influences on activation 202
STEMI 475–6
PLATFORM trial 423
PLATO trial 423
plexogenic pulmonary arteriopathy (PPA) 1118, 1119–20
PODIS study 242
point mutations 289
POISE trial
diagnosis of perioperative MI 53
incidence of perioperative complications 47–8
pathophysiology of perioperative MI 52
perioperative beta-blockers 54–6, 1073–5, 1183–4
predictors of postoperative ischemia 1070
Poland 98, 106, 112, 239
policies
cost-effectiveness and 45
diet and nutrition 320–1
policosanol 155
polygenic disorders 288, 296–9
Polypill concept 337–9
polyunsaturated fatty acids (PUFAs) 307–8
atrial fibrillation prevention 569, 575–7
n-3 (omega-3) see omega-3 polyunsaturated fatty acids
n-6 (omega-6) 307
Pompe disease 816

Index

- POPP trial 646–7
population
 approach to prevention 104–6
 growth and aging 100
portopulmonary hypertension 1127–8
Portugal, cardiovascular mortality 96
Portuguese Salt Trial 312
Post-CABG study 157
post-test probability 17–18
post-test referral bias 18–19
post-transplant lymphoproliferative disorder (PTLD) 1105–6
potassium
 dietary intake 312–13
 supplementation 168, 169, 312–13
potassium channel gene mutations 291, 292, 707–8, 711
Potts shunt 1022
power, study 29, 30
PPP Project 149–50, 158, 159
practice-based research networks 74–5
PRAGUE-4 trial 383
PRAISE trial 761
prasugrel
 acute STEMI 477, 478
 NSTE acute coronary syndrome 423, 424–5
 PCI 366
pravastatin 149, 150, 151
 atrial fibrillation prevention 573, 574–5
 combination therapy 157
 cost effectiveness 160
 diabetes mellitus 158–9
 elderly 157–8
 heart failure prevention 745, 746
 NSTE acute coronary syndrome 433–5
precordial thump 695
prediabetes 179, 180
 see also impaired fasting glucose; impaired glucose tolerance
prednisone/prednisolone
 myocarditis 789–90, 810, 811
 rheumatic fever 865
pre-eclampsia 1001
 effects on offspring 260, 261
pregnancy 993–1002
 balloon valvuloplasty 920, 994, 995, 996
 cardiac surgery 994
 cardiovascular physiology 993
 congenital heart disease 993–6, 998, 999
 coronary artery disease 997
 Eisenmenger syndrome 995, 1001, 1002, 1024, 1127
 heart disease and 993–1002
 antepartum care 999–1001
 labor and delivery 1001–2
 management 997–1002
 outcomes 993–7
 risk stratification and counseling 997–9
 hypertension in 1001
 hypertrophic cardiomyopathy 997
 peripartum cardiomyopathy 996–7
 prosthetic valve recipients 875, 994, 1000–1
 pulmonary hypertension 995, 1127
 rheumatic heart disease 996
 undernutrition during 260
prehospital settings
 acute MI 444–52
 diagnosis 447
 integrated system-wide reperfusion program 451–2
 management 447–51
 patient's response 419, 444–7
 see also emergency medical systems (EMS), prehospital
 acute stroke 972–3
 defibrillation 448, 692
 see also emergency medical systems (EMS), prehospital
prehypertension 165, 166
 natural history 166–8
PREMIER trial 312
preoperative cardiac risk prediction 48–52, 1068–73, 1074
 case history 1183–5
 clinical models 48–50
 co-morbid conditions 1069–71
 diagnostic testing 50–2, 1070, 1071–2
 history and physical examination 1069
 type of surgery 1071–3
pressure wire, PCI 364–5
pretest probability 15–16, 17–18
PREVAIL trial 978
PREVALENT Risk Score 1052
PREVENT-HF trial 650
prevention of cardiovascular disease 104–6, 328–41
 aircraft pilots 83–4
 antihypertensive therapy 169–74
 cost effectiveness 44, 106–7
 ethnic populations 238–52
 EUROACTION program 336–7, 338
 evidence to support action 107
 exercise and physical activity 191–2
 fetal/early childhood determinants and 264
 glucose-lowering therapy 185–6
 high-risk strategy 104, 328, 329–31
 integrated approach 106, 333–4, 336–7, 338, 339–40
 lipid-lowering agents 140, 147–61
 Polypill concept 337–9
 population strategy 104–6, 328, 329
 primary 334–6, 341
 primordial 106
 secondary *see* secondary prevention of cardiovascular disease
 smoking cessation interventions 129–34
 strategies 328–9
 tobacco control 117, 118, 119, 127
prevention paradox 104
PRIMA trial 517
PRINCE study 149
PRISM-PLUS trial 426
PROACT-II study 976
PROACTIVE study 185, 186
probability trade-off technique 6, 11
PROBE study designs 27
procainamide
 atrial fibrillation 537, 538, 541, 561
 atrioventricular reciprocating tachycardia 613
PROFESS trial 982
PROGRESS trial 171, 980
propafenone
 atrial fibrillation 537–9, 538, 545–6, 561
 atrioventricular reciprocating tachycardia 614
 paroxysmal supraventricular tachycardia 608
Propafenone Atrial Fibrillation Trial (PAFT) 545
propranolol
 atrial fibrillation 555, 558
 chronic stable angina 349
 NSTE acute coronary syndrome 421
proprotein convertase subtilisin/kexin type 9 (PCSK9) 271, 282
prospective randomized open-label blinded endpoint (PROBE) study designs 27
Prospective Studies Collaboration (PSC) 138–9, 140
PROSPECT study 659
PROSPER trial 157–8
prostacyclin
 pulmonary hypertension 1124, 1125
 unstable angina 423
prostaglandins
 peripheral arterial disease 1061, 1063
 pulmonary hypertension 1124, 1125, 1126, 1127
prosthetic grafts
 aortic disease 1087–8, 1092, 1093
 peripheral arterial disease 1062
prosthetic heart valves 931–5
 ACC/AHA guidelines 935
 antithrombotic therapy 957–66
 mechanical vs. biologic 931, 932
 models 959
 new developments 931–5
 pregnancy and 875, 994, 1000–1
 thromboembolism risk 960
 thrombogenicity 957–9, 961
 types 931
 see also valve replacement surgery
prosthetic valve endocarditis (PVE) 941, 942
 antibiotic therapy 945, 947, 949, 950
 mortality 953
 surgical treatment 945
protease-activated receptor (PAR) antagonists, NSTE acute coronary syndrome 427
protein, urinary excretion *see* proteinuria
protein C deficiency 1035
protein S deficiency 1035
proteinuria 1111–12
 cardiovascular risk 1112–13
 pathophysiologic effects 1113–14
 therapeutic implications 1113–15
prothrombin gene polymorphism 276, 1035
prourokinase, intra-arterial, acute stroke 976
PROVED trial 757
PROVE-IT trial 433–5, 521, 745, 746, 1149
providers, healthcare
 barriers to knowledge translation 66–8
 educational interventions 69, 70, 75
 quality improvement interventions 69–70
 see also hospitals; physicians
PRT060128, NSTE acute coronary syndrome 423
pseudoaneurysms, left ventricular 501
psychiatric disorders, syncope 679
psychologic treatment 206
psychosocial factors 201–7
 cardiovascular disease risk 202–4, 212–15
 established cardiovascular disease 204–5, 213
 interventions targeting 205–6
 patient delay in acute MI 446
 potential mechanisms 201–2, 215
psychosocial interventions, postinfarction 506–7
psychosocial problems
 postinfarction patients 506–7
 see also stress
PTCA *see* percutaneous transluminal coronary angioplasty
publication bias 32–3
 genetic studies 275
 psychosocial studies 205, 206
pulmonary angiography
 pulmonary embolism 1037, 1039
 pulmonary hypertension 1123
pulmonary arteriopathy, plexogenic (PPA) 1118, 1119–20
pulmonary artery banding 1022
pulmonary artery catheterization
 non-cardiac surgery 1077
 postinfarction 496
pulmonary autograft 934–5
 see also Ross procedure
pulmonary congestion
 mitral regurgitation 870
 postinfarction 496–8
pulmonary disease
 non-cardiac surgery 1069
 pulmonary arterial hypertension 1118, 1119
pulmonary edema
 heart failure 758
 infective endocarditis 952
pulmonary embolism (PE) 1032
 Chagas' cardiomyopathy 830
 diagnosis 1037–9
 fibrinolytic therapy 698
 natural history and prognosis 1032–5
 postoperative 1042
 prevention 1033, 1041, 1042–3
 stroke patients 978
 syncope 679
 treatment 1033–4, 1040–2
Pulmonary Embolism Prevention (PEP) trial 57
pulmonary (arterial) hypertension (PAH) 1118–28
 acute vasodilator response 1125–6
 atrioventricular septal defect 1011

- balloon mitral valvuloplasty 914–15, 920
 children 1126–7
 chronic liver disease 1127–8
 chronic thromboembolic (CTEPH) 1118, 1121, 1122, 1126
 diagnosis 1121–3
 Eisenmenger syndrome 1023
 etiology 1118, **1119**
 familial 1123
 genetic aspects 1123
 HIV disease 1120, 1128
 idiopathic 1118, 1123
 mitral stenosis 875
 natural history 1120–1
 pathology 1119–20
 pathophysiology 1123–4
 pregnancy 995, 1127
 quality of life 1120
 survival 1120
 syncope 679
 therapeutic options 1124–6
 therapeutic targets 1124, *1125*
 ventricular septal defect 1009
- pulmonary regurgitation (PR)
 pregnancy 994
 tetralogy of Fallot 1019
- pulmonary thromboembolic disease, chronic 1118
 investigations 1121, 1122, 1123
 treatment 1126
- pulmonary thromboendarterectomy 1126
- pulmonary valve replacement (PVR) 1017
- pulmonary valve stenosis (PVS) 1016–17
 management 1017
 pregnancy 995
- pulmonary vascular resistance (PVR)
 heart donors 1101–2
 pulmonary hypertension 1120, 1123
- pulmonary veins (PVs)
 atrial fibrillation triggers 597
 isolation *see* atrial fibrillation (AF), ablation therapy
 stenosis, complicating RF ablation 601–2
- pulse oximetry
 Ebstein anomaly 1017
 Eisenmenger syndrome 1023
- pulses, peripheral 1053
- PURSUIT score 417, 418
- PURSUIT trial 426
- P values 8
- Q fever 812
- quality-adjusted life years (QALYs) 43–4
- quality improvement 68–75
 framework for categorizing 69
 future directions 72–5
 improving provider education 75
 science (research) 64, 68–75
 strategies 68–72
- quality of life, pulmonary hypertension 1120
- quinapril
 chronic stable angina 347
 heart failure 763
- quinidine
 atrial fibrillation
 pharmacologic cardioversion 537, **538**, 541
 prophylaxis 544–5
 Brugada syndrome 714
 short QT syndrome 713
- RAAFT studies 598
- RACE study 533, **534**, 558, 596
- racial groups *see* ethnic groups
- radial artery grafts, CABG 385
- Radial Artery Patency Study (RAPS) 385
- RADIANCE study 757
- radiofrequency catheter ablation *see* catheter ablation
- radionuclide angiography, incremental value 18, 22
- RAFT trial 545–6, 660
- rail transport 79, 83
- RALES study 497, 519, 622, 759, 789
- ramipril
 acute coronary syndromes 1149
 heart failure 762, 763
 heart failure prevention **745**, 746
 hypertension **173**
 peripheral arterial disease 1057
 postinfarction 498
 sudden cardiac death prevention 622
- random errors 29–30
- randomized controlled trials (RCTs) 26
 alternatives to 34–5
 Data Monitoring Committee (DMC) 31
 interim analyses 31
 large-scale 30–1
 level of evidence 7–8
 recognizing limitations 1135–6
 stopping rules 31
 uncertainty principle 30–1
 underlying principles 26–31
- Randomized study of Ibutilide vs Procainamide **548–9**
- randomized treatment allocation 26–7
- ranolazine
 chronic stable angina 350–1
 NSTE acute coronary syndrome 421–2
- rapamycin *see* sirolimus
- RAPID 2 study 463
- RAPPORT study 480
- Rastelli procedure 1020
- REACH registry 65, 738
- REACT trial 446–7
- receiver operating characteristic (ROC) curves 19, 20, 21
- red wine 310, 317
- reference tests 18–19
- regulatory quality improvement interventions **70**, 71, 72
- rehabilitation, cardiac 332–4, 339–41
 defined 332
 EUROACTION program 336–7, **338**
 exercise training 193–4, 332–3
 implementation 334, **335**
 psychologic treatment 206
 psychosocial support 506–7
 STEMI 521–2
see also secondary prevention of cardiovascular disease
- relaxation therapy 206
- REMATCH study 771, 1106–7
- reminder systems 69, **70**, 71
- remodeling, left ventricular *see* left ventricular remodeling
- RENAAL study 171, **745**
- renal disease 1110–15
 antihypertensive therapy 171, 172, **173**
 CABG 383
 cardiovascular risk factors 1110–15
 implications for therapy 1114–15
 indications for measuring 1112
 pathophysiologic mechanisms 1113–14
 population-wide impact 1112–13
 definition 1110–12
 heart failure and 743, 1114–15, 1165
 heart transplant recipients 1106
 NSTE acute coronary syndrome 414, *1113*, 1115
 peripheral arterial disease 1051–2
- renin-angiotensin-aldosterone system (RAAS), atrial fibrillation 709
- REPAIR-AMI trial 518
- reperfusion therapy
 acute STEMI 456–69
 adjunctive antithrombotics 461, 475, 490
 benefits of delayed therapy 460
 benefits of very early therapy 460
 choice of strategy 449, **450**
 gaps in implementing evidence 65
 historic perspective 456–7
 integrated system-wide program 451–2
 left ventricular function after 497
 mechanical 464–9
 optimal time to initiation 444, *445*, 463
 patient delay and 444–7
 pharmacological 457–63
 prehospital settings 449–51
 acute stroke 972–3, 974–6
 cardiogenic shock 451, 464, 469, 499
 NSTE acute coronary syndrome 431–3, 1144–5
 RV infarction 500
 STEMI after early phase 516–17
see also coronary artery bypass grafting; fibrinolytic therapy; myocardial revascularization; percutaneous coronary intervention
- REPLACE-2 study 368–9
- research evidence *see* evidence
- resins *see* bile acid sequestrants
- RESOLVD study 742, 763
- respiratory disease *see* pulmonary disease
- respiratory support, acute MI 448
- rest pain, ischemic 1050, 1063
- resuscitation *see* cardiopulmonary resuscitation
- reteplase (rPA) 458
 acute MI 463
 adjunctive anticoagulants **485**
 adjunctive Gp IIb/IIIa antagonists 479, 480
 acute stroke 976
 risks 461
- RethinQ trial 659
- retrograde cerebral perfusion, aortic arch replacement 1091
- retroperitoneal hemorrhage 1148
- revascularization, myocardial *see* myocardial revascularization
- REVERSE trial 660
- REVERT trial 749
- reviparin, acute STEMI 484–5, 486
- rheumatic carditis 810–12
 prophylactic antibiotics 811–12, 864
 treatment 811–12, 865–6
- rheumatic fever 861–6
 diagnosis 862
 epidemiology 861
 management 864–6
 pathogenesis 861–2
 primary prevention 862–4, **866**
 secondary prevention 864, **866**
 pregnant women 1000
- rheumatic heart disease (RHD) 861–6
 aortic regurgitation 886–7
 epidemiologic transition 97
 global burden 96
 mitral stenosis 874
 pathogenesis 861–2
 pregnancy 996
 prevention 747–8, 811–12, 862–4, **866**
 surgical management 929–30
- rho-kinase inhibitors, pulmonary hypertension 1126
- ribavirin, acute myocarditis 789
- rickettsial infections 812
- rifampin, infective endocarditis **950**
- right bundle branch block
 pacing 643, 644
 postinfarction 506
- right heart catheterization, pulmonary hypertension 1120, 1123
- right ventricle (RV)
 infarction 499–500
 systemic, pregnancy and 995–6
- right ventricular (RV) failure 499–500
- mitral stenosis 875
 pulmonary hypertension 1122
- right ventricular outflow tract (RVOT) obstruction
 pulmonary valve stenosis 1016–17
 tetralogy of Fallot 1018–20
- rimonabant 133–4, 226–7, 1160
- RISC study 422, 428
- risk
 absolute 104, *105*
 total cardiovascular 104, 329–31

Index

- risk assessment
 cardiovascular disease 104, 105, 329–31
 preoperative 48–52
- risk factors, cardiovascular 102–4
 cardiovascular disease epidemic 100
 childhood and adolescence 258
 clinical vs. prevention norms 102
 diagnostic value 15, 16, 17
 early life influences 260–1, 262, 263
 epidemiologic transition 97–8
 ethnic groups 101–2, 236–52
 genetic studies 279–80
 global projections 99
 kidney-related 1110–15
 management
 chronic stable angina 346–7
 coronary artery disease 332–4
 evidence supporting 107
 integrated approach 336–41, 338, 339–40
 NSTEMI acute coronary syndrome 435
 primary prevention 334–6
 strategies 104–6, 328–31
 suboptimal 333–4, 335, 336
- multiple
 early life influences 262, 263
 interventions 332–6
 multiplicative risk 104
- risk continuum 102–4
 social determinants 216–17
 trends in prevalence 333–4
 see also specific risk factors
- risk scores (indices)
 cardiovascular mortality 330–1
 maternal cardiac events during pregnancy 998
 NSTEMI acute coronary syndrome 417–18
 perioperative cardiac risk 48–50
 peripheral arterial disease 1052, 1053
- risk stratification
 acute coronary syndromes 413, 1142–3
 clinical decision-making 1136
 hypertension 165, 166
 non-cardiac surgery 1071–3
 postoperative venous thromboembolism 1042
 pregnancy in heart disease 997–9
 see also high-risk individuals
- risk-treatment paradox 66
 RITA 2 trial 370
 RITA 3 trial 432, 1144
 rituximab 1105
 rivaroxaban, atrial fibrillation 586
 road traffic accidents 80
 road transport 79, 80, 83
 robotics, CABG 384
 Rocky Mountain spotted fever 812
 Romano–Ward syndrome 711
 Ross procedure 934–5, 1013–14
 pregnancy after 994
- rosuvastatin 150
 acute pericarditis 847
 combination therapy 157
 cost-effectiveness 160
 heart failure 770
- rotational atherectomy, coronary 363
 Roth spots 942
 Rotterdam study 576, 577, 735, 739
 Roux-en-Y gastric bypass 228, 229
 rPA *see* reteplase
- rural–urban differences
 epidemiologic transition 98
 risk factors 240, 241–3, 244
 Russia 211, 238
- ryanodine receptor (RYR2) gene mutations 295, 723
- SADHEART study 206
 SAFE-PACE trial 651
 SAFE-T study 539, 547
 SAFIRE-D study 540, 548–9, 550
 SAGE trial 158
 St Jude valve 934, 958
 salt consumption *see* sodium, dietary intake
- sample size, study 8, 29, 30
 San Antonio Heart Disease study 247–8
 San Francisco Syncope Rule 683
 San Luis Valley Diabetes Cohort Study 247
 saphenous vein grafts (SVGs) 386
 diabetic patients 401
 history 379
 percutaneous intervention 373–4
 SAPIENT™ aortic valve (Edwards Lifesciences) 905, 905, 906, 909
 sarcoglycan mutations 294, 295
 sarcoidosis, cardiac (CS) 785, 814–15
 saturated fatty acids (SFAs) 141, 306–8
 Saudi Arabia 246
 SAVE PACe trial 649
 SAVE trial 518, 740, 748–9, 762, 1149
 Scandinavian Simvastatin Survival Study (4S) 157, 159–60, 521, 745, 746
 SCD *see* sudden cardiac death
 SCD-HeFT *see* Sudden Cardiac Death in Heart Failure trial
 scleroderma, pulmonary hypertension 1120
 SCN5A gene 708, 711, 713
 SCORE charts 330–1
 SCOUT study 227, 230
 secondary prevention of cardiovascular disease 328, 329
 case history 1157–61
 exercise training 193–4
 heart failure prevention 745
 integrated approach 332–4, 339–41
 lipid-lowering therapy 1157–61
 peripheral arterial disease 1057–60
 STEMI patients 520–2
 see also prevention of cardiovascular disease; rehabilitation, cardiac
 second-hand smoke (SHS) 126
 sedentary lifestyle 190
 SEEDS study 683
- seizures
 acute ischemic stroke 978
 vs. syncope 679, 680
- self-efficacy 214
 self-esteem 214
 selodenoson, atrial fibrillation 556
 SENIORS trial 767, 772
 Senning operation 1020
 late complications 1021, 1024, 1025
 pregnancy after 995–6
 septal ablation, percutaneous alcohol 803–4
 septal myectomy, surgical 803
 sertraline, postinfarction patients 206, 507
 SESAMI trial 467
 sestamibi imaging, incremental prognostic value 23
 Seven Countries Study 211, 236, 305, 306
 SHEP study 166, 167, 169, 745
 SHIELD trial 626–7
 shipping 79, 80
 SHOCK trial 464, 499, 503, 504
 Shone's syndrome 1012
 short QT syndrome 291, 712–13
 atrial fibrillation 708
 genetics 710, 712
 sibrafiban 427
 sibutramine 226–7
 sick sinus syndrome
 pacing 644–5, 646
 see also sinus node dysfunction
- SIFA study 585
 sildenafil
 Eisenmenger syndrome 1024
 nitroglycerin interaction 420
 pulmonary hypertension 1124, 1126, 1127
- simvastatin 150, 151
 animal model of hypertrophic cardiomyopathy 299
 atrial fibrillation prevention 573, 574
 cholesterol-lowering efficacy 144
 combination therapy 156, 157
 cost-effectiveness 160
- diabetes mellitus 159
 elderly 157
 heart failure prevention 745, 746
 peripheral arterial disease 1058
 pharmacogenetics 283
 pulmonary hypertension 1126
 secondary stroke prevention 983
- single gene disorders 288–96
 arrhythmias 706–15
 cardiovascular diseases 289, 290–6
 coronary heart disease 270–2
 family history 290
 genetic counseling 290
 genetic testing 281, 296
 inheritance patterns 289–90
 mutations responsible 288–9
- single nucleotide polymorphisms (SNPs) 273–5, 276–7, 297
- single photon emission computed tomography (SPECT) 23
- single ventricle *see* univentricular heart
- sinoatrial disease *see* sinus node dysfunction
- sinoatrial re-entrant tachycardia (SANRT) 606, 609
- Sino-MONICA project 98, 100, 240
- sinus bradycardia, athletes 644, 1179
- sinus node dysfunction (SND) 644–8
 case history 1178, 1179–80, 1181
 congenital heart disease 1025
 genetics 707, 709–10
 new paradigm for physiologic pacing 648–9
 pacemaker mode selection 644–8, 650, 1179–81
 pacing indications 639, 641, 644
 syncope 676, 678
- sinus of Valsalva aneurysms 1080, 1081
 prognostic evaluation 1085
 surgical management 929, 1087–8
- sinus tachycardia 609
 inappropriate 609
- SIPS trial 364
- SIRIUS study 362
- sirolimus, heart transplant recipients 1103–4, 1105
- sirolimus-eluting stents
 coronary artery 361, 362–3
 acute STEMI 467
 safety 396–7
 peripheral arteries 1061–2
- sitaxsentan, pulmonary hypertension 1124
- sitosterolemia 272
- six-minute walk test, pulmonary hypertension 1120
- skin cancer, heart transplant recipients 1105
- SLCO1B1 genotype 283
- sleep apnea
 heart failure 1165
 pacemaker therapy 654
- small-dense LDL-C particles (phenotype B) 159
- SMART study 383
- SMILE study 518
- smoke, second-hand (SHS) 126
- smoker's paradox 126
- smoking
 epidemiologic transition 97, 100
 ethnic populations 239, 240, 241, 242, 244, 246
 health consequences 112–15, 125
 heart failure risk 743
 maternal, effects on offspring 261, 262, 263
 mortality 99, 100, 112–14, 115, 116
 passive 126
 pathophysiologic effects 126
 peripheral arterial disease and 1051, 1062
 prevalence 111, 112
 prevention 116–22
 restrictions 116–17, 118, 216
 social determinants 216
 trends 111–12, 333–4
 see also cigarettes; tobacco
- smoking cessation 125–34
 5 As approach 129
 benefits 114–15, 116, 126–7
 counseling 44, 129–30
 difficulty 128–9

- heart failure prevention 744, 747
 hospital-based programs 130, 131
 integrated risk factor interventions 332, 335–6, 337
 interventions 129–34
 peripheral arterial disease 1055–6
 pharmacotherapy 130–4
 preoperative 1184
 STEMI 520
 treatments 119
 trends 111–12
 SNP Consortium 274
 SOCESP study 546, 548–9
 social capital 213–14
 social determinants of cardiovascular disease 211–17
 broader environment 215–17
 individual environment 212–15
 mechanisms and interpretation 215
see also psychosocial factors
 social networks 204, 213–14
 social support
 coronary artery disease and 204, 212–14
 interventions 206
 Society of Thoracic Surgeons (STS) risk models 898
 socioeconomic status (SES)
 cardiovascular disease mechanisms 201–2
 coronary artery disease and 204, 205
 epidemiologic transition and 98
 gaps in implementing evidence and 65–6
 sodium, dietary intake 311–12
 cardiovascular disease relationship 311–12
 efficacy of reducing 168, 169, 312, 319
 orthostatic syncope 685
 recommendations 312, 313
 sodium bicarbonate, cardiac arrest 698
 sodium channel blockers, long QT syndrome 711–12
 sodium channel gene mutations 291, 707, 708, 713
 sodium current, late inward 350
 SOFA study 628
 SOLVD-P trial 740, 748
 SOLVD trial 569, 570, 747, 762–3
 SOPAT study 544–5, 546, 548–9
 sotalol
 arrhythmogenic right ventricular cardiomyopathy 726
 atrial fibrillation
 acute cardioversion 537, 538, 539
 after cardiac surgery 560
 with electrical cardioversion 542
 prophylactic use 546–7
 rate control 555–6, 557, 558
 atrioventricular reciprocating tachycardia 614
 heart failure 769
 ICD recipients 626
 paroxysmal supraventricular tachycardia 608
 sudden cardiac death prevention 620, 621
 d,l-Sotalol Atrial Fibrillation/Flutter study (d,l-SAFFS) 546–7
 Sotalol Atrial Fibrillation Study 557
 South Asians 242–4
 disease burden 242, 245
 migrants 243, 245
 prevention strategies 243–4
 risk factors 96, 242–3, 244
 Soviet Union, former 211
 soy 316
 SPAF trial 581–2, 583, 586–7
 SPAF II trial 582–4, 587
 SPAF III trial 584
 Spain, cardiovascular mortality 96
 SPARCL trial 983
 SPEED trial 479
 SPINAF trial 581–2, 583
 spinal cord stimulation (SCS), stable angina 351
 spirochetal infections 812
 spironolactone (Aldactone)
 acute myocarditis 789
 animal model of hypertrophic cardiomyopathy 299–300
 Chagas' cardiomyopathy 834
 heart failure 759, 1166
 mineralocorticoid receptor mutation and 299
 postinfarction 497, 498, 519
 renal insufficiency 1114
 sudden cardiac death prevention 622
 SPORTIF III and V trials 585–6
 STAF study 533, 534, 596
 staphylococcal endocarditis, antibiotic therapy 950
Staphylococcus aureus
 endocarditis 942, 945, 950
 myocarditis 810
 pericarditis 849
 Starr–Edwards valve 934, 957, 958
 STARS trial 365
 statins (HMG-CoA reductase inhibitors) 149–51
 acute pericarditis 847
 adverse reactions 143, 151
 animal model of hypertrophic cardiomyopathy 299, 300
 aortic stenosis 881
 atrial fibrillation prevention 569, 572–5
 chronic stable angina 347–8
 clinical use 144, 151
 combination therapy 156–7
 costs and cost effectiveness 44, 159–60
 diabetes mellitus 158–9
 dosage 150
 elderly 157–8
 heart failure 770
 heart failure prevention 745, 746
 heart transplant recipients 1105
 lipid-lowering effects 140, 144, 150–1
 mechanism of action 149
 myopathic adverse effects 143, 151, 282–3
 NSTEMI acute coronary syndrome 433–5, 1149
 perioperative 57–8, 1075–6, 1184
 peripheral arterial disease 1058
 pharmacogenetics 282–3
 pleiotropic effects 149–50, 160
 renal insufficiency 1115
 safety 142–3
 secondary prevention of MI 1157–8, 1159
 STEMI 519, 521
 stroke prevention 150, 983–4
 statistical significance 8
 STEEPLE trial 368
 stem cell therapy
 Chagas' cardiomyopathy 835
 STEMI 518–19
 STEMI *see* myocardial infarction (MI), ST segment elevation
 Steno-2 trial 1057
 Stenting Versus Internal Mammary Artery (SIMA) trial 399
 Stent or Surgery (SoS) trial 398
 stents
 aortic disease 1089, 1090, 1093
 carotid artery 985
 coronary *see* coronary stents
 peripheral arterial disease 1061–2
 STILE trial 1063
 Stockholm Ischemic Heart Disease Study 1159
 Stokes–Adams attacks 643
 STOP-AF study 646–7
 STOP-H2 study 570, 571
 STOP study 745
 streptococcal endocarditis 941–2, 946–7
 streptococcal pharyngitis, group A *see* group A streptococcal (GAS) pharyngitis
 streptococcal skin infections 862
 streptokinase (SK) 457, 458
 acute MI
 adjunctive anticoagulants 482, 485, 487
 adjunctive Gp IIb/IIIa antagonists 479
 comparative trials 462, 463
 efficacy 459, 460
 subgroup analyses 28
 acute stroke 975
 adverse effects 461
 historic perspective 456–7
 stress (psychosocial)
 cardiovascular disease mechanisms 201–2, 215
 coronary artery disease and 203, 205, 211–12
 management training 205
 postinfarction patients 506–7
 stress tests
 incremental value 14, 17, 18–19, 20, 21–2
 preoperative, non-cardiac surgery 50–1, 1071–2
see also exercise testing
 STRESS trial 359
 stroke 971–86
 acute ischemic (AIS) 972–8
 acute neurologic complications 978
 anticoagulants 977
 antiplatelet agents 977
 blood pressure control 974
 emergency department 973
 general supportive care 973–4
 intra-arterial thrombolysis 976–7
 intravenous thrombolysis 974–6
 neuroprotection 977
 prehospital settings 972–3
 preventing early complications 977–8
 proven strategies 972
 venous thromboembolism 978
 after balloon mitral valvuloplasty 921
 after CABG 383
 aortic surgery and 1091, 1093
 atrial fibrillation 581
 anticoagulation after 587, 982
 antithrombotic prophylaxis 581–92
 complicating ablation therapy 601
 postcardioversion 590
 rate vs. rhythm control trials 532–3
 risk stratification 586–7
 atrial flutter 591, 611
 Chagas' cardiomyopathy 836
 diabetes-related risk 181–2
 diagnosis 979
 dysglycemia-related risk 181–3
 epidemiologic transition 97, 98
 epidemiology 971, 972
 ethnic variations 239, 240, 250, 251
 genetic factors 278–9
 global mortality 95–6
 global projections 99
 hemorrhagic 971, 972, 979
 hypertension-related risk 166, 167
 infective endocarditis 945, 952
 ischemic 971–2, 979
 management of acute *see* stroke, acute ischemic
 TOAST criteria 971–2
 nomenclature and definitions 971–2
 patient information 10
 peripheral arterial disease and 1051
 postinfarction 502
 preoperative risk prediction 48, 50
 primary prevention
 antihypertensive agents 169–74
 dietary factors 313, 314
 lipid-lowering agents 150, 154
 recurrence risk 979
 secondary prevention 979–86
 anticoagulation 982–3
 antiplatelet therapy 981–2
 blood pressure-lowering therapy 979–80
 carotid revascularization 984–5
 cholesterol-lowering therapy 983–4
 serum cholesterol and 141–2, 983
 stroke care units (SCU) 972, 977–8
 Strong Heart Study 250, 308
 ST segment
 depression 414
 elevation
 LV aneurysms 500
 myocardial infarction (STEMI) *see under* myocardial infarction
 RV infarction 500
 transient 414–15
 stunned myocardium 380–2, 497

Index

- subarachnoid hemorrhage (SAH) 972, 979
- subclavian artery, aberrant origin 1082, 1084
- subgroup analyses 28
- sudden cardiac death (SCD) 619–32
 - African Americans 251
 - aortic regurgitation 886
 - aortic stenosis 880–1
 - arrhythmogenic right ventricular cardiomyopathy 715, 722, 724
 - asymptomatic left ventricular systolic dysfunction 750
 - Brugada syndrome 291, 713
 - cardiomyopathies 629
 - Chagas' cardiomyopathy 830
 - congenital heart disease 1025
 - exercise-related 195
 - heart failure 769, 1167
 - hypertrophic cardiomyopathy 292, 293, 714, 798–9
 - incidence 619
 - long QT syndrome 291
 - pregnancy 997
 - prevention 619–32
 - antiarrhythmics 619–21
 - beta-blockers 621
 - ICDs 623–9
 - postinfarction 519–20
 - upstream therapy 622
 - risk stratification 619
 - syncope patients 675
- Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)
 - amiodarone 551, 621, 769
 - atrial fibrillation 574
 - ICD therapy 520, 625, 626, 627, 661, 1167
 - statins 573, 574
- sudden infant death syndrome (SIDS) 713
- sudden unexplained nocturnal death syndrome (SUNDS) 713–14
- sulfinpyrazone, NSTEMI acute coronary syndrome 422
- supraventricular tachycardia (SVT) 606–14
 - classification 607
 - evaluation 606–7
 - Fontan circulation 1022–3
 - incessant 606
 - management 607–9
 - mechanisms 606
 - pacemaker therapy 639
 - paroxysmal (PSVT) 606–9, 610, 612
 - syncope 676, 679, 684, 685
- surgery (non-cardiac)
 - atrial fibrillation patients 591–2, 593
 - cardiac risk/vascular complications 47–59, 1068–77
 - magnitude of problem 47–8
 - preoperative prediction 48–52, 1068, 1069
 - prevention 54–8, 1073–7, 1077
 - perioperative beta-blockers 54–6, 1073–5, 1077, 1183–4
 - perioperative statins 57–8, 1075–6, 1184
 - venous thromboembolism
 - prophylaxis 1042–3
 - risk stratification 1042
 - see also* preoperative cardiac risk prediction
- surgical treatment
 - Chagas' cardiomyopathy 834–5
 - heart failure 771
 - hypertrophic cardiomyopathy 802–3
 - see also specific procedures*
- survival, cost-effectiveness analysis 43
- Swedish Coronary Angiography and Angioplasty Registry (SCARR) 396
- Swedish Obesity Study (SOS) 229
- Swedish Twin Study 268
- Switzerland 95, 96, 238
- SWORD trial 620
- SYDIT study 652
- syncope 673–86
 - cardiac 675, 676, 677
 - cardio-inhibitory 676
 - case histories 1178–81
 - classification of causes 676–9
 - cost-effectiveness issues 686
 - diagnostic evaluation 679–83, 686
 - epidemiology 673–4
 - ICD therapy 675, 685
 - management units 683
 - mimics 677, 679
 - mortality 674–5
 - neurocardiogenic (neurally mediated reflex) 676–8
 - pacing 639, 650–2
 - treatment 684–5
 - nomenclature 673, 674
 - orthostatic (postural) 676, 677, 678
 - treatment 685
 - pathophysiology 675–6
 - prognosis 675
 - recurrence rates 674
 - situational 676–7
 - treatment 684–5
 - vasovagal *see* vasovagal syncope
- SYNERGY trial 1146
- SYNPACE study 652
- SYNTAX trial 400
- syphilis 812, 886
- systemic right ventricle, pregnancy 995–6
- Syst-Eur study 171, 745
- Systolic Hypertension in the Elderly Program *see* SHEP study
- tachycardia
 - mediated cardiomyopathy 606
 - pacing to prevent 639
 - see also* atrial tachycardia; sinus tachycardia; ventricular tachycardia; *other specific types of tachycardia*
- tachycardia-bradycardia syndrome, pacing 646
- tacrolimus, heart transplant recipients 1102–4
- TACTICS-TIMI 18 study 432, 1144
- tadalafil, nitroglycerin interaction 420
- taffazin mutations 295
- tamponade
 - acute pericarditis 846
 - chronic idiopathic pericardial effusion 848
 - complicating balloon mitral valvuloplasty 921
 - neoplastic pericarditis 853
 - postinfarction 502
 - tuberculous pericarditis 850
- Tangier disease 271, 297
- Tanzania 251
- TAPAS trial 467
- TAVR *see* transcatheter aortic valve replacement
- TAXUS IV study 362
- tecadenoson, atrial fibrillation 556
- telemetry, mobile cardiac outpatient (MCOT) 681, 682
- telmisartan
 - acute coronary syndromes 1149
 - atrial fibrillation prevention 571
- TEMPEST trial 556
- tendon xanthomas 270
- tenecteplase (TNK-tPA) 458
 - acute MI 463
 - adjunctive anticoagulants 485
 - adjunctive Gp IIb/IIIa antagonists 479, 480
 - acute stroke 976
 - cardiac arrest 698
 - risks 461
- tetralogy of Fallot (TOF) 1018–20
 - arrhythmias 1025
 - diagnostic evaluation 1019
 - management 1019–20
 - pregnancy 994
- tezosentan, heart failure 770
- thallium imaging, incremental value 19, 20, 22
- thiazide diuretics, heart failure prevention 744, 745
- thiazolidinediones (TZDs), cardiac risks 743, 1164
- thienopyridines
 - acute STEMI 477–8
 - NSTEMI acute coronary syndrome 423–5
- PCI 365–6
 - peripheral vascular disease 1059
 - see also* clopidogrel; prasugrel; ticlopidine
- thiotepa, intrapericardial 854
- thoracic surgery, cardiac risk 1071–3
- thrifty gene hypothesis 100–1
- thrombectomy
 - acute stroke 976
 - intracoronary 467–8
- thrombin 418
 - direct inhibitors *see* direct thrombin inhibitors
- thromboembolism
 - atrial fibrillation 581, 590
 - Chagas' cardiomyopathy 830, 835–6
 - complicating atrial fibrillation ablation 601
 - postinfarction 502
 - preventive therapy *see* antithrombotic therapy
 - prosthetic valve recipients 932, 960, 962–3
 - venous *see* venous thromboembolism
 - see also* stroke
- Thrombolysis in Myocardial Infarction score *see* TIMI score
- thrombolytic therapy *see* fibrinolytic therapy
- thrombosis
 - early (coronary) stent 1154–5
 - exercise and 197
 - late (coronary) stent 362–3, 366, 396–7
 - PCI site 365
 - valve 928
- thrombus 1032
 - intracoronary *see* intracoronary thrombus
 - LV, postinfarction 502, 1153–4
- THUNDER trial 1061–2
- thyrotoxicosis, atrial fibrillation 587
- Tianjin Trial 312
- ticagrelor 423
- ticlopidine
 - acute STEMI 477
 - NSTEMI acute coronary syndrome 423–4
 - PCI 365
 - peripheral vascular disease 1059
 - prosthetic valve recipients 965
- tilt-table testing
 - syncope 681, 682–3
 - vasovagal syncope 651–2
- tilt-training, vasovagal syncope 684
- TIME trial 380
- TIMI-3B trial 431–2
- TIMI-5 trial 487
- TIMI-9B trial 429, 487, 489
- TIMI-10 trial 463
- TIMI-11A trial 417
- TIMI-11B trial 429
- TIMI-14 trial 479
- TIMI-III registry 414
- TIMI myocardial perfusion (TMP) score 456
- TIMI score 417–18, 456
 - primary PCI and 449
- Timothy syndrome 711, 712
- tirofiban
 - acute STEMI 481
 - NSTEMI acute coronary syndrome 425–6, 431, 435, 1145
 - PCI 366
- tissue factor (TF) 418, 481
- tissue plasminogen activator (tPA) 457, 458
 - acute MI
 - accelerated dosing 462
 - comparative trials 462, 463
 - cost effectiveness 44
 - efficacy 459
 - vs. primary PCI 464
 - acute stroke 974–6, 979
 - risks 461
 - see also* alteplase
- titin mutations 293
- TNK-tPA *see* tenecteplase
- TNT study 158, 521, 745
- TOAST criteria, ischemic stroke 971–2

- tobacco 111–22
 advertising/promotion bans 117–19
 consumption
 epidemiologic transition 97, 100
 ethnic groups 243, 245
 health consequences 112–15, 125
 peripheral arterial disease 1051
 projected mortality 99, 114
 see also smoking
 control 116–22, 216
 comprehensive programs 121–2
 cost-effectiveness 119–21
 effectiveness 119–21, 127
 strategies 116–19
 health information and counter-advertising 117
 smokeless 126, 243
 taxation 116, 120
 see also nicotine
- tolvaptan, heart failure 770
- tomato-based foods 310–11
- TOPAS trial 1063
- TOPPS trial 365
- torcetrapib 144, 155, 1158, 1160
- Toronto SPV bioprosthesis 934
- TOSCA-1 trial 359
- TOSCA-2 trial 374, 517
- total cavopulmonary connection (TCPC) 1022
- total quality management (TQM) 69
- Toxoplasma gondii*, heart transplant recipients 1106
- tPA *see* tissue plasminogen activator
- TRACE trial 518, 569, 570, 762
- trandolopril
 asymptomatic left ventricular systolic dysfunction 748
 heart failure 569, 762, 763
 heart failure prevention 745, 746
 postinfarction 498
- transcatheter aortic valve replacement (TAVR)
 881, 896, 904–9, 1189
 balloon-expandable aortic valve 904–7, 909
 transapical approach 906–7
 transarterial procedure 905–6
 transvenous procedure 904–5
 complications 905, 906, 907–8
 indications and risk assessment 898, 909
 learning curve 907
 long-term follow-up 907
 self-expanding aortic valve 907, 909
 vs. percutaneous balloon aortic valvuloplasty 908, 909
- transcranial Doppler, acute stroke 976
- transesophageal echocardiography (TEE)
 atrial fibrillation 590–1, 592
 infective endocarditis 944, 952
 mitral regurgitation 871–2
 mitral stenosis 916
 percutaneous balloon mitral valvuloplasty 918
- trans* fatty acids (t-FAs) 141, 307, 308
- transforming growth factor-beta (TGF- β)
 aortic aneurysmal disease 1085–6
 type 3 (TGF β 3) gene mutations 723
- transfusion, preoperative 1070
- transient ischemic attacks (TIAs) 972, 979
 prevention of stroke after 979–85
- transient loss of consciousness (TLOC) 673, 674
see also syncope
- transmyocardial laser revascularization (TMR)
 351
- transportation industry, employment fitness standards 79–90
- transposition of great arteries (TGA) 1020–1
 complete (d-TGA) 1020
 congenitally corrected (ccTGA) 1020–1, 1025
 pregnancy 995–6
- transthyretin (TTR) amyloidosis 813–14
- trastuzumab, cardiomyopathy risk 743
- treadmill testing *see* exercise testing
- treatment
 blinding of allocation 27
 effect, power of study to detect 29
 randomized allocation 26–7
- Treponema whippelii* 810
- treprostinil, pulmonary hypertension 1126
- Trial of Nonpharmacologic Interventions in the Elderly (TONE) 312
- Trials of Hypertension Prevention (TOHP) 312
- triamcinolone, intrapericardial 847
- tricuspid regurgitation
 balloon mitral valvuloplasty and 920
 pregnancy and 994
 pulmonary hypertension 1122
 valve repair 931
- tricuspid valve (TV)
 Ebstein anomaly *see* Ebstein anomaly
 repair 931
 surgery 1018
- trifascicular block, pacing indications 638
- triflusal
 atrial fibrillation 585
 prosthetic valve recipients 964
 secondary stroke prevention 981
- triglycerides (TGs), serum
 dietary carbohydrates and 308–9
 effects of lipid-lowering agents 150, 152, 153
 genetic influences 279, 280
 ischemic heart disease and 143
 obesity 225–6
see also hypertriglyceridemia
- trimetazidine, chronic stable angina 351
- triplet repeat syndrome, dilated cardiomyopathy 294–5
- TRITON TIMI-38 trial 424–5, 478
- TROICA trial 698
- alpha-tropomyosin mutations 293
- troponins, serum
 myocarditis 786, 809
 NSTEMI acute coronary syndrome 410–11, 415, 417, 1143–4
 postinfarction left ventricular dysfunction 497
 postoperative rise 53
- troponin T (cTnT) mutations 293, 294, 295
- trypanocidal therapy 830–2, 833
- Trypanosoma cruzi* 824, 825
 mechanisms of myocardial damage 828–9
see also Chagas' disease
- Tubbs dilator 919
- tuberculosis, cardiac 810
- tuberculous pericarditis 845, 850–3
 effusive constrictive pericarditis 852
 epidemiology 850
 pericardial constriction 851–2
 pericardial effusion 850–1
 steroid therapy 852–3
- Turner's syndrome
 coarctation of aorta 1014
 pregnancy 994, 995
- T-wave inversions 414
- 22q11 deletion syndrome 1006–7
 tetralogy of Fallot 1019
 transmission to offspring 999, 1007
- twin studies 268
- type I error 29, 31
- type II error 29
- type A behavior 202–3, 205
- type D personality 203, 205
- TYPHOON trial 467
- UKPACE trial 646, 647, 1180
- ularitide, heart failure 760
- ultrafiltration, heart failure 758
- ultrasound imaging
 carotid 984
 peripheral arterial disease 1055
 venous (VUI) 1036, 1037, 1039
see also Doppler ultrasound; echocardiography;
 intravascular ultrasound
- uncertainty principle 30–1
- unfractionated heparin *see* heparin, unfractionated
- United Arab Emirates (UAE) 246
- United Kingdom (UK)
 tobacco control 116, 117, 122
 tobacco use 111–12, 113
- United Kingdom Prospective Diabetes Study (UKPDS) 181, 185–6, 225, 745, 747
- United States
 Aboriginal populations 248–50
 African Americans 251–2
 cardiovascular mortality 95–6, 238
 European populations 237–9
 Hispanic populations 247–8
 prevention approaches 239
 tobacco control 116, 117, 118, 122
- univentricular heart 1021–3
 pregnancy 996
 surgical procedures 1022
- unsaturated fatty acids 141, 307–8
- unstable angina (UA) 409
 12-lead ECG 414–15
 biomarkers 415–17
 clinical diagnosis 410
 clinical features 410, 413
 diabetes mellitus 413–14
 incidence, natural history and prognosis 411–13
 management 419–35
 non-cardiac surgery 1070, 1072
 pathophysiology 418–19
see also acute coronary syndromes
- upstream therapy
 atrial fibrillation 531–2, 568–78
 sudden cardiac death prevention 622
- urokinase (UK) 457, 458
- acute limb ischemia 1063
- intra-arterial, acute stroke 976
- intraoperative 849, 851
- venous thromboembolism 1033
- vaccination, Eisenmenger syndrome 1024
- vagal maneuvers, supraventricular tachycardias 607, 610, 612, 613
- VA-HIT 154, 160, 745, 746, 1159
- valaciclovir 1106
- valganciclovir 1106
- Val-HeFT trial 569–71, 763, 764
- VALLANT study 518, 749, 1149
- valsartan
 asymptomatic left ventricular systolic dysfunction 749
 atrial fibrillation prevention 571, 572
 heart failure 569–71, 763, 764
 heart failure prevention 745, 1149
 hypertension 172, 173
 STEMI 518
- VALUE trial 172, 173, 571, 745
- valve deterioration, structural 928
- valve dysfunction, non-structural 928
- valve replacement surgery 931–5
 antithrombotic therapy 957–66
 choice of valve 931–5
 pregnancy 994
 rheumatic carditis 812
 thromboembolism risk 960
see also aortic valve replacement; mitral valve replacement; prosthetic heart valves
- valve thrombosis 928
- valvular heart disease
 heart failure 743
 pregnancy 994
 surgical management 927–36
 indications 927
 nomenclature and definitions 927, 928
 timing of surgery 1187–9
 valve repair 927–31
 valve replacement *see* valve replacement surgery
see also rheumatic heart disease
- vancomycin, infective endocarditis 946, 947, 948, 949, 950
- VANQWISH study 432
- vardenafil, nitroglycerin interaction 420
- varenicline, smoking cessation 132–3, 1056
- vascular surgery
 assessing cardiac risk 1183–5
 cardiac risk 52–3, 1068, 1071–3

Index

- vascular surgery (*cont.*)
peripheral arterial disease 1061–2
preventing cardiac complications 56–8, 1073, 1075–6, **1077**
see also specific procedures
- vasoactive intestinal peptide, pulmonary hypertension 1126
- vasodilators
acute aortic syndromes 1087
aortic regurgitation 888–9
heart failure 759–61
intermittent claudication 1061
pulmonary hypertension 1125–6
- vasopressin, cardiac arrest 697
- vasopressin antagonists, heart failure 770
- vasopressors, cardiac arrest 697
- Vasovagal International Study (VASIS) 652
- Vasovagal Pacemaker Study (VPS) 651–2
- Vasovagal Pacemaker Study II (VPS II) 652
- vasovagal syncope 676–7
diagnosis 680, 1179
pacing 651–2
treatment 684–5
- vegetables *see* fruit and vegetables
- vegetarian diets 318
- vegetations 942, 944, Plate 59.1
- venography 1036, **1037**
- venous grafts
CABG 386
peripheral arterial disease 1062
- venous stasis 1035
- venous thromboembolism (VTE) 1032–43
diagnosis 1036–9
incidence 1032
inferior vena cava filters **1034**, 1041
natural history and prognosis 1032–5
pathophysiology 1035
postoperative
prophylaxis 1042–3
risk stratification **1042**
prevention 1042–3
landmark trials 1032, **1033**
risk factors **1035**
stroke patients 978
treatment **1033–4**, 1039–42
acute 1039–40
subacute and long-term 1040–1
thrombolysis 1041–2
see also deep vein thrombosis; pulmonary embolism
- venous wall damage 1035
- ventilation
advanced life support 697
basic life support 693, 694
- ventilation-perfusion (V/Q) lung scanning
pulmonary embolism 1038, **1039**
pulmonary hypertension 1123
- ventricular arrhythmias 619–32
arrhythmogenic right ventricular cardiomyopathy 725
Chagas' cardiomyopathy 832–4
monogenic disorders 711–15
myocarditis 790–1
postinfarction 504–5
prevention 619–32
reperfusion therapy 451, 469
risk stratification 619
- ventricular assist devices *see* left ventricular assist devices
- ventricular dyssynchrony
cardiac resynchronization therapy 659–60
pacemaker therapy 649
- ventricular fibrillation (VF)
defibrillation *see* defibrillation
ICD therapy for survivors 625–6
idiopathic 291
inducible
ICD therapy 623
short QT syndrome 712
postinfarction 504, 1174–5
precordial thump 695
primary 1174
ventricular premature beats, postinfarction 504–5
ventricular remodeling *see* left ventricular remodeling
- ventricular septal defect (VSD) 1009–10
management 1010
pregnancy 993
transposition of great arteries 1020
- ventricular septal rupture, postinfarction 503–4
- ventricular tachycardia (VT)
arrhythmogenic right ventricular cardiomyopathy 725
catecholaminergic polymorphic *see* catecholaminergic polymorphic ventricular tachycardia
Chagas' cardiomyopathy 832–4
congenital heart disease 1025
ICD therapy for survivors 625–6
idiopathic **289**
inducible, ICD therapy 623
non-sustained (NSVT)
hypertrophic cardiomyopathy 799
ICD therapy 623, 625
pacing to prevent **639**
postinfarction 500, 504–5
pulseless, precordial thump 695
syncope 676, 678–9, 685
- ventriculography *see* cardiac catheterization
- VEPARAF trial 542
- verapamil
atrial fibrillation 541, 542, 554–5, 558–9
atrial tachycardia 609–10
atrioventricular reciprocating tachycardia 613
chronic stable angina 349
hypertrophic cardiomyopathy 799
NSTEMI acute coronary syndrome 421
paroxysmal supraventricular tachycardia 607
- VERDICT trial 542
- verification bias 18–19
- vernakalant, atrial fibrillation 542, 553
- very low-calorie diets (VLCDs) 224
- Veteran Affairs Co-operative Study (VACS) 58
- Veteran Affairs Model, preoperative cardiac risk 48–9
- Veterans Administration Coronary Artery Bypass Surgery Co-operative Study Group (VA) 380, 392–3
- Veterans Administration Diabetes Trial (VADT) 185, 186
- Veterans Administration Study 422
- V-HeFT trials 760–1
- viral infections
acute pericarditis 846
myocarditis *see* myocarditis, viral
- Virchow, Rudolph 1032
- Virchow's triad 1032, 1035
- VISION study 49–50, **51**, 52, 53
- vital exhaustion 203
- vitamin C 310
- vitamin E 310
- Vitamin Intervention for Stroke Prevention (VISP) 311
- vitamin K antagonists (VKAs)
peripheral arterial disease 1060
prosthetic valve recipients 959–60, 961–5
venous thromboembolism 1040
see also oral anticoagulants; warfarin
- vitamin K epoxide reductase (VKORC1) genotype 282
- volume loading, RV infarction 500
- vulnerable populations, gaps in implementing evidence 65
- Vytorin Versus Atorvastatin (VYVA) trial 347
- waist circumference 221, **222**
- warfarin
aircraft pilots 81, 87
atrial fibrillation 581–5, 587–8, **589**
cardioversion 590
case history 1171, 1172
postinfarction 591
stroke prevention 982
during surgical procedures 591–2
contraindications 982
- NSTEMI acute coronary syndrome 430
pharmacogenetics 282
during pregnancy 1000
prosthetic valve recipients 959–60, 961–5
secondary stroke prevention 982–3
STEMI 521, 1154
venous thromboembolism 1040
venous thromboprophylaxis 1042
- Waterston shunt 1022
- WAVE trial 1059, 1060
- weight gain
infancy 262, **263**, 264
medications causing 225
natural history and prognosis 222
see also obesity
- weight loss
antiobesity medications 227
bariatric surgery 228–9
cardiovascular benefits 230
diabetes 225
dyslipidemia 225–6
heart failure prevention 747
hypertension 168, **169**, 224–5
lifestyle modifications 224
obesity 223, 224
postinfarction 520
- Wellcome Trust Case–Control Consortium (WTCCC) study 276–7, 279, 298
- Wernicke's encephalopathy 230
- WEST study 486–7, 516
- Whipple disease 810
- Whitehall Study 203, 213
- widowhood 212–13
- Williams' syndrome 1007, 1012
- Wisconsin Epidemiologic Study of Diabetic Retinopathy 181
- Wolff–Parkinson–White (WPW) syndrome 292, **707**
Ebstein anomaly 1025
hypertrophic cardiomyopathy and 714
supraventricular tachycardias 613, 614
- women
clinical diagnosis of CAD 15–16
delay in presentation of acute MI 444–6
Gp IIb/IIa antagonists 427
lipid-lowering therapy 158
NSTEMI acute coronary syndrome 413
young, mitral valve surgery 875
see also gender differences
- Women's Health Study (WHS) 192, **315**
- Women's Ischemic Syndrome Evaluation (WISE) study 15–16, 19
- work
environment 214–15
fitness standards *see* employment fitness standards
related physical activity 191
stress 203, 205, 214–15
work-up bias 18–19
- World Health Organization (WHO)
functional status in pulmonary hypertension **1121**
risk prediction charts 331
- WOSCOPS study 150, 157, 160
- xanthinol nicotinate, peripheral arterial disease 1059
- xemilofiban 427
- ximelagatran
atrial fibrillation 585–6
NSTEMI acute coronary syndrome 430
venous thromboembolism 1040
- X-linked inheritance 289, 290
- Yacoub procedure 928
- young people, atherosclerosis 258–9
- young women, mitral valve surgery 875
- zotarolimus-eluting coronary stents 361